CUMULATIVE
SUPPLEMENT 11
NOVEMBER 2001



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Information Technology
Division of Data Management and Services

2001

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Cumulative Supplement 11

November 2001

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

CUMULATIVE SUPPLEMENT 11
NOVEMBER 2001

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 21st Edition List will then be added to the "Discontinued Drug Product List" appearing in the 22nd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated

Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
BAXTER PHARMACEUTICAL PRODUCTS INC (BAXTER PHARM PROD)	BAXTER HEALTHCARE CORPORATION ANESTHESIA & CRITICAL CARE (BAXTER HLTHCARE CORP)
CAMALL CO INC (CAMALL)	ABC HOLDING CORPORATION (ABC HOLDING)
CIBA VISION CORP DIV NOVARTIS CO (CIBA)	NOVARTIS OPHTHALMICS INC (NOVARTIS)
CIBA VISION OPHTHALMICS (CIBA VISION OPHTHLMC)	NOVARTIS OPHTHALMICS INC (NOVARTIS)
DEY LABORATORIES INC (DEY)	DEY LP (DEY)
KNOLL PHARMACEUTICAL COMPANY (KNOLL PHARM)	ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS (ABBOTT)
LOTUS BIOCHEMICAL CORPORATION (LOTUS BIOCHEM)	NEW RIVER PHARMACEUTICALS INC (NEW RIVER)
MARSAM PHARMACEUTICALS INC (MARSAM PHARMS)	MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS)
MEDEVA AMERICAS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS CA INC (MEDEVA PHARMS CA)	CELLTECH MANUFACTURING CA INC (CELLTECH MFG CA INC)
MEDEVA PHARMACEUTICALS MA INC (MEDEVA PHARMS MA)	CELLTECH MANUFACTURING INC (CELLTECH MFG)
NOVOPHARM LTD (NOVOPHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM PHARMACEUTICAL CO (NOVOPHARM PHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM NC INC (NOVOPHARM NC)	TEVA PHARMACEUTICALS USA (TEVA)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
OHMEDA PHARMACEUTICAL PRODUCTS DIV (OHMEDA)	BAXTER HEATHCARE CORPORATION ANESTHESIA & CRITICAL CARE (BAXTER HLTHCARE CORP)
ROBERTS LABORATORIES INC (ROBERTS LABS)	SHIRE PHARMACEUTICAL DEVELOPMENT INC (SHIRE PHARM)
ROBERTS PHARMACEUTICAL CORP (ROBERTS PHARM)	SHIRE PHARMACEUTICAL DEVELOPMENT INC (SHIRE PHARM)
ZENITH GOLDLINE (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC (IVAX PHARMS)
ZENITH GOLDLINE PHARMACEUTICALS INC (ZENITH GOLDLINE)	IVAX PHARMACEUTICALS INC (IVAX PHARMS)

1.3 AVAILABILITY OF THE EDITION

The 21st Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $101.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 21st annual edition of the 2000 Orange Book Patent and Exclusivity List is at http://www.fda.gov/cder/orange/21bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2000) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2000	MAR 2001	JUN 2001	SEP 2001
DRUG PRODUCTS LISTED	10360	10372	10155	10094
SINGLE SOURCE	2682 (25.9%)	2696 (26.0%)	2665 (26.2%)	2643 (26.2%)
MULTISOURCE	7568 (73.1%)	7566 (72.9%)	7380 (72.7%)	7341 (72.7%)
THERAPEUTICALLY EQUIVALENT	7257 (70.0%)	7263 (70.0%)	7078 (69.7%)	7050 (69.8%)
NOT THERAPEUTICALLY EQUIVALENT	311 (3.0%)	303 (2.9%)	302 (3.0%)	291 (2.9%)
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)	110 (1.1%)	110 (1.1%)
NEW MOLECULAR ENTITIES APPROVED	2	6	3	4
NUMBER OF APPLICANTS	594	582	579	572

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The 21st Edition Orange book (OB) Cumulative Supplement (CS) layout has changed. The new format follows the Annual Edition and previous CS format. The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form;Route and then by trade name. The manner of displaying the individual product information has changed.

The individual product record follows the previous format layout for Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. Two new columns have been added to provide more information. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form;route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

1.6 CHANGE OF A THERAPEUTIC EQUIVALENT CODE FOR A DRUG ENTITY

Metaxalone Tablets

In Cumulative Supplement 6 of the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition, (the Orange Book), the Agency proposed to reclassifiy metaxalone tablets from a drug product not presenting bioequivalence problems to one that has a known or potential bioequivalence problem that requires an in vivo demonstration of bioequivalence as a condtiion of approval for an ANDA. The Agency solicited comments from interested persons to be received no later than November 30, 2001. No comments were received. Accordingly, the therapeutic equivalence category for metaxalone tablets will be changed from a "nonbioproblem drug" to a "bioproblem drug." An ANDA for metaxalone tablets must include acceptable in vivo bioequivalence study or studies.

As long as metaxalone tablets are a single source drug product, no therapeutic equivalence code will be assigned to the product in the Orange Book. If the Agency approves an ANDA for metaxalone tablets, the innovator's NDA for metaxalone (Skelaxin) tablets and the approved ANDA will both be coded as "AB".

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

	@ MIKART	150MG;180MG;15MG	N81095 001	OCT 26, 1990	MAY	DISC
	@	150MG;180MG;60MG	N81097 001	OCT 26, 1990	MAY	DISC

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

TRIAPRIN

	@ DUNHALL	325MG;50MG	N89268 001	JUL 02, 1987	FEB	WDRP

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

	@ ROBERTS AND HAUCK	325MG;50MG;40MG	N87628 001	OCT 01, 1986	FEB	WDRP

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AB	ABLE	325MG;50MG;40MG	N40390 001	JUL 23, 2001	JUL	NEWA
AB		500MG;50MG;40MG	N40394 001	JUL 23, 2001	JUL	NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE

AB	WEST WARD	325MG;50MG;40MG;30MG	N75618 001	MAR 23, 2001	MAR	NEWA

FIORICET W/ CODEINE

AB	+ NOVARTIS	325MG;50MG;40MG;30MG	N20232 001	JUL 30, 1992	MAR	CFTG

PHRENILIN WITH CAFFEINE AND CODEINE

AB	AMARIN PHARMS	325MG;50MG;40MG;30MG	N74911 001	AUG 22, 2001	AUG	NEWA

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

	+ MIKART	356.4MG;30MG;16MG	N40109 001	AUG 26, 1997	OCT	CRLD

DHC PLUS

	@ PURDUE FREDERICK	356.4MG;30MG;16MG	N88584 001	MAR 04, 1986	OCT	DISC

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

	+ MIKART	712.8MG;60MG;32MG	N40316 001	APR 28, 1999	JAN	CTNA

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	MALLINCKRODT	300MG;15MG	N40419 001	MAY 31, 2001	MAY	NEWA
AA		300MG;30MG	N40419 002	MAY 31, 2001	MAY	NEWA
AA		300MG;60MG	N40419 003	MAY 31, 2001	MAY	NEWA

CAPITAL WITH CODEINE

	@ CARNRICK	325MG;30MG	N83643 001	MAY 31, 1974	FEB	WDRP

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	MALLINCKRODT	500MG/15ML;7.5MG/15ML	N40418 001	JUN 27, 2001	JUN	NEWA

AA	+ MIKART	500MG/15ML;7.5MG/15ML	N81051 001	AUG 28, 1992	JUN	CDFR
		500MG/15ML;5MG/15ML	N81226 001	OCT 27, 1992	JUN	CDFR
	+	500MG/15ML;5MG/15ML	N89557 001	APR 29, 1992	JUN	CDFR
AA	PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001	MAR 13, 1998	JUN	CDFR
	TABLET; ORAL					
	+ ENDO PHARMS	400MG;5MG	N40288 001	NOV 27, 1998	SEP	CTEC
	+	400MG;7.5MG	N40288 002	NOV 27, 1998	SEP	CTEC
	+	400MG;10MG	N40288 003	NOV 27, 1998	SEP	CTEC
	+ WATSON LABS	325MG;7.5MG	N40248 001	APR 28, 2000	JUL	DISC
	@	325MG;7.5MG	N40248 001	APR 28, 2000	AUG	DISC
	+	750MG;10MG	N40094 004	MAR 22, 1999	APR	NEWA
	LORTAB					
AA	+ WATSON LABS	325MG;5MG	N40099 001	JUN 25, 1997	JAN	CAHN
	NORCO					
AA	WATSON LABS	325MG;7.5MG	N40148 003	SEP 12, 2000	APR	NEWA
AA	+	325MG;7.5MG	N40148 003	SEP 12, 2000	JUL	CRLD
	ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE					
	TABLET; ORAL					
	PERCOCET					
>A>	+ ENDO PHARMS	325MG;7.5MG	N40434 001	NOV 23, 2001	NOV	NEWA
>A>	+	325MG;10MG	N40434 002	NOV 23, 2001	NOV	NEWA
	ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE					
	TABLET; ORAL					
	PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN					
AB	ABLE	650MG;100MG	N75838 001	JUL 11, 2001	JUL	NEWA
	@ HALSEY	325MG;50MG	N70115 001	JUN 12, 1985	MAY	DISC
	@	650MG;100MG	N70116 001	JUN 12, 1985	MAY	DISC
AB	MALLINCKRODT	650MG;100MG	N75738 001	FEB 02, 2001	FEB	NEWA
AB	VINTAGE PHARMS	325MG;50MG	N74843 002	FEB 15, 2001	FEB	NEWA
	ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE					
	TABLET; ORAL					
	ULTRACET					
	+ JOHNSON RW	325MG;37.5MG	N21123 001	AUG 15, 2001	AUG	NEWA
	ACYCLOVIR SODIUM					
	INJECTABLE; INJECTION					
	ACYCLOVIR					
AP	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75627 001	MAR 28, 2001	MAR	NEWA
	ACYCLOVIR SODIUM					
AP	AM PHARM PARTNERS	EQ 500MG BASE/VIAL	N75015 001	APR 30, 1998	OCT	CAHN
	ALBUTEROL					
	AEROSOL, METERED; INHALATION					
	ALBUTEROL					
AB	ARMSTRONG PHARMS	0.09MG/INH	N72273 001	AUG 14, 1996	JUN	CAHN
AB	GENPHARM	0.09MG/INH	N73045 001	AUG 19, 1997	OCT	CAHN

	ALBUTEROL SULFATE						
	AEROSOL, METERED; INHALATION						
	VENTOLIN HFA						
	+ GLAXO	EQ 0.09MG BASE/INH	N20983	001	APR 19, 2001	APR	NEWA
	CAPSULE; INHALATION						
	VENTOLIN ROTACAPS						
	@ GLAXO WELLCOME	EQ 0.2MG BASE	N19489	001	MAY 04, 1988	JUL	DISC
	SOLUTION; INHALATION						
	ACCUNEB						
	+ DEY	EQ 0.021% BASE	N20949	002	APR 30, 2001	APR	NEWA
	+	EQ 0.042% BASE	N20949	001	APR 30, 2001	APR	NEWA
	ALBUTEROL SULFATE						
AN	NEPHRON	EQ 0.5% BASE	N75664	001	JUN 26, 2001	JUN	NEWA
AN	ROXANE	EQ 0.083% BASE	N75129	001	FEB 13, 2001	FEB	NEWA
	VENTOLIN						
	@ GLAXO WELLCOME	EQ 0.083% BASE	N19773	001	APR 23, 1992	JUL	DISC
	@	EQ 0.5% BASE	N19269	002	JAN 16, 1987	JUL	DISC
	TABLET; ORAL						
	@ GLAXO WELLCOME	EQ 2MG BASE	N19112	001	JUL 10, 1986	JUN	DISC
	@	EQ 4MG BASE	N19112	002	JUL 10, 1986	JUN	DISC
	ALBUTEROL SULFATE; IPRATROPIUM BROMIDE						
	SOLUTION; INHALATION						
	DUONEB						
	+ DEY	EQ 0.083% BASE;0.017%	N20950	001	MAR 21, 2001	MAR	NEWA
	ALLOPURINOL						
	TABLET; ORAL						
	ZYLOPRIM						
AB	PROMETHEUS LABS	100MG	N16084	001	AUG 19, 1966	MAY	CAHN
AB	+	300MG	N16084	002	JAN 14, 1974	MAY	CAHN
	ALMOTRIPTAN MALATE						
	TABLET; ORAL						
	AXERT						
	PHARMACIA AND UPJOHN	EQ 6.25MG BASE	N21001	001	MAY 07, 2001	MAY	NEWA
	+	EQ 12.5MG BASE	N21001	002	MAY 07, 2001	MAY	NEWA
	ALPRAZOLAM						
	SOLUTION; ORAL						
	ALPRAZOLAM						
	@ ROXANE	0.5MG/5ML	N74314	001	OCT 31, 1993	SEP	DISC
	AMIKACIN SULFATE						
	INJECTABLE; INJECTION						
	AMIKACIN SULFATE						
	@ ABBOTT	EQ 250MG BASE/ML	N63265	001	NOV 30, 1994	APR	DISC
	@	EQ 250MG BASE/ML	N63266	001	OCT 31, 1994	APR	DISC
	@	EQ 250MG BASE/ML	N64099	001	JUN 20, 1995	MAY	DISC
	@ ELKINS SINN	EQ 250MG BASE/ML	N63275	001	MAY 18, 1992	APR	DISC

AMINOCAPROIC ACID							
TABLET; ORAL							
AMICAR							
AB + IMMUNEX	500MG	N15197 001	JUN 03, 1964	MAY	CFTG		
AMINOCAPROIC							
AB MIKART	500MG	N75602 001	MAY 24, 2001	MAY	NEWA		
AMIODARONE HYDROCHLORIDE							
TABLET; ORAL							
AMIODARONE HCL							
AB BARR	200MG	N75389 001	JAN 25, 2001	JAN	NEWA		
AB TARO	200MG	N75424 001	MAR 30, 2001	MAR	NEWA		
AMITRIPTYLINE HYDROCHLORIDE							
TABLET; ORAL							
AMITRIPTYLINE HCL							
@ TEVA	75MG	N85030 001	NOV 22, 1976	JUL	DISC		
AMLEXANOX							
PASTE; DENTAL							
APHTHASOL							
+ GLAXOSMITHKLINE CONS	5%	N20511 001	DEC 17, 1996	SEP	CAHN		
AMOXICILLIN							
CAPSULE; ORAL							
AMOXICILLIN							
@ LABS ATRAL	250MG	N62528 001	AUG 07, 1985	FEB	WDRP		
@	500MG	N62528 002	AUG 07, 1985	FEB	WDRP		
@ MYLAN	250MG	N62067 001	AUG 14, 1980	APR	DISC		
@	500MG	N62067 002	AUG 14, 1980	APR	DISC		
@ TEVA	250MG	N63030 001	FEB 28, 1989	APR	DISC		
@	500MG	N63031 001	FEB 28, 1989	APR	DISC		
TRIMOX							
@ APOTHECON	250MG	N63099 001	MAR 20, 1992	APR	DISC		
@	500MG	N63099 002	MAR 20, 1992	APR	DISC		
WYMOX							
@ WYETH AYERST	250MG	N62120 001	APR 28, 1978	APR	DISC		
@	500MG	N62120 002	APR 28, 1978	APR	DISC		
FOR SUSPENSION; ORAL							
TRIMOX							
@ APOTHECON	50MG/ML	N61886 001	DEC 09, 1974	MAY	DISC		
@	125MG/5ML	N61886 002	DEC 09, 1974	MAY	DISC		
@	250MG/5ML	N61886 003	DEC 09, 1974	MAY	DISC		
AMOXICILLIN; CLAVULANATE POTASSIUM							
FOR SUSPENSION; ORAL							
AUGMENTIN ES-600							
+ GLAXOSMITHKLINE	600MG/5ML;EQ 42.9MG BASE/5ML	N50755 001	JUN 22, 2001	JUN	NEWA		

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE						
CAPSULE, EXTENDED RELEASE; ORAL						
ADDERALL XR 10						
SHIRE LABS	2.5MG;2.5MG;2.5MG;2.5MG	N21303 001	OCT 11, 2001	OCT	NEWA	
ADDERALL XR 20						
SHIRE LABS	5MG;5MG;5MG;5MG	N21303 002	OCT 11, 2001	OCT	NEWA	
ADDERALL XR 30						
+ SHIRE LABS	7.5MG;7.5MG;7.5MG;7.5MG	N21303 003	OCT 11, 2001	OCT	NEWA	
TABLET; ORAL						
ADDERALL 7.5						
SHIRE LABS	1.875MG;1.875MG;1.875MG;1.875MG	N11522 011	AUG 31, 2000	APR	CRLD	
AMPHOTERICIN B						
INJECTABLE; INJECTION						
AMPHOTERICIN B						
@ ABBOTT	50MG/VIAL	N64141 001	DEC 23, 1996	MAY	DISC	
INJECTABLE, LIPID COMPLEX; INJECTION						
AMPHOTEC						
+ INTERMUNE PHARMS	50MG/VIAL	N50729 001	NOV 22, 1996	FEB	CAHN	
+	100MG/VIAL	N50729 002	NOV 22, 1996	FEB	CAHN	
AMPICILLIN SODIUM						
INJECTABLE; INJECTION						
AMPICILLIN SODIUM						
@ ELKINS SINN	EQ 125MG BASE/VIAL	N62692 001	JUN 24, 1986	MAY	DISC	
@	EQ 250MG BASE/VIAL	N62692 002	JUN 24, 1986	MAY	DISC	
@	EQ 500MG BASE/VIAL	N62692 003	JUN 24, 1986	MAY	DISC	
@	EQ 1GM BASE/VIAL	N62692 004	JUN 24, 1986	MAY	DISC	
@	EQ 2GM BASE/VIAL	N62692 005	JUN 24, 1986	MAY	DISC	
@	EQ 10GM BASE/VIAL	N62692 006	JUN 24, 1986	MAY	DISC	
@ HANFORD GC	EQ 125MG BASE/VIAL	N63143 001	APR 15, 1993	APR	DISC	
@	EQ 250MG BASE/VIAL	N63145 001	APR 15, 1993	APR	DISC	
@	EQ 500MG BASE/VIAL	N63146 001	APR 15, 1993	APR	DISC	
@	EQ 500MG BASE/VIAL	N63147 001	APR 15, 1993	APR	DISC	
@	EQ 1GM BASE/VIAL	N62772 001	APR 15, 1993	MAY	DISC	
@	EQ 1GM BASE/VIAL	N63139 001	APR 15, 1993	APR	DISC	
@	EQ 2GM BASE/VIAL	N63140 001	APR 15, 1993	APR	DISC	
@	EQ 2GM BASE/VIAL	N63141 001	APR 15, 1993	APR	DISC	
@	EQ 10GM BASE/VIAL	N63142 001	APR 15, 1993	APR	DISC	
@ IBI	EQ 125MG BASE/VIAL	N62797 001	JUL 12, 1993	MAY	DISC	
@	EQ 2GM BASE/VIAL	N62797 002	JUL 12, 1993	MAY	DISC	
@ MARSAM	EQ 10GM BASE/VIAL	N62994 001	SEP 15, 1988	JUL	DISC	
OMNIPEN-N						
@ WYETH AYERST	EQ 125MG BASE/VIAL	N62718 001	DEC 16, 1986	MAY	DISC	
@	EQ 250MG BASE/VIAL	N62718 002	DEC 16, 1986	MAY	DISC	
@	EQ 500MG BASE/VIAL	N62718 003	DEC 16, 1986	MAY	DISC	
@	EQ 1GM BASE/VIAL	N62718 004	DEC 16, 1986	MAY	DISC	
@	EQ 2GM BASE/VIAL	N62718 005	DEC 16, 1986	MAY	DISC	
TOTACILLIN-N						
SMITHKLINE BEECHAM	EQ 10GM BASE/VIAL	N60677 006	MAY 04, 1976	JUL	CTEC	

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE

@ BIOCHEMIE	EQ 250MG BASE	N64082 001	AUG 29, 1995	MAY	DISC
@	EQ 500MG BASE	N64082 002	AUG 29, 1995	MAY	DISC

FOR SUSPENSION; ORAL

@ MYLAN	EQ 125MG BASE/5ML	N61829 002	JUL 29, 1974	MAY	DISC
@	EQ 250MG BASE/5ML	N61829 001	JUL 29, 1974	MAY	DISC

TOTACILLIN

@ SMITHKLINE BEECHAM	EQ 125MG BASE/5ML	N60666 001	MAY 07, 1970	FEB	WDRP
@	EQ 250MG BASE/5ML	N60666 002	MAY 07, 1970	FEB	WDRP

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION; ORAL

PROBAMPACIN

@ TEVA	EQ 3.5GM BASE/BOT;1GM/BOT	N61741 001	OCT 10, 1973	MAY	DISC

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA

@ GENSIA AUTOMEDICS	0.05MG/ML	N20420 001	SEP 12, 1997	MAR	DISC

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO

@ PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	JUL	CAHN
@	10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	JUL	CAHN
@ WYETH AYERST	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	MAY	DISC
@	10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	MAY	DISC

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+ SABEX	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265 001	FEB 21, 2001	FEB	NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION; IV (INFUSION)

M.V.I. PEDIATRIC

+ ASTRAZENECA	80MG/VIAL;0.02MG/VIAL;0.00 1MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/V				

		IAL	N18920 001	SEP 21, 2000	FEB	NEWA
	+ NEOSAN PHARMS	80MG/VIAL;0.02MG/VIAL;0.00 1MG/VIAL;5MG/VIAL;0.01MG/V IAL;0.14MG/VIAL;17MG/VIAL; 0.2MG/VIAL;1MG/VIAL;1.4MG/ VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/V IAL	N18920 001	SEP 21, 2000	OCT	CAHN

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12

AP	+ NEOSAN PHARMS	10MG/ML;0.006MG/ML;0.5UGM/ ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4 MG/ML;0.36MG/ML;0.3MG/ML;3 30 UNITS/ML;1 IU/ML	N08809 004	AUG 08, 1985	OCT	CAHN

MVC PLUS

	@ STERIS	10MG/ML;0.006MG/ML;0.5UGM/ ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4 MG/ML;0.36MG/ML;0.3MG/ML;3 30 UNITS/ML;1 IU/ML	N18439 002	AUG 08, 1985	SEP	DISC

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

LANORINAL

	@ LANNETT	325MG;50MG;40MG	N86986 002	OCT 18, 1985	JUL	DISC

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

>A>	AB	ANABOLIC	325MG;50MG;40MG;30MG	N75231 001	NOV 30, 2001	NOV	NEWA

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

>A>		+ WOMEN FIRST HLTHCARE	356.4MG;30MG;16MG	N11483 004	SEP 06, 1983	NOV	CAHN
>D>		+ WYETH AYERST	356.4MG;30MG;16MG	N11483 004	SEP 06, 1983	NOV	CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

INVAGESIC

	AB	GENEVA PHARMS TECH	385MG;30MG;25MG	N74817 001	NOV 27, 1996	JAN	CAHN

INVAGESIC FORTE

	AB	GENEVA PHARMS TECH	770MG;60MG;50MG	N74817 002	NOV 27, 1996	JAN	CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE COMPOUND 65

		@ EON	389MG;32.4MG;65MG	N80044 002	SEP 16, 1983	MAY	DISC

PROPOXYPHENE COMPOUND-65

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE
CAPSULE; ORAL
PROPOXYPHENE COMPOUND-65

			@ GENEVA PHARMS	389MG;32.4MG;65MG	N83101	002	JUN 24, 1985	MAY	DISC

ASPIRIN; MEPROBAMATE
TABLET; ORAL
EQUAGESIC

>A>	AB	+	WOMEN FIRST HLTHCARE	325MG;200MG	N11702	003	DEC 29, 1983	NOV	CAHN
>D>	AB	+	WYETH AYERST	325MG;200MG	N11702	003	DEC 29, 1983	NOV	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE
TABLET; ORAL
ROXIPRIN

			@ ROXANE	325MG;4.5MG;0.38MG	N87743	001	JUN 04, 1982	OCT	DISC

ATENOLOL
TABLET; ORAL
ATENOLOL

			@ GENPHARM	25MG	N74126	003	AUG 26, 1998	JUL	DISC
			@	50MG	N74126	001	MAR 23, 1994	JUL	DISC
			@	100MG	N74126	002	MAR 23, 1994	JUL	DISC

ATORVASTATIN CALCIUM
TABLET; ORAL
LIPITOR

			PFIZER	EQ 10MG BASE	N20702	001	DEC 17, 1996	MAR	CAHN
				EQ 20MG BASE	N20702	002	DEC 17, 1996	MAR	CAHN
				EQ 40MG BASE	N20702	003	DEC 17, 1996	MAR	CAHN
		+		EQ 80MG BASE	N20702	004	APR 07, 2000	MAR	CAHN

ATROPINE SULFATE
INJECTABLE; IM-IV-SC
ATROPINE SULFATE ANSYR PLASTIC SYRINGE

			ABBOTT	0.05MG/ML	N21146	002	JUL 09, 2001	JUL	NEWA
		+		0.1MG/ML	N21146	001	JUL 09, 2001	JUL	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE
TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE

			@ INWOOD LABS	0.025MG;2.5MG	N85509	001	MAR 09, 1978	FEB	WDRP
	AA		LANNETT	0.025MG;2.5MG	N85372	001	FEB 21, 1978	AUG	CMFD
			@ R AND S PHARMA	0.025MG;2.5MG	N85035	001	JUL 05, 1977	MAY	DISC
			@ WEST WARD	0.025MG;2.5MG	N87765	001	MAR 15, 1982	JUL	DISC

DIPHENOXYLATE HCL W/ ATROPINE SULFATE

	AA		EON	0.025MG;2.5MG	N86173	001	AUG 28, 1981	AUG	CMFD
			@ PVT FORM	0.025MG;2.5MG	N85766	001	DEC 22, 1978	MAY	DISC

AURANOFIN
CAPSULE; ORAL
RIDAURA

		+	PROMETHEUS LABS	3MG	N18689	001	MAY 24, 1985	MAY	CAHN

AZATHIOPRINE
TABLET; ORAL
IMURAN
@ PROMETHEUS LABS 25MG N16324 002 MAR 21, 1980 MAY CAHN
AB + 50MG N16324 001 MAR 20, 1968 MAY CAHN

AZELASTINE HYDROCHLORIDE
SPRAY, METERED; NASAL
ASTELIN
+ WALLACE PHARMS EQ 0.125MG BASE/SPRAY N20114 001 NOV 01, 1996 OCT CAHN

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE
FOR SUSPENSION; TABLET; ORAL
TROVAN/ZITHROMAX COMPLIANCE PAK
@ PFIZER EQ 1GM BASE;EQ 100MG BASE N50762 001 DEC 18, 1998 MAY DISC

BACITRACIN ZINC
POWDER; FOR RX COMPOUNDING
ZIBA-RX
@ PHARMA TEK 500,000 UNITS/BOT N61737 001 APR 26, 1973 MAY DISC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
OINTMENT; OPHTHALMIC
NEO-POLYCIN
@ DOW PHARM 500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM N60647 001 APR 19, 1954 FEB WDRP

BENDROFLUMETHIAZIDE; NADOLOL
TABLET; ORAL
CORZIDE
KING PHARMS 5MG;40MG N18647 001 MAY 25, 1983 AUG CAHN
+ 5MG;80MG N18647 002 MAY 25, 1983 AUG CAHN

BENZQUINAMIDE HYDROCHLORIDE
INJECTABLE; INJECTION
EMETE-CON
+ PFIZER EQ 50MG BASE/VIAL N16820 001 MAR 20, 1974 MAY CAHN

BETAMETHASONE DIPROPIONATE
CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE
@ CLAY PARK EQ 0.05% BASE N74579 001 NOV 26, 1997 APR DISC
DISC; TOPICAL
DIPROSONE
@ SCHERING EQ 0.1% BASE N17829 001 MAY 24, 1977 AUG DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE
CREAM; TOPICAL
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE
AB ALTANA EQ 0.05% BASE;1% N75502 001 JUN 05, 2001 JUN NEWA
AB TARO EQ 0.05% BASE;1% N75673 001 MAY 29, 2001 MAY NEWA
LOTRISONE

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE							
CREAM; TOPICAL							
LOTRISONE							
AB	+ SCHERING	EQ 0.05% BASE;1%	N18827 001	JUL 10, 1984	MAY	CFTG	
BETAXOLOL HYDROCHLORIDE							
SOLUTION/DROPS; OPHTHALMIC							
BETAXOLOL HCL							
AT	BAUSCH AND LOMB	EQ 0.5% BASE	N75630 001	APR 12, 2001	APR	NEWA	
BETHANECHOL CHLORIDE							
INJECTABLE; INJECTION							
URECHOLINE							
@ SIDMAK LABS	5MG/ML	N06536 001	OCT 12, 1948	AUG	CAHN		
TABLET; ORAL							
DUVOID							
@ WELLSPRING PHARM	10MG	N86262 001	MAR 22, 1978	JUN	CAHN		
@	25MG	N86263 001	MAR 22, 1978	JUN	CAHN		
@	50MG	N85882 003	MAR 22, 1978	JUN	CAHN		
URECHOLINE							
@ SIDMAK LABS	5MG	N06536 003	FEB 03, 1949	AUG	CAHN		
@	10MG	N06536 002	OCT 12, 1948	AUG	CAHN		
@	25MG	N06536 004	OCT 12, 1948	AUG	CAHN		
@	50MG	N06536 005	JUN 24, 1980	AUG	CAHN		
BIMATOPROST							
SOLUTION/DROPS; OPHTHALMIC							
LUMIGAN							
+ ALLERGAN	0.03%	N21275 001	MAR 16, 2001	MAR	NEWA		
BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE							
TABLET, CHEWABLE, TABLET, CAPSULE; ORAL							
HELIDAC							
+ PROMETHEUS LABS	262.4MG;250MG;500MG	N50719 001	AUG 15, 1996	MAY	DISC		
BISOPROLOL FUMARATE							
TABLET; ORAL							
BISOPROLOL FUMARATE							
AB	COPLEY PHARM	5MG	N75644 001	JUN 26, 2001	JUN	NEWA	
AB		10MG	N75644 002	JUN 26, 2001	JUN	NEWA	
BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE							
TABLET; ORAL							
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE							
@ APOTHECON	2.5MG;6.25MG	N75642 002	DEC 27, 2000	JUN	DISC		
@	5MG;6.25MG	N75642 001	DEC 27, 2000	JUN	DISC		
@	10MG;6.25MG	N75642 003	DEC 27, 2000	JUN	DISC		
AB	TEVA	2.5MG;6.25MG	N75686 001	JAN 19, 2001	JAN	NEWA	
AB		5MG;6.25MG	N75686 002	JAN 19, 2001	JAN	NEWA	
AB		10MG;6.25MG	N75686 003	JAN 19, 2001	JAN	NEWA	

		BLEOMYCIN SULFATE					
		INJECTABLE; INJECTION					
		BLEOMYCIN					
AP		BEDFORD	EQ 15 UNITS BASE/VIAL	N65042 002	OCT 17, 2001	OCT	NEWA
AP			EQ 30 UNITS BASE/VIAL	N65042 001	OCT 17, 2001	OCT	NEWA
>A>		BOSENTAN					
>A>		TABLET; ORAL					
>A>		TRACLEER					
>A>		ACTELION	62.5MG	N21290 001	NOV 20, 2001	NOV	NEWA
>A>	+		125MG	N21290 002	NOV 20, 2001	NOV	NEWA
		BRIMONIDINE TARTRATE					
		SOLUTION/DROPS; OPHTHALMIC					
		ALPHAGAN					
	@	ALLERGAN	0.5%	N20490 001	MAR 13, 1997	APR	DISC
		ALPHAGAN P					
	+	ALLERGAN	0.15%	N21262 001	MAR 16, 2001	MAR	NEWA
		BUDESONIDE					
		CAPSULE; ORAL					
		ENTOCORT EC					
	+	ASTRAZENECA	3MG	N21324 001	OCT 02, 2001	OCT	NEWA
		BUPIVACAINE HYDROCHLORIDE					
		INJECTABLE; SPINAL					
		MARCAINE					
AP	+	ABBOTT	0.75%	N18692 001	MAY 04, 1984	JUN	CAHN
		BUPRENORPHINE HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		BUPRENEX					
AP	+	RECKITT BENCKISER	EQ 0.3MG BASE/ML	N18401 001	DEC 29, 1981	JUL	CAHN
		BUPROPION HYDROCHLORIDE					
		TABLET, EXTENDED RELEASE; ORAL					
		WELLBUTRIN SR					
		GLAXO WELLCOME	50MG	N20358 001	OCT 04, 1996	APR	CTEC
			100MG	N20358 002	OCT 04, 1996	APR	CTEC
		BUSPIRONE HYDROCHLORIDE					
		TABLET; ORAL					
		BUSPAR					
AB		BRISTOL MYERS SQUIBB	5MG	N18731 001	SEP 29, 1986	MAR	CFTG
AB			10MG	N18731 002	SEP 29, 1986	MAR	CFTG
AB			15MG	N18731 003	APR 22, 1996	MAR	NEWA
AB	+		30MG	N18731 004	APR 22, 1996	JUN	CFTG
		BUSPIRONE HCL					
AB		DANBURY PHARMA	5MG	N74253 001	MAR 28, 2001	MAR	NEWA
AB			10MG	N74253 002	MAR 28, 2001	MAR	NEWA
AB		MYLAN	15MG	N75272 003	MAR 28, 2001	MAR	NEWA
AB		MYLAN TECHNOLOGIES	30MG	N76008 001	JUN 28, 2001	JUN	NEWA

AB	PAR PHARM	7.5MG	N75467 002	MAR 28, 2001	MAR	NEWA

BUTABARBITAL SODIUM
TABLET; ORAL
BUTISOL SODIUM

+	WALLACE LABS	15MG	N00793 002	JUN 05, 1939	MAY	CTEC

SODIUM BUTABARBITAL

@	LANNETT	15MG	N85849 001	AUG 21, 1978	MAY	DISC
@		30MG	N85866 001	JUL 20, 1978	MAY	DISC

BUTOCONAZOLE NITRATE
CREAM; VAGINAL
GYNAZOLE-1

+	KV PHARM	2%	N19881 001	FEB 07, 1997	SEP	CTNA

BUTORPHANOL TARTRATE
INJECTABLE; INJECTION
BUTORPHANOL TARTRATE

AP	APOTEX	2MG/ML	N75697 001	OCT 23, 2001	OCT	NEWA

BUTORPHANOL TARTRATE PRESERVATIVE FREE

AP	APOTEX	1MG/ML	N75695 001	OCT 23, 2001	OCT	NEWA
AP		2MG/ML	N75695 002	OCT 23, 2001	OCT	NEWA

SPRAY, METERED; NASAL
BUTORPHANOL TARTRATE

AB	MYLAN	1MG/SPRAY	N75759 001	AUG 08, 2001	AUG	NEWA

STADOL

AB	+ BRISTOL MYERS SQUIBB	1MG/SPRAY	N19890 001	DEC 12, 1991	AUG	CFTG

CALCITONIN, SALMON
INJECTABLE; INJECTION
CALCITONIN-SALMON

@	ASTRAZENECA	200 IU/ML	N73690 001	APR 14, 1995	JUN	DISC

CALCITRIOL
CAPSULE; ORAL
CALCITRIOL

AB	TEVA	0.25UGM	N75765 001	OCT 12, 2001	OCT	NEWA
AB		0.5UGM	N75765 002	OCT 12, 2001	OCT	NEWA

ROCALTROL

AB	ROCHE	0.25UGM	N18044 001	AUG 17, 1978	OCT	CFTG
AB +		0.5UGM	N18044 002	AUG 17, 1978	OCT	CFTG

CALCIUM ACETATE
CAPSULE; ORAL
PHOSLO

	BRAINTREE	EQ 84.5MG CALCIUM	N21160 001	APR 02, 2001	APR	NEWA
@		EQ 84.5MG CALCIUM	N21160 001	APR 02, 2001	AUG	DISC
+		EQ 169MG CALCIUM	N21160 002	APR 02, 2001	APR	NEWA
+ @		EQ 169MG CALCIUM	N21160 002	APR 02, 2001	AUG	DISC

PHOSLO GELCAPS

+	BRAINTREE	EQ 169MG CALCIUM	N21160 003	APR 02, 2001	AUG	NEWA

CAPTOPRIL
TABLET; ORAL
CAPTOPRIL

AB	GENEVA PHARMS TECH	12.5MG	N74481 001	FEB 13, 1996	JAN	CAHN
AB		25MG	N74481 002	FEB 13, 1996	JAN	CAHN
AB		50MG	N74481 003	FEB 13, 1996	JAN	CAHN
AB		100MG	N74481 004	FEB 13, 1996	JAN	CAHN

CARBACHOL
SOLUTION; INTRAOCULAR
CARBASTAT

AT	NOVARTIS	0.01%	N73677 001	APR 28, 1995	FEB	CAHN

CARBAMAZEPINE
TABLET, CHEWABLE; ORAL
CARBAMAZEPINE

AB	CARACO	100MG	N75712 001	JUL 05, 2001	JUL	NEWA

TABLET, EXTENDED RELEASE; ORAL
TEGRETOL-XR

	NOVARTIS	100MG	N20234 001	MAR 25, 1996	JUL	CRLD
		200MG	N20234 002	MAR 25, 1996	JUL	CRLD

CARBIDOPA; LEVODOPA
TABLET; ORAL
CARBIDOPA AND LEVODOPA

	@ SCS	10MG;100MG	N74080 001	MAR 25, 1994	FEB	WDRP
	@	25MG;100MG	N74080 002	MAR 25, 1994	FEB	WDRP
	@	25MG;250MG	N74080 003	MAR 25, 1994	FEB	WDRP

CARISOPRODOL
TABLET; ORAL
CARISOPRODOL

AA	ABLE	350MG	N40421 001	JUN 21, 2001	JUN	NEWA

CASPOFUNGIN ACETATE
INJECTABLE; IV (INFUSION)
CANCIDAS

+	MERCK RES	50MG/VIAL	N21227 001	JAN 26, 2001	JAN	NEWA
+		70MG/VIAL	N21227 002	JAN 26, 2001	JAN	NEWA

CEFACLOR
CAPSULE; ORAL
CECLOR

AB	CEPH INTL	EQ 250MG BASE	N62205 001	JUL 28, 1979	JUN	CAHN
AB		EQ 500MG BASE	N62205 002	JUL 28, 1979	JUN	CAHN

FOR SUSPENSION; ORAL
CEFACLOR

	@ ZENITH GOLDLINE	EQ 125MG BASE/5ML	N64087 001	APR 28, 1995	MAY	DISC
	@	EQ 187MG BASE/5ML	N64086 001	APR 28, 1995	MAY	DISC
	@	EQ 250MG BASE/5ML	N64085 001	APR 28, 1995	MAY	DISC

TABLET, EXTENDED RELEASE; ORAL
CECLOR CD

CEFACLOR
TABLET, EXTENDED RELEASE; ORAL
CECLOR CD
LILLY — EQ 375MG BASE — N50673 001 — JUN 28, 1996 — APR — CTEC
AB + — EQ 500MG BASE — N50673 002 — JUN 28, 1996 — JAN — CFTG
CEFACLOR
AB ZENITH GOLDLINE — EQ 500MG BASE — N65057 001 — JAN 05, 2001 — JAN — NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE
TABLET; ORAL
CEFADROXIL
@ ZENITH GOLDLINE — EQ 1GM BASE — N62774 001 — APR 08, 1987 — MAY — DISC

CEFAMANDOLE NAFATE
INJECTABLE; INJECTION
MANDOL
@ LILLY — EQ 1GM BASE/VIAL — N62560 001 — SEP 10, 1985 — MAY — DISC
@ — EQ 2GM BASE/VIAL — N62560 002 — SEP 10, 1985 — MAY — DISC

CEFAZOLIN SODIUM
INJECTABLE; INJECTION
CEFAZOLIN SODIUM
AP HIKMA — EQ 500MG BASE/VIAL — N65047 001 — SEP 18, 2001 — SEP — NEWA
AP — EQ 1GM BASE/VIAL — N65047 002 — SEP 18, 2001 — SEP — NEWA
@ TEVA — EQ 250MG BASE/VIAL — N63016 001 — MAR 14, 1989 — APR — DISC
@ — EQ 500MG BASE/VIAL — N63016 002 — MAR 14, 1989 — APR — DISC
@ — EQ 1GM BASE/VIAL — N63016 003 — MAR 14, 1989 — APR — DISC
KEFZOL
@ LILLY — EQ 500MG BASE/VIAL — N62557 001 — SEP 10, 1985 — MAY — DISC
@ — EQ 1GM BASE/VIAL — N62557 002 — SEP 10, 1985 — MAY — DISC

CEFDITOREN PIVOXIL
TABLET; ORAL
SPECTRACEF
+ TAP PHARM — 200MG — N21222 001 — AUG 29, 2001 — AUG — NEWA

CEFONICID SODIUM
INJECTABLE; INJECTION
MONOCID
+ @ SMITHKLINE BEECHAM — EQ 500MG BASE/VIAL — N50579 001 — MAY 23, 1984 — AUG — DISC
+ @ — EQ 1GM BASE/VIAL — N50579 002 — MAY 23, 1984 — AUG — DISC
@ — EQ 1GM BASE/VIAL — N63295 001 — JUL 26, 1993 — APR — DISC
@ — EQ 10GM BASE/VIAL — N50579 004 — MAY 23, 1984 — AUG — DISC

CEFOPERAZONE SODIUM
INJECTABLE; INJECTION
CEFOBID
@ PFIZER — EQ 1GM BASE/VIAL — N63333 001 — MAR 31, 1995 — MAY — DISC
@ — EQ 2GM BASE/VIAL — N63333 002 — MAR 31, 1995 — MAY — DISC

CEFORANIDE

INJECTABLE; INJECTION

PRECEF

@	APOTHECON	500MG/VIAL	N62579 001	NOV 26, 1984	MAY	DISC
@		1GM/VIAL	N62579 002	NOV 26, 1984	MAY	DISC
@		2GM/VIAL	N62579 003	NOV 26, 1984	MAY	DISC
@		10GM/VIAL	N62579 004	NOV 26, 1984	MAY	DISC
@		20GM/VIAL	N62579 005	NOV 26, 1984	MAY	DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@	MERCK	EQ 20MG BASE/ML	N50581 003	SEP 20, 1984	JUL	DISC
@		EQ 40MG BASE/ML	N50581 004	SEP 20, 1984	JUL	DISC

CEFTAZIDIME

INJECTABLE; INJECTION

TAZICEF

AP	ABBOTT	500MG/VIAL	N62662 001	MAR 06, 1986	JAN	CAHN
AP		1GM/VIAL	N62662 002	MAR 06, 1986	JAN	CAHN
AP		1GM/VIAL	N64032 001	OCT 31, 1993	JAN	CAHN
AP		2GM/VIAL	N62662 003	MAR 06, 1986	JAN	CAHN
AP		2GM/VIAL	N64032 002	OCT 31, 1993	JAN	CAHN
AP		6GM/VIAL	N62662 004	MAR 06, 1986	JAN	CAHN

TAZIDIME IN PLASTIC CONTAINER

@	LILLY	1GM/VIAL	N62739 001	JUL 10, 1986	MAY	DISC
@		2GM/VIAL	N62739 002	JUL 10, 1986	MAY	DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME

AB	AM PHARM PARTNERS	EQ 750MG BASE/VIAL	N65001 001	MAY 30, 2001	MAY	NEWA
AB	TEVA	EQ 750MG BASE/VIAL	N64192 002	APR 16, 1998	MAY	CDFR

CEFUROXIME SODIUM

AB	HANFORD GC	EQ 750MG BASE/VIAL	N64125 001	MAY 30, 1997	MAY	CDFR

KEFUROX

AB	LILLY	EQ 750MG BASE/VIAL	N62591 001	JAN 10, 1986	MAY	CDFR

ZINACEF

AB	+ GLAXO WELLCOME	EQ 750MG BASE/VIAL	N50558 002	OCT 19, 1983	MAY	CDFR

INJECTABLE; INJECTION

CEFUROXIME

AP	AM PHARM PARTNERS	EQ 1.5GM BASE/VIAL	N65001 002	MAY 30, 2001	MAY	NEWA

CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER

+	B BRAUN	EQ 15MG BASE/ML	N50780 001	FEB 21, 2001	FEB	NEWA
+		EQ 30MG BASE/ML	N50780 002	FEB 21, 2001	FEB	NEWA

KEFUROX IN PLASTIC CONTAINER

@	LILLY	EQ 1.5GM BASE/VIAL	N62590 002	JAN 10, 1986	MAY	DISC

INJECTABLE; INTRAVENOUS

@	LILLY	EQ 750MG BASE/VIAL	N62590 001	JAN 10, 1986	MAY	DISC

CEPHALEXIN
CAPSULE; ORAL
CEPHALEXIN
@ STEVENS J — EQ 500MG BASE — N62869 001 — MAR 17, 1988 — JUL — DISC
@ TEVA — EQ 500MG BASE — N62823 001 — FEB 05, 1988 — MAY — DISC
KEFLEX
AB CEPH INTL — EQ 250MG BASE — N62118 001 — MAR 27, 1978 — JUN — CAHN
AB — EQ 500MG BASE — N62118 002 — MAR 27, 1978 — JUN — CAHN
FOR SUSPENSION; ORAL
CEPHALEXIN
@ BARR — EQ 125MG BASE/5ML — N62778 001 — AUG 06, 1987 — MAY — DISC
AB RANBAXY — EQ 125MG BASE/5ML — N65081 001 — JUL 27, 2001 — JUL — NEWA
AB — EQ 250MG BASE/5ML — N65081 002 — JUL 27, 2001 — JUL — NEWA
KEFLEX
+ CEPH INTL — EQ 100MG BASE/ML — N62117 001 — MAR 27, 1978 — JUN — CAHN
AB — EQ 125MG BASE/5ML — N62117 002 — MAR 27, 1978 — JUN — CAHN
AB + — EQ 250MG BASE/5ML — N62117 003 — MAR 27, 1978 — JUN — CAHN
TABLET; ORAL
KEFLET
@ LILLY — EQ 250MG BASE — N62745 001 — DEC 01, 1986 — JUL — DISC
@ — EQ 500MG BASE — N62745 002 — DEC 01, 1986 — JUL — DISC

CEPHALOTHIN SODIUM
INJECTABLE; INJECTION
KEFLIN IN PLASTIC CONTAINER
@ LILLY — EQ 1GM BASE/VIAL — N62549 001 — SEP 10, 1985 — APR — DISC
@ — EQ 2GM BASE/VIAL — N62549 002 — SEP 10, 1985 — APR — DISC

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
ZYRTEC-D 12 HOUR
+ PFIZER — 5MG;120MG — N21150 001 — AUG 10, 2001 — AUG — NEWA

CEVIMELINE HYDROCHLORIDE
CAPSULE; ORAL
EVOXAC
>A> + DAIICHI — EQ 30MG BASE — N20989 002 — JAN 11, 2000 — NOV — CAHN
>D> + SNOWBRAND — EQ 30MG BASE — N20989 002 — JAN 11, 2000 — NOV — CAHN

CHLORAMPHENICOL
CAPSULE; ORAL
CHLORAMPHENICOL
@ ZENITH GOLDLINE — 250MG — N62247 001 — APR 28, 1980 — MAY — DISC
CHLOROMYCETIN
@ PARKEDALE — 50MG — N60591 001 — DEC 08, 1950 — MAY — DISC
@ — 100MG — N60591 003 — DEC 08, 1950 — MAY — DISC
@ — 250MG — N60591 002 — DEC 08, 1950 — MAY — DISC
MYCHEL
+ ARMENPHARM — 250MG — N60851 001 — JUN 20, 1967 — MAY — CRLD
SOLUTION/DROPS; OPHTHALMIC
CHLORAMPHENICOL
@ AKORN — 0.5% — N62042 001 — AUG 31, 1981 — FEB — WDRP

@ ALCON	0.5%	N62628 001	SEP 25, 1985	MAY	DISC	
CHLOROPTIC						
+ ALLERGAN	0.5%	N50091 001	MAR 20, 1968	MAY	CTEC	

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZACHEL					
@ RACHELLE	5MG	N85086 001	MAY 11, 1976	FEB	WDRP
@	10MG	N84639 001	MAY 11, 1976	FEB	WDRP
@	25MG	N85087 001	MAY 11, 1976	FEB	WDRP
CHLORDIAZEPOXIDE HCL					
@ FERRANTE	5MG	N85118 001	SEP 02, 1981	FEB	WDRP
@	10MG	N85119 001	SEP 02, 1976	FEB	WDRP
@	25MG	N85120 001	SEP 02, 1976	FEB	WDRP
@ GENEVA PHARMS	5MG	N84678 001	JUN 15, 1976	JUL	DISC
@	10MG	N84041 001	JUN 15, 1976	MAY	DISC
@	25MG	N84679 002	SEP 07, 1976	MAY	DISC
@ IMPAX LABS	5MG	N86213 001	JUL 10, 1979	JUL	DISC
@	25MG	N86212 001	JUL 10, 1979	JUL	DISC
@ ROSEMONT	5MG	N84644 001	FEB 24, 1976	MAY	DISC
@	25MG	N84645 001	FEB 24, 1976	JUL	DISC

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE					
@ TEVA	EQ 150MG BASE	N87504 001	JAN 13, 1982	JUL	DISC

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE					
@ ABC HOLDING	250MG	N85569 001	MAR 08, 1978	MAY	DISC
@ CHELSEA LABS	250MG	N86795 001	AUG 15, 1983	JUL	DISC
@ DANBURY PHARMA	250MG	N85173 001	NOV 04, 1977	MAY	DISC

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

CHLORPHENIRAMINE MALEATE					
@ STERIS	10MG/ML	N86096 001	OCT 09, 1979	JUL	DISC

TABLET; ORAL

@ GENEVA PHARMS	4MG	N80961 001	DEC 20, 1972	MAY	DISC
AA + ICN	4MG	N80598 001	FEB 11, 1972	MAY	CRLD
@ PHARMAVITE	4MG	N85104 001	FEB 11, 1977	FEB	WDRP
@ WEST WARD	4MG	N83787 001	OCT 18, 1973	FEB	WDRP

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CHLORPHENIRAMINE MALEATE AND PHENYLPROPANOLAMINE HCL					
@ GENEVA PHARMS	12MG;75MG	N88940 001	JAN 26, 1989	SEP	DISC
DRIZE					
@ ASCHER	12MG;75MG	N88359 001	FEB 13, 1986	SEP	DISC
ORNADE					
@ SMITHKLINE BEECHAM	12MG;75MG	N12152 004	JAN 06, 1981	SEP	DISC

CHLORPROMAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
CHLORPROMAZINE HCL
@ STERIS — 25MG/ML — N80365 001 FEB 13, 1974 MAY DISC

CHLORTHALIDONE
TABLET; ORAL
CHLORTHALIDONE
@ GENEVA PHARMS — 25MG — N87380 001 MAY 01, 1981 JUL DISC

CHLORZOXAZONE
TABLET; ORAL
CHLORZOXAZONE
@ DANBURY PHARMA — 500MG — N81019 001 JUL 29, 1991 MAY DISC

CICLOPIROX
CREAM; TOPICAL
LOPROX
>D> + AVENTIS PHARMS — 0.77% — N18748 001 DEC 30, 1982 NOV CAHN
>A> + MEDICIS PHARM — 0.77% — N18748 001 DEC 30, 1982 NOV CAHN
GEL; TOPICAL
>D> + AVENTIS PHARMS — 0.77% — N20519 001 JUL 21, 1997 NOV CAHN
>A> + MEDICIS PHARM — 0.77% — N20519 001 JUL 21, 1997 NOV CAHN
LOTION; TOPICAL
>D> + AVENTIS PHARMS — 0.77% — N19824 001 DEC 30, 1988 NOV CAHN
>A> + MEDICIS PHARM — 0.77% — N19824 001 DEC 30, 1988 NOV CAHN

CIMETIDINE
TABLET; ORAL
CIMETIDINE
AB GENEVA PHARMS TECH — 200MG — N74506 001 JAN 24, 1996 JAN CAHN
AB — 300MG — N74506 002 JAN 24, 1996 JAN CAHN
AB — 400MG — N74506 003 JAN 24, 1996 JAN CAHN
AB — 800MG — N74506 004 JAN 24, 1996 JAN CAHN

CINOXACIN
CAPSULE; ORAL
CINOBAC
LILLY — 250MG — N18067 001 JUN 13, 1980 JUL CTEC
+ — 500MG — N18067 002 JUN 13, 1980 JUL CTEC
CINOXACIN
@ TEVA — 250MG — N73005 001 FEB 28, 1992 JUL DISC
@ — 500MG — N73006 001 FEB 28, 1992 JUL DISC

CLINDAMYCIN HYDROCHLORIDE
CAPSULE; ORAL
CLEOCIN HCL
AB + PHARMACIA AND UPJOHN — EQ 300MG BASE — N50162 003 APR 14, 1988 FEB CFTG
CLINDAMYCIN HCL
AB RANBAXY — EQ 150MG BASE — N65061 001 FEB 02, 2001 FEB NEWA
AB — EQ 300MG BASE — N65061 002 FEB 02, 2001 FEB NEWA

		CLINDAMYCIN PHOSPHATE						
		GEL; TOPICAL						
		CLINDAMYCIN PHOSPHATE						
MAY	DISC	BT GALDERMA LABS LP	EQ 1% BASE	N50782 001	NOV 27, 2000	SEP	CAHN	
		INJECTABLE; INJECTION						
		CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
		AP + PHARMACIA AND UPJOHN	EQ 18MG BASE/ML	N50639 003	APR 10, 1991	JUN	CFTG	
		CLINDAMYCIN PHOSPHATE						
JUL	DISC	@ ABBOTT	EQ 150MG BASE/ML	N62943 001	SEP 29, 1988	MAY	DISC	
		@ ELKINS SINN	EQ 150MG BASE/ML	N62806 001	OCT 15, 1987	MAY	DISC	
		@	EQ 150MG BASE/ML	N62953 001	APR 21, 1988	MAY	DISC	
		@ GENSIA SICOR PHARMS	EQ 150MG BASE/ML	N63041 001	DEC 29, 1989	APR	DISC	
		@	EQ 150MG BASE/ML	N63282 001	MAY 29, 1992	APR	DISC	
MAY	DISC	@ LEDERLE	EQ 150MG BASE/ML	N63068 001	AUG 28, 1989	MAY	DISC	
		CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
		AP ABBOTT	EQ 6MG BASE/ML	N65027 001	JUN 29, 2001	JUN	NEWA	
		AP	EQ 12MG BASE/ML	N65027 002	JUN 29, 2001	JUN	NEWA	
		AP	EQ 18MG BASE/ML	N65027 003	JUN 29, 2001	JUN	NEWA	
NOV	CAHN	SOLUTION; TOPICAL						
NOV	CAHN	CLINDAMYCIN PHOSPHATE						
		@ COPLEY PHARM	EQ 1% BASE	N62944 001	JAN 11, 1989	MAY	DISC	
NOV	CAHN	@ TEVA	EQ 1% BASE	N62930 001	JUN 28, 1989	MAY	DISC	
NOV	CAHN							
		CLOBETASOL PROPIONATE						
NOV	CAHN	CREAM; TOPICAL						
NOV	CAHN	CLOBETASOL PROPIONATE						
		AB1 STIEFEL	0.05%	N75338 001	FEB 09, 2001	FEB	NEWA	
		AB2	0.05%	N75733 001	AUG 22, 2001	AUG	NEWA	
		CLOMIPRAMINE HYDROCHLORIDE						
JAN	CAHN	CAPSULE; ORAL						
JAN	CAHN	ANAFRANIL						
JAN	CAHN	AB TYCO HLTHCARE	25MG	N19906 001	DEC 29, 1989	JUN	CAHN	
JAN	CAHN	AB +	50MG	N19906 002	DEC 29, 1989	JUN	CAHN	
		AB	75MG	N19906 003	DEC 29, 1989	JUN	CAHN	
		CLONAZEPAM						
JUL	CTEC	TABLET; ORAL						
JUL	CTEC	CLONAZEPAM						
		AB CARACO	0.5MG	N75423 001	APR 27, 2001	APR	NEWA	
		AB	1MG	N75423 002	APR 27, 2001	APR	NEWA	
JUL	DISC	AB	2MG	N75423 003	APR 27, 2001	APR	NEWA	
JUL	DISC							
		CLONIDINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		DURACLON						
		+ ELAN PHARMS	0.1MG/ML	N20615 001	OCT 02, 1996	SEP	CAHN	
FEB	CFTG							
		CLORAZEPATE DIPOTASSIUM						
FEB	NEWA	CAPSULE; ORAL						
FEB	NEWA	CLORAZEPATE DIPOTASSIUM						
		@ ABLE	3.75MG	N71777 001	JUL 14, 1987	JAN	DISC	

		@	7.5MG	N71778 001	JUL 14, 1987	JAN	DISC	
		@	15MG	N71779 001	JUL 14, 1987	JAN	DISC	
		TABLET; ORAL						
		@ GENEVA PHARMS	3.75MG	N72512 001	MAY 11, 1990	JUL	DISC	>A>
		COLCHICINE; PROBENECID						
		TABLET; ORAL						
		PROBENECID AND COLCHICINE						
		@ IMPAX LABS	0.5MG;500MG	N83720 002	SEP 06, 1977	OCT	DISC	>A>
		CORTICOTROPIN						
		INJECTABLE; INJECTION						
		H.P. ACTHAR GEL						
BC	+	QUESTCOR PHARMS	40 UNITS/ML	N08372 006	FEB 06, 1956	AUG	CAHN	
BC	+		80 UNITS/ML	N08372 008	FEB 06, 1956	AUG	CAHN	
		CORTISONE ACETATE						
		TABLET; ORAL						
		CORTISONE ACETATE						
		@ CHELSEA LABS	25MG	N85884 001	MAY 15, 1978	MAY	DISC	
		CROMOLYN SODIUM						
		AEROSOL, METERED; INHALATION						
		INTAL						
	+	AVENTIS	0.8MG/INH	N18887 001	DEC 05, 1985	SEP	CAHN	
		SOLUTION/DROPS; OPHTHALMIC						
		CROMOLYN SODIUM						
AT		NOVEX	4%	N75615 001	JAN 26, 2001	JAN	NEWA	
		CYCLACILLIN						
		TABLET; ORAL						
		CYCLACILLIN						
		@ TEVA	250MG	N62895 001	AUG 04, 1988	MAY	DISC	
		@	500MG	N62895 002	AUG 04, 1988	MAY	DISC	>D> >A>
		CYPROHEPTADINE HYDROCHLORIDE						>D>
		TABLET; ORAL						>A>
		CYPROHEPTADINE HCL						
		@ GENEVA PHARMS	4MG	N86808 001	FEB 24, 1981	JUL	DISC	
		CYTARABINE						>D>
		INJECTABLE; INJECTION						>A>
		CYTARABINE						
>D>	AP	GENSIA SICOR PHARMS	500MG/VIAL	N75206 002	DEC 30, 1998	NOV	CRLD	>D>
>A>	AP +		500MG/VIAL	N75206 002	DEC 30, 1998	NOV	CRLD	>D> >A>
		DACARBAZINE						>A>
		INJECTABLE; INJECTION						
		DACARBAZINE						
	AP	BEDFORD	200MG/VIAL	N75812 001	JUN 15, 2001	JUN	NEWA	
	AP	FAULDING	200MG/VIAL	N75940 001	OCT 18, 2001	OCT	NEWA	

JAN DISC
JAN DISC

DAUNORUBICIN HYDROCHLORIDE
INJECTABLE; INJECTION
DAUNORUBICIN HCL

JUL DISC
>A> AP SUPERGEN — EQ 5MG BASE/VIAL — N65034 001 NOV 20, 2001 NOV NEWA

DEFEROXAMINE MESYLATE
INJECTABLE; INJECTION
DESFERAL

OCT DISC
>A> + NOVARTIS — 2MG/VIAL — N16267 002 MAY 25, 2000 NOV NEWA

DELAVIRDINE MESYLATE
TABLET; ORAL
RESCRIPTOR

AUG CAHN
AUG CAHN
AGOURON — 100MG — N20705 001 APR 04, 1997 AUG CRLD
+ — 200MG — N20705 002 JUL 14, 1999 AUG NEWA

DESERPIDINE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
ORETICYL 25

MAY DISC
@ ABBOTT — 0.125MG;25MG — N12148 001 DEC 14, 1959 MAR DISC
ORETICYL 50
@ ABBOTT — 0.125MG;50MG — N12148 003 DEC 14, 1959 MAR DISC
ORETICYL FORTE

SEP CAHN
@ ABBOTT — 0.25MG;25MG — N12148 002 DEC 14, 1959 MAR DISC

DESONIDE
OINTMENT; TOPICAL
DESONIDE

JAN NEWA
AB ALTANA — 0.05% — N75751 001 MAR 12, 2001 MAR NEWA

DESOXIMETASONE
CREAM; TOPICAL
TOPICORT

MAY DISC
MAY DISC
>D> AB + AVENTIS PHARMS — 0.25% — N17856 001 FEB 28, 1977 NOV CAHN
>A> AB + MEDICIS PHARM — 0.25% — N17856 001 FEB 28, 1977 NOV CAHN
TOPICORT LP
>D> AB + AVENTIS PHARMS — 0.05% — N18309 001 MAR 28, 1980 NOV CAHN
>A> AB + MEDICIS PHARM — 0.05% — N18309 001 MAR 28, 1980 NOV CAHN

JUL DISC
GEL; TOPICAL
TOPICORT
>D> AB + AVENTIS PHARMS — 0.05% — N18586 001 MAR 29, 1982 NOV CAHN
>A> AB + MEDICIS PHARM — 0.05% — N18586 001 MAR 29, 1982 NOV CAHN
OINTMENT; TOPICAL

NOV CRLD
>D> @ AVENTIS PHARMS — 0.05% — N18594 001 JAN 17, 1985 NOV CAHN
NOV CRLD
>D> AB + — 0.25% — N18763 001 SEP 30, 1983 NOV CAHN
>A> @ MEDICIS PHARM — 0.05% — N18594 001 JAN 17, 1985 NOV CAHN
>A> AB + — 0.25% — N18763 001 SEP 30, 1983 NOV CAHN

DEXAMETHASONE
TABLET; ORAL

JUN NEWA
OCT NEWA
DEXAMETHASONE
@ DANBURY PHARMA — 0.75MG — N80968 001 MAY 03, 1973 MAY DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

@	DELL LABS	EQ 4MG PHOSPHATE/ML	N83161 001	JUN 06, 1978	FEB	WDRP
@	GENSIA SICOR PHARMS	EQ 4MG PHOSPHATE/ML	N81125 001	AUG 31, 1990	MAY	DISC

OINTMENT; OPHTHALMIC

DECADRON

@	MERCK	EQ 0.05% PHOSPHATE	N11977 001	SEP 02, 1959	MAY	DISC

MAXIDEX

+	ALCON	EQ 0.05% PHOSPHATE	N83342 001	OCT 23, 1973	MAY	CTEC

SOLUTION/DROPS; OTIC

DEXAMETHASONE SODIUM PHOSPHATE

@	AKORN	EQ 0.1% PHOSPHATE	N84855 001	JUN 29, 1976	FEB	WDRP

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

SOLUTION/DROPS; OPHTHALMIC

NEODECADRON

+	MERCK	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N50322 001	JUL 06, 1959	MAY	CTEC

NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE

@	ALCON UNIVERSAL	EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML	N62714 001	JUL 21, 1986	MAY	DISC

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

DEXACIDIN

AT	NOVARTIS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566 001	FEB 22, 1985	FEB	CAHN
	@	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N62566 001	FEB 22, 1985	MAY	DISC

SUSPENSION/DROPS; OPHTHALMIC

AT	NOVARTIS	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62544 001	OCT 29, 1984	FEB	CAHN

>A> DEXMETHYLPHENIDATE HYDROCHLORIDE

>A> TABLET; ORAL

>A> FOCALIN

>A>	NOVARTIS	2.5MG	N21278 001	NOV 13, 2001	NOV	NEWA
>A>		5MG	N21278 002	NOV 13, 2001	NOV	NEWA
>A>	+	10MG	N21278 003	NOV 13, 2001	NOV	NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	BARR	5MG	N40361 001	JAN 31, 2001	JAN	NEWA	>A>
AA		10MG	N40361 002	JAN 31, 2001	JAN	NEWA	

DEXTROSTAT

AA	+ SHIRE RICHWOOD	10MG	N84051 002	MAY 29, 1975	JAN	CFTG

			DIAZEPAM					
			GEL; RECTAL					
			DIASTAT					
FEB	WDRP		+ XCEL PHARMS	2.5MG/0.5ML	N20648 001	JUL 29, 1997	JUL	CAHN
MAY	DISC			5MG/ML	N20648 002	JUL 29, 1997	JUL	CAHN
				10MG/2ML	N20648 003	JUL 29, 1997	JUL	CAHN
				15MG/3ML	N20648 004	JUL 29, 1997	JUL	CAHN
MAY	DISC		+	20MG/4ML	N20648 005	JUL 29, 1997	JUL	CAHN
MAY	CTEC		DICLOFENAC POTASSIUM					
			TABLET; ORAL					
			DICLOFENAC POTASSIUM					
FEB	WDRP	AB	EON	50MG	N75582 001	FEB 23, 2001	FEB	NEWA
			DICLOFENAC SODIUM					
			GEL; TOPICAL					
			SOLARAZE					
			+ BIOGLAN PHARMA PLC	3%	N21005 001	OCT 16, 2000	MAR	CAHN
MAY	CTEC		DICLOXACILLIN SODIUM					
			CAPSULE; ORAL					
MAY	DISC		DYCILL					
			@ SMITHKLINE BEECHAM	EQ 250MG BASE	N62238 001	DEC 31, 1979	APR	DISC
			@	EQ 500MG BASE	N62238 002	DEC 31, 1979	APR	DISC
			DICYCLOMINE HYDROCHLORIDE					
			CAPSULE; ORAL					
FEB	CAHN		DICYCLOMINE HCL					
			@ HALSEY	10MG	N84505 001	OCT 21, 1986	MAY	DISC
MAY	DISC		INJECTABLE; INJECTION					
			@ STERIS	10MG/ML	N80614 001	FEB 11, 1986	JUL	DISC
FEB	CAHN		DIETHYLPROPION HYDROCHLORIDE					
			TABLET, EXTENDED RELEASE; ORAL					
			TENUATE DOSPAN					
			+ AVENTIS PHARMS	75MG	N12546 001	NOV 07, 1960	JUL	CTEC
			TEPANIL TEN-TAB					
NOV	NEWA		@ 3M	75MG	N17956 001	MAY 25, 1977	JUL	DISC
NOV	NEWA		DILTIAZEM HYDROCHLORIDE					
NOV	NEWA		CAPSULE, EXTENDED RELEASE; ORAL					
			DILTIAZEM HCL					
		AB2	MYLAN	120MG	N75124 002	MAR 18, 1998	MAR	CTEC
			INJECTABLE; INJECTION					
JAN	NEWA	>A> AP	INTL MEDICATION	5MG/ML	N75749 001	NOV 21, 2001	NOV	NEWA
JAN	NEWA		DIPHENHYDRAMINE HYDROCHLORIDE					
JAN	CFTG		CAPSULE; ORAL					
			DIPHENHYDRAMINE HCL					
			@ CHELSEA LABS	50MG	N85083 001	JUN 29, 1976	MAY	DISC
			@ NEWTRON PHARMS	25MG	N86543 001	FEB 08, 1979	FEB	WDRP
			@	50MG	N86544 001	FEB 08, 1979	FEB	WDRP

DIPHENHYDRAMINE HYDROCHLORIDE
INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL PRESERVATIVE FREE

	@ AM PHARM PARTNERS	50MG/ML	N80586 002	JAN 10, 1973	JUL	DISC

DISULFIRAM
TABLET; ORAL
ANTABUSE

	ODYSSEY PHARMS	250MG	N88482 001	DEC 08, 1983	JAN	CAHN
+		500MG	N88483 001	DEC 08, 1983	JAN	CAHN
	@ SIDMAK LABS	250MG	N07883 003	NOV 03, 1970	MAR	CAHN
	@	500MG	N07883 002	JUN 01, 1953	MAR	CAHN

DOXAZOSIN MESYLATE
TABLET; ORAL
DOXAZOSIN MESYLATE

AB	SIDMAK LABS	EQ 1MG BASE	N75750 001	JUN 08, 2001	JUN	NEWA
AB		EQ 2MG BASE	N75750 002	JUN 08, 2001	JUN	NEWA
AB		EQ 4MG BASE	N75750 003	JUN 08, 2001	JUN	NEWA
AB		EQ 8MG BASE	N75750 004	JUN 08, 2001	JUN	NEWA
AB	TEVA	EQ 1MG BASE	N75353 001	JAN 12, 2001	JAN	NEWA
AB		EQ 2MG BASE	N75353 002	JAN 12, 2001	JAN	NEWA
AB		EQ 4MG BASE	N75353 003	JAN 12, 2001	JAN	NEWA
AB		EQ 8MG BASE	N75353 004	JAN 12, 2001	JAN	NEWA

DOXYCYCLINE
FOR SUSPENSION; ORAL
DOXYCHEL

	@ RACHELLE	EQ 25MG BASE/5ML	N61720 001	JUN 18, 1973	FEB	WDRP

VIBRAMYCIN

+	PFIZER	EQ 25MG BASE/5ML	N50006 001	DEC 06, 1967	FEB	CTEC

DOXYCYCLINE HYCLATE
CAPSULE; ORAL
DOXY-LEMMON

	@ TEVA	EQ 50MG BASE	N62497 001	AUG 23, 1984	APR	DISC
	@	EQ 100MG BASE	N62497 002	JUN 15, 1984	APR	DISC

DOXYCYCLINE HYCLATE

	@ CHELSEA LABS	EQ 50MG BASE	N62142 001	AUG 12, 1981	APR	DISC
	@	EQ 100MG BASE	N62142 002	AUG 12, 1981	APR	DISC
AB	HALSEY	EQ 50MG BASE	N61717 001	JUL 17, 1973	JUN	CAHN
	@	EQ 50MG BASE	N62418 001	JAN 28, 1983	APR	DISC
AB		EQ 100MG BASE	N61717 002	JUL 17, 1973	JUN	CAHN
	@	EQ 100MG BASE	N62418 002	JAN 28, 1983	APR	DISC

CAPSULE, COATED PELLETS; ORAL

	@ SIDMAK LABS NJ	EQ 100MG BASE	N63187 001	JUN 30, 1992	MAY	DISC

INJECTABLE; INJECTION
DOXYCHEL HYCLATE

	@ RACHELLE	EQ 100MG BASE/VIAL	N61953 001	SEP 10, 1980	FEB	WDRP

DOXYCYCLINE

	@ BEDFORD	EQ 100MG BASE/VIAL	N62569 001	MAR 09, 1988	MAY	DISC

	@	EQ 200MG BASE/VIAL	N62569	002	MAR 09, 1988	MAY	DISC
	@ ELKINS SINN	EQ 100MG BASE/VIAL	N62450	001	OCT 27, 1983	APR	DISC
	@	EQ 200MG BASE/VIAL	N62450	002	OCT 27, 1983	APR	DISC
	DOXYCYCLINE HYCLATE						
	@ LEDERLE	EQ 100MG BASE/VIAL	N62992	001	FEB 16, 1989	MAY	DISC
	@	EQ 200MG BASE/VIAL	N62992	002	FEB 16, 1989	MAY	DISC
	TABLET; ORAL						
	DOXY-LEMMON						
	@ TEVA	EQ 100MG BASE	N62581	001	MAR 15, 1985	MAY	DISC
	DOXYCYCLINE HYCLATE						
AB	HALSEY	EQ 100MG BASE	N62269	001	SEP 03, 1980	JUN	CAHN
AB		EQ 100MG BASE	N62269	002	NOV 08, 1982	JUN	CAHN
	@	EQ 100MG BASE	N62391	001	SEP 30, 1982	APR	DISC
	DOXYCYCLINE HYLATE						
	@ HALSEY	EQ 50MG BASE	N62269	003	SEP 03, 1980	JUN	CAHN
	PERIOSTAT						
	+ COLLAGENEX PHARMS	20MG	N50783	001	FEB 02, 2001	FEB	NEWA
	DROPERIDOL; FENTANYL CITRATE						
	INJECTABLE; INJECTION						
	FENTANYL CITRATE AND DROPERIDOL						
	@ ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	N72027	001	APR 13, 1989	JUL	DISC
	DROSPIRENONE; ETHINYL ESTRADIOL						
	TABLET; ORAL-28						
	YASMIN						
	+ BERLEX LABS	3MG;0.03MG	N21098	001	MAY 11, 2001	MAY	NEWA
>A>	DUTASTERIDE						
>A>	CAPSULE; ORAL						
>A>	DUTASTERIDE						
>A>	+ GLAXOSMITHKLINE	0.5MG	N21319	001	NOV 20, 2001	NOV	NEWA
	DYCLONINE HYDROCHLORIDE						
	SOLUTION; TOPICAL						
	DYCLONE						
	@ ASTRAZENECA	0.5%	N09925	002	JUN 13, 1974	AUG	DISC
	@	1%	N09925	001	AUG 03, 1955	AUG	DISC
	ENALAPRIL MALEATE						
	TABLET; ORAL						
	ENALAPRIL MALEATE						
AB	TARO	2.5MG	N75657	001	JAN 23, 2001	JAN	NEWA
AB		5MG	N75657	002	JAN 23, 2001	JAN	NEWA
AB		10MG	N75657	003	JAN 23, 2001	JAN	NEWA
AB		20MG	N75657	004	JAN 23, 2001	JAN	NEWA
AB	TORPHARM	2.5MG	N75178	002	MAR 23, 2001	MAR	NEWA
AB		5MG	N75178	001	MAR 23, 2001	MAR	NEWA
AB		10MG	N75178	003	MAR 23, 2001	MAR	NEWA
AB		20MG	N75178	004	MAR 23, 2001	MAR	NEWA

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

AB	DR REDDYS LABS LTD	5MG;12.5MG	N75909 001	OCT 15, 2001	OCT	NEWA
AB		10MG;25MG	N75909 002	OCT 15, 2001	OCT	NEWA
AB	EON	5MG;12.5MG	N76116 001	SEP 19, 2001	SEP	NEWA
AB		10MG;25MG	N76116 002	SEP 19, 2001	SEP	NEWA
AB	MYLAN	5MG;12.5MG	N75624 001	SEP 18, 2001	SEP	NEWA
AB		10MG;25MG	N75624 002	SEP 18, 2001	SEP	NEWA
AB	TARO PHARM INDS	5MG;12.5MG	N75788 001	SEP 18, 2001	SEP	NEWA
AB		10MG;25MG	N75788 002	SEP 18, 2001	SEP	NEWA
AB	TEVA	5MG;12.5MG	N75727 001	SEP 18, 2001	SEP	NEWA
AB		10MG;25MG	N75727 002	SEP 18, 2001	SEP	NEWA

VASERETIC

AB	MERCK RES LABS	5MG;12.5MG	N19221 003	JUL 12, 1995	SEP	CFTG
AB +		10MG;25MG	N19221 001	OCT 31, 1986	SEP	CFTG

ENFLURANE

LIQUID; INHALATION

ENFLURANE

AN	MINRAD	99.9%	N74396 001	JUL 29, 1994	FEB	CAHN

ENOXAPARIN SODIUM

INJECTABLE; SUBCUTANEOUS

LOVENOX

+	AVENTIS	30MG/0.3ML	N20164 001	MAR 29, 1993	APR	CAHN
+		40MG/0.4ML	N20164 002	JAN 30, 1998	APR	CAHN
+		60MG/0.6ML	N20164 003	MAR 27, 1998	APR	CAHN
+		80MG/0.8ML	N20164 004	MAR 27, 1998	APR	CAHN
+		90MG/0.6ML	N20164 006	JUN 02, 2000	APR	CAHN
+		100MG/ML	N20164 005	MAR 27, 1998	APR	CAHN
+		120MG/0.8ML	N20164 007	JUN 02, 2000	APR	CAHN
+		150MG/ML	N20164 008	JUN 02, 2000	APR	CAHN

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

@	ASTRAZENECA	0.005MG/ML;1.5%	N17751 007	AUG 30, 1976	SEP	DISC
+	DENTSPLY PHARM	0.005MG/ML;1%	N17751 006	AUG 30, 1976	APR	CAHN
+		0.005MG/ML;1.5%	N17751 007	AUG 30, 1976	APR	CAHN
+		0.005MG/ML;1.5%	N21384 001	AUG 30, 1976	SEP	NEWA

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CITANEST FORTE

@	ASTRAZENECA	0.005MG/ML;4%	N14763 008	JUN 29, 1970	SEP	DISC
+	DENTSPLY PHARM	0.005MG/ML;4%	N21383 001	JUN 29, 1970	SEP	NEWA

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURANEST

@	DENTSPLY PHARM	0.005MG/ML;0.5%	N17751 004	AUG 30, 1976	APR	CAHN

		EPINEPHRINE; LIDOCAINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		LIDOCAINE HCL W/ EPINEPHRINE						
OCT	NEWA	@ INTL MEDICATION	0.01MG/ML;1%	N86402	001	FEB 04, 1980	JUL	DISC
OCT	NEWA	@ STERIS	0.01MG/ML;1%	N80377	003	FEB 20, 1974	JUL	DISC
SEP	NEWA	@	0.01MG/ML;2%	N80377	004	FEB 20, 1974	JUL	DISC
SEP	NEWA	LIDOCATON						
SEP	NEWA	@ PHARMATON	0.02MG/ML;2%	N84728	001	AUG 17, 1983	FEB	WDRP
SEP	NEWA	XYLOCAINE W/ EPINEPHRINE						
SEP	NEWA	@ ASTRAZENECA	0.01MG/ML;2%	N06488	003	NOV 19, 1948	SEP	DISC
SEP	NEWA	+ DENTSPLY PHARM	0.01MG/ML;2%	N21381	001	NOV 19, 1948	SEP	NEWA
SEP	NEWA		0.02MG/ML;2%	N21381	002	NOV 19, 1948	SEP	NEWA
SEP	NEWA							
>A>		EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE						
>A>		TABLET; ORAL						
SEP	CFTG	TEVETEN HCT						
SEP	CFTG	UNIMED PHARMS	600MG;12.5MG	N21268	001	NOV 01, 2001	NOV	NEWA
>A>		+	600MG;25MG	N21268	002	NOV 01, 2001	NOV	NEWA
		ERGOCALCIFEROL						
		CAPSULE; ORAL						
FEB	CAHN	VITAMIN D						
		@ IMPAX LABS	50,000 IU	N80951	001	JUL 13, 1973	FEB	DISC
		ERGOLOID MESYLATES						
APR	CAHN	TABLET; ORAL						
APR	CAHN	ERGOLOID MESYLATES						
APR	CAHN	@ DANBURY PHARMA	1MG	N87244	001	AUG 16, 1982	JUL	DISC
APR	CAHN	TABLET; SUBLINGUAL						
APR	CAHN	@ DANBURY PHARMA	1MG	N87183	001	APR 16, 1981	JUL	DISC
APR	CAHN							
APR	CAHN	ERTAPENEM SODIUM						
APR	CAHN	INJECTABLE; INTRAMUSCULAR, IV (INFUSION)						
		INVANZ						
>A>		+ MERCK	EQ 1GM BASE/VIAL	N21337	001	NOV 21, 2001	NOV	NEWA
		ERYTHROMYCIN						
SEP	DISC	SOLUTION; TOPICAL						
APR	CAHN	ERYTHROMYCIN						
APR	CAHN	@ CLAY PARK	2%	N63038	001	JAN 11, 1991	APR	DISC
	AT		2%	N63038	001	JAN 11, 1991	MAY	CMFD
SEP	NEWA	TABLET, DELAYED RELEASE; ORAL						
		E-BASE						
		@ BARR	333MG	N63028	001	MAY 15, 1990	APR	DISC
		ILOTYCIN						
		@ DISTA	250MG	N61910	001	FEB 27, 1975	MAY	DISC
SEP	DISC							
SEP	NEWA							
		ERYTHROMYCIN ESTOLATE						
		CAPSULE; ORAL						
		ERYTHROMYCIN ESTOLATE						
		+ BARR	EQ 250MG BASE	N62162	002	JUN 15, 1981	MAY	CTEC
APR	CAHN	@ DANBURY PHARMA	EQ 250MG BASE	N62087	001	JUN 14, 1979	APR	DISC

ERYTHROMYCIN ESTOLATE
CAPSULE; ORAL
ILOSONE
@ LILLY EQ 125MG BASE N61897 001 JAN 06, 1975 MAY DISC
@ EQ 250MG BASE N61897 002 JAN 06, 1975 MAY DISC
FOR SUSPENSION; ORAL
ILOSONE
@ DISTA EQ 125MG BASE/5ML N61893 001 JAN 06, 1975 MAY DISC
SUSPENSION/DROPS; ORAL
@ LILLY EQ 100MG BASE/ML N61894 003 JAN 07, 1975 APR DISC
TABLET; ORAL
@ LILLY EQ 500MG BASE N61896 001 JAN 03, 1975 APR DISC
TABLET, CHEWABLE; ORAL
@ DISTA EQ 125MG BASE N61895 001 JAN 03, 1975 MAY DISC
@ EQ 250MG BASE N61895 002 JAN 03, 1975 MAY DISC

ERYTHROMYCIN ETHYLSUCCINATE
TABLET; ORAL
ERYTHROMYCIN ETHYLSUCCINATE
@ BARR EQ 400MG BASE N62256 001 APR 28, 1980 MAY DISC

ERYTHROMYCIN GLUCEPTATE
INJECTABLE; INJECTION
ILOTYCIN GLUCEPTATE
@ DISTA EQ 250MG BASE/VIAL N50370 001 JUN 23, 1964 JUL DISC
@ EQ 500MG BASE/VIAL N50370 002 JUN 23, 1964 JUL DISC
@ EQ 1GM BASE/VIAL N50370 003 JUN 23, 1964 JUL DISC

ERYTHROMYCIN STEARATE
TABLET; ORAL
ERYTHROMYCIN STEARATE
@ BARR EQ 500MG BASE N63179 001 MAY 15, 1990 MAY DISC
@ ZENITH GOLDLINE EQ 250MG BASE N61461 001 SEP 04, 1971 MAY DISC
@ EQ 500MG BASE N61461 002 APR 11, 1980 MAY DISC
WYAMYCIN S
@ WYETH AYERST EQ 250MG BASE N61675 001 OCT 06, 1972 APR DISC
@ EQ 500MG BASE N61675 002 JUL 13, 1973 APR DISC

ESOMEPRAZOLE MAGNESIUM
CAPSULE, DELAYED REL PELLETS; ORAL
NEXIUM
+ ASTRAZENECA EQ 20MG BASE N21153 001 FEB 20, 2001 FEB NEWA
+ EQ 40MG BASE N21153 002 FEB 20, 2001 FEB NEWA

ESTRADIOL VALERATE
INJECTABLE; INJECTION
DELESTROGEN
+ KING PHARMS 10MG/ML N09402 002 AUG 18, 1962 AUG CAHN
AO + 20MG/ML N09402 004 JUN 23, 1961 AUG CAHN
AO + 40MG/ML N09402 003 FEB 24, 1961 AUG CAHN

	ESTRADIOL; NORETHINDRONE ACETATE						
	FILM, EXTENDED RELEASE; TRANSDERMAL						
	COMBIPATCH						
	NOVARTIS	0.05MG/24HR;0.14MG/24HR	N20870 001	AUG 07, 1998	MAR	CAHN	
	+	0.05MG/24HR;0.25MG/24HR	N20870 002	AUG 07, 1998	MAR	CAHN	
	ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE						
	TABLET; ORAL-28						
	PREMPRO						
	+ WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5MG	N20527 001	NOV 17, 1995	JAN	CTNA	
	+	0.625MG;0.625MG;5MG;5MG	N20527 003	JAN 09, 1998	JAN	CTNA	
	PREMPRO (PREMARIN;CYCRIN)						
	+ WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5MG	N20303 001	DEC 30, 1994	JAN	CTNA	
	ESTROGENS, ESTERIFIED						
	TABLET; ORAL						
	ESTRATAB						
	@ SOLVAY	0.3MG	N86715 001	APR 08, 1981	JUL	DISC	
	@	0.625MG	N83209 001	JUN 17, 1977	JUL	DISC	
	MENEST						
	+ MONARCH PHARMS	0.3MG	N84951 001	SEP 28, 1977	JUL	CTEC	
		0.625MG	N84948 001	SEP 28, 1977	JUL	CTEC	
	ESTROPIPATE						
	TABLET; ORAL						
	ORTHO-EST						
AB	WOMEN FIRST HLTHCARE	0.75MG	N89567 001	FEB 27, 1991	JAN	CAHN	
AB		1.5MG	N89582 001	JUL 17, 1991	JAN	CAHN	
	ETHAMBUTOL HYDROCHLORIDE						
	TABLET; ORAL						
	ETHAMBUTOL HCL						
>A> AB	BARR	400MG	N76057 001	NOV 26, 2001	NOV	NEWA	
	ETHINYL ESTRADIOL; ETONOGESTREL						
	RING; VAGINAL						
	NUVARING						
	+ ORGANON INC	0.015MG;0.12MG	N21187 001	OCT 03, 2001	OCT	NEWA	
	ETHINYL ESTRADIOL; LEVONORGESTREL						
	TABLET; ORAL-21						
	ALESSE						
AB	+ WYETH AYERST	0.02MG;0.1MG	N20683 001	MAR 27, 1997	APR	CTEC	
	AVIANE-21						
AB	DURAMED	0.02MG;0.1MG	N75796 002	APR 30, 2001	APR	NEWA	
	TABLET; ORAL-21, ORAL-28						
	ENPRESSE-21						
AB	DURAMED	0.03MG,0.04MG;0.03MG,0.05MG; 0.075MG,0.125MG	N75809 001	JUL 16, 2001	JUL	NEWA	
	TABLET; ORAL-28						

ETHINYL ESTRADIOL; LEVONORGESTREL
TABLET; ORAL-28
ALESSE
AB WYETH AYERST 0.02MG;0.1MG N20683 002 MAR 27, 1997 APR CTEC
AVIANE-28
AB DURAMED 0.02MG;0.1MG N75796 001 APR 30, 2001 APR NEWA
ENPRESSE-28
AB DURAMED 0.03MG,0.04MG;0.03MG,0.05MG; 0.075MG,0.125MG N75809 002 JUL 16, 2001 JUL NEWA

>A> ETHINYL ESTRADIOL; NORELGESTROMIN
>A> FILM, EXTENDED RELEASE; TRANSDERMAL
>A> ORTHO EVRA
>A> + JOHNSON RW 0.02MG/24HR;0.015MG/24HR N21180 001 NOV 20, 2001 NOV NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE
TABLET; ORAL-28
LOESTRIN FE 1.5/30
AB + PARKE DAVIS 0.03MG;1.5MG N17355 001 APR 30, 1973 FEB CFTG
LOESTRIN FE 1/20
AB + PARKE DAVIS 0.02MG;1MG N17354 001 APR 30, 1973 FEB CFTG
MICROGESTIN FE 1.5/30
AB WATSON LABS 0.03MG;1.5MG N75548 001 FEB 05, 2001 FEB NEWA
MICROGESTIN FE 1/20
AB WATSON LABS 0.02MG;1MG N75647 001 FEB 05, 2001 FEB NEWA

ETHINYL ESTRADIOL; NORGESTREL
TABLET; ORAL-21
>A> CRYSELLE
>A> AB DURAMED 0.03MG;0.3MG N75840 001 NOV 30, 2001 NOV NEWA
TABLET; ORAL-28
>A> CRYSELLE
>A> AB DURAMED 0.03MG;0.3MG N75840 002 NOV 30, 2001 NOV NEWA

ETHOSUXIMIDE
SYRUP; ORAL
ZARONTIN
AA + PARKE DAVIS 250MG/5ML N80258 001 FEB 13, 1974 JAN CRLD

ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURANEST
@ DENTSPLY PHARM 0.5% N17751 003 AUG 30, 1976 APR CAHN
+ 1% N17751 005 AUG 30, 1976 APR CAHN

ETODOLAC
TABLET, EXTENDED RELEASE; ORAL
ETODOLAC
>A> AB ANDRX PHARM 400MG N75829 001 NOV 30, 2001 NOV NEWA
>A> AB 500MG N75829 002 NOV 30, 2001 NOV NEWA
AB TEVA 400MG N75665 003 FEB 05, 2001 FEB NEWA

		ETOPOSIDE						
		CAPSULE; ORAL						
		ETOPOSIDE						
	AB	GENPHARM	50MG	N75635 001	SEP 19, 2001	SEP	NEWA	
		VEPESID						
	AB	+ BRISTOL	50MG	N19557 001	DEC 30, 1986	SEP	CFTG	
		INJECTABLE; INJECTION						
		ETOPOSIDE						
		@ PIERRE FABRE	20MG/ML	N74813 001	JUL 09, 1997	SEP	WDAG	
		ETOPOSIDE PHOSPHATE						
		INJECTABLE; INJECTION						
		ETOPOPHOS PRESERVATIVE FREE						
		@ BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N20906 001	FEB 27, 1998	JUN	DISC	
		@	EQ 1GM BASE/VIAL	N20906 002	FEB 27, 1998	JUN	NEWA	
		FAMCICLOVIR						
		TABLET; ORAL						
		FAMVIR						
		NOVARTIS	125MG	N20363 003	DEC 11, 1995	JAN	CAHN	
			250MG	N20363 001	APR 26, 1996	JAN	CAHN	
		+	500MG	N20363 002	JUN 29, 1994	JAN	CAHN	
		FAMOTIDINE						
		INJECTABLE; INJECTION						
		FAMOTIDINE						
>A>	AP	ABBOTT	10MG/ML	N75870 001	NOV 23, 2001	NOV	NEWA	
>A>	AP		10MG/ML	N75905 001	NOV 23, 2001	NOV	NEWA	
	AP	AM PHARM PARTNERS	10MG/ML	N75709 001	APR 16, 2001	APR	NEWA	
	AP	APOTHECON	10MG/ML	N75707 001	APR 16, 2001	APR	NEWA	
		@	10MG/ML	N75707 001	APR 16, 2001	MAY	DISC	
	AP	BEDFORD	10MG/ML	N75651 001	APR 16, 2001	APR	NEWA	
	AP		10MG/ML	N75684 001	APR 16, 2001	APR	NEWA	
	AP	ESI LEDERLE	10MG/ML	N75488 001	APR 16, 2001	APR	NEWA	
	AP	FAULDING	10MG/ML	N75705 001	APR 16, 2001	APR	NEWA	
		FAMOTIDINE PRESERVATIVE FREE						
	AP	AM PHARM PARTNERS	10MG/ML	N75813 001	APR 16, 2001	APR	NEWA	
	AP	APOTHECON	10MG/ML	N75708 001	APR 16, 2001	APR	NEWA	
		@	10MG/ML	N75708 001	APR 16, 2001	MAY	DISC	
	AP	BEDFORD	10MG/ML	N75622 001	APR 16, 2001	APR	NEWA	
	AP	BEN VENUE	10MG/ML	N75825 001	APR 17, 2001	APR	NEWA	
	AP	ESI LEDERLE	10MG/ML	N75486 001	APR 16, 2001	APR	NEWA	
	AP	FAULDING	10MG/ML	N75669 001	APR 16, 2001	APR	NEWA	
		FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER						
	AP	BAXTER HLTHCARE	0.4MG/ML	N75591 001	MAY 10, 2001	MAY	NEWA	
		PEPCID						
	AP	+ MERCK	10MG/ML	N19510 001	NOV 04, 1986	APR	CFTG	
		PEPCID PRESERVATIVE FREE						
	AP	+ MERCK	10MG/ML	N19510 004	NOV 04, 1986	APR	CFTG	
		PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER						
	AP	+ MERCK	0.4MG/ML	N20249 001	FEB 18, 1994	MAY	CFTG	
		TABLET; ORAL						

FAMOTIDINE
TABLET; ORAL
FAMOTIDINE

AB	CARLSBAD	20MG	N75805 001	APR 16, 2001	APR	NEWA
AB		40MG	N75805 002	APR 16, 2001	APR	NEWA
AB	DANBURY PHARMA	20MG	N75062 002	APR 16, 2001	APR	NEWA
AB		40MG	N75062 001	APR 16, 2001	APR	NEWA
AB	DR REDDYS LABS LTD	20MG	N75718 001	APR 16, 2001	APR	NEWA
AB		40MG	N75718 002	APR 16, 2001	APR	NEWA
AB	EON	20MG	N75793 001	APR 16, 2001	APR	NEWA
AB		40MG	N75793 002	APR 16, 2001	APR	NEWA
AB	GENEVA PHARMS	20MG	N75302 001	APR 16, 2001	APR	NEWA
AB		40MG	N75302 002	APR 16, 2001	APR	NEWA
AB	GENPHARM	20MG	N75457 001	APR 18, 2001	APR	NEWA
AB		40MG	N75457 002	APR 18, 2001	APR	NEWA
AB	INVAMED	20MG	N75607 001	MAY 10, 2001	MAY	NEWA
AB		40MG	N75607 002	MAY 10, 2001	MAY	NEWA
AB	MYLAN	20MG	N75704 001	APR 16, 2001	APR	NEWA
AB		40MG	N75704 002	APR 16, 2001	APR	NEWA
AB	PUREPAC PHARM	20MG	N75650 001	SEP 14, 2001	SEP	NEWA
AB		40MG	N75650 002	SEP 14, 2001	SEP	NEWA
AB	TEVA	20MG	N75311 001	APR 16, 2001	APR	NEWA
AB		40MG	N75311 002	APR 16, 2001	APR	NEWA
AB	TORPHARM	20MG	N75611 001	JUL 23, 2001	JUL	NEWA
AB		40MG	N75611 002	JUL 23, 2001	JUL	NEWA
AB	WOCKHARDT	20MG	N75786 001	APR 16, 2001	APR	NEWA
AB		40MG	N75786 002	APR 16, 2001	APR	NEWA
AB	ZENITH GOLDLINE	20MG	N75511 001	APR 16, 2001	APR	NEWA
AB		40MG	N75511 002	APR 16, 2001	APR	NEWA
	PEPCID					
AB	MERCK	20MG	N19462 001	OCT 15, 1986	APR	CFTG
AB +		40MG	N19462 002	OCT 15, 1986	APR	CFTG

FELODIPINE
TABLET, EXTENDED RELEASE; ORAL
PLENDIL

ASTRAZENECA	2.5MG	N19834 004	SEP 22, 1994	OCT	CRLD
	5MG	N19834 001	JUL 25, 1991	OCT	CRLD

FENOFIBRATE
TABLET; ORAL
TRICOR

ABBOTT	54MG	N21203 001	SEP 04, 2001	AUG	NEWA
+	160MG	N21203 003	SEP 04, 2001	SEP	NEWA

FENTANYL
FILM, EXTENDED RELEASE; TRANSDERMAL
DURAGESIC

ALZA	1.2MG/24HR	N19813 003	AUG 07, 1990	MAY	CTEC
	1.8MG/24HR	N19813 002	AUG 07, 1990	MAY	CTEC
	2.4MG/24HR	N19813 001	AUG 07, 1990	MAY	CTEC

FENTANYL CITRATE
INJECTABLE; INJECTION
FENTANYL CITRATE PRESERVATIVE FREE

	@ MARSAM	EQ 0.05MG BASE/ML	N74917 001	FEB 03, 1998	JAN	DISC	

FLECAINIDE ACETATE
TABLET; ORAL
FLECAINIDE ACETATE

AB	ALPHAPHARM	50MG	N75442 001	JUL 31, 2001	JUL	NEWA	
AB		100MG	N75442 002	JUL 31, 2001	JUL	NEWA	
AB		150MG	N75442 003	JUL 31, 2001	JUL	NEWA	
	TAMBOCOR						
AB	3M	50MG	N18830 004	AUG 23, 1988	JUL	CFTG	
AB		100MG	N18830 001	OCT 31, 1985	JUL	CFTG	
AB +		150MG	N18830 003	JUN 03, 1988	JUL	CFTG	

FLOXURIDINE
INJECTABLE; INJECTION
FLOXURIDINE

AP	AM PHARM PARTNERS	500MG/VIAL	N75837 001	FEB 22, 2001	FEB	NEWA	

FLUDEOXYGLUCOSE, F-18
INJECTABLE; INJECTION
FLUDEOXYGLUCOSE F 18

+	DOWNSTATE CLINCL	4-90mCi/ML	N20306 002	SEP 25, 2001	SEP	NEWA	

FLUNISOLIDE
SPRAY, METERED; NASAL
NASALIDE

>D>	BX +	DURA	0.025MG/SPRAY	N18148 001	SEP 24, 1981	NOV	CAHN	
>A>	BX +	IVAX RES	0.025MG/SPRAY	N18148 001	SEP 24, 1981	NOV	CAHN	
	NASAREL							
>D>	BX +	DURA	0.025MG/SPRAY	N20409 001	MAR 08, 1995	NOV	CAHN	
>A>	BX +	IVAX RES	0.025MG/SPRAY	N20409 001	MAR 08, 1995	NOV	CAHN	

FLUOCINOLONE ACETONIDE
CREAM; TOPICAL
FLUOCINOLONE ACETONIDE

	@ CLAY PARK	0.01%	N86810 001	MAR 04, 1982	APR	DISC	
	@	0.025%	N86811 001	MAR 04, 1982	APR	DISC	

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE
CREAM; TOPICAL
NEO-SYNALAR

	@ MEDICIS	0.025%;EQ 3.5MG BASE/GM	N60700 001	JUN 11, 1963	MAY	DISC	

FLUOROMETHOLONE
SUSPENSION/DROPS; OPHTHALMIC
FLUOR-OP

AB	NOVARTIS	0.1%	N70185 001	FEB 27, 1986	FEB	CAHN	

	FLUOROURACIL						
	CREAM; TOPICAL						
	CARAC						
	+ DERMIK LABS	0.5%	N20985 001	OCT 27, 2000	MAY	CTNA	
	FLUOXETINE HYDROCHLORIDE						
	CAPSULE; ORAL						
	FLUOXETINE						
AB	BARR	EQ 20MG BASE	N74803 001	AUG 02, 2001	AUG	NEWA	
AB	DR REDDYS LABS LTD	EQ 40MG BASE	N75465 003	AUG 02, 2001	AUG	NEWA	
AB	GENEVA PHARMS	EQ 10MG BASE	N75049 001	AUG 02, 2001	AUG	NEWA	
	PROZAC						
AB	LILLY	EQ 10MG BASE	N18936 006	DEC 23, 1992	AUG	CFTG	
AB		EQ 20MG BASE	N18936 001	DEC 29, 1987	AUG	CFTG	
AB	+	EQ 40MG BASE	N18936 003	JUN 15, 1999	AUG	CFTG	
	CAPSULE, DELAYED REL PELLETS; ORAL						
	PROZAC WEEKLY						
	+ LILLY	EQ 90MG BASE	N21235 001	FEB 26, 2001	FEB	NEWA	
	SOLUTION; ORAL						
	FLUOXETINE						
AT	TEVA	EQ 20MG BASE/5ML	N75506 001	AUG 02, 2001	AUG	NEWA	
	PROZAC						
AT	+ LILLY	EQ 20MG BASE/5ML	N20101 001	APR 24, 1991	AUG	CFTG	
	TABLET; ORAL						
	FLUOXETINE HCL						
AB	ALPHAPHARM	EQ 10MG BASE	N75755 001	AUG 02, 2001	AUG	NEWA	
	+	EQ 20MG BASE	N75755 002	AUG 02, 2001	AUG	NEWA	
	PROZAC						
AB	+ LILLY	EQ 10MG BASE	N20974 001	MAR 09, 1999	AUG	CFTG	
	FLUPHENAZINE DECANOATE						
	INJECTABLE; IM-SC						
	FLUPHENAZINE DECANOATE						
AO	APOTEX	25MG/ML	N75918 001	AUG 17, 2001	AUG	NEWA	
	FLUPHENAZINE HYDROCHLORIDE						
	TABLET; ORAL						
	PERMITIL						
	@ SCHERING	10MG	N12034 006	JAN 07, 1964	OCT	DISC	
	FLURAZEPAM HYDROCHLORIDE						
	CAPSULE; ORAL						
	FLURAZEPAM HCL						
	@ CHELSEA LABS	15MG	N72368 001	MAR 30, 1989	JUL	DISC	
	@ PUREPAC PHARM	15MG	N71927 001	SEP 09, 1987	JUL	DISC	
	@	30MG	N71551 001	SEP 09, 1987	JUL	DISC	
	FLURBIPROFEN						
	TABLET; ORAL						
	FLURBIPROFEN						
AB	CARACO	50MG	N75058 001	APR 27, 2001	APR	NEWA	
AB		100MG	N75058 002	APR 27, 2001	APR	NEWA	

FLUTAMIDE							
CAPSULE; ORAL							
EULEXIN							
AB + SCHERING	125MG	N18554 001	JAN 27, 1989	SEP	CFTG		
FLUTAMIDE							
AB BARR	125MG	N75820 001	SEP 18, 2001	SEP	NEWA		
AB EON	125MG	N75818 001	SEP 18, 2001	SEP	NEWA		
AB IVAX PHARMS	125MG	N75780 001	SEP 19, 2001	OCT	NEWA		
AB TEVA	125MG	N75298 001	SEP 18, 2001	SEP	NEWA		
FLUVOXAMINE MALEATE							
TABLET; ORAL							
FLUVOXAMINE MALEATE							
AB BARR	25MG	N75897 001	JAN 25, 2001	JAN	NEWA		
AB	50MG	N75897 002	JAN 25, 2001	JAN	NEWA		
AB	100MG	N75897 003	JAN 25, 2001	JAN	NEWA		
AB GENPHARM	50MG	N75950 001	OCT 15, 2001	OCT	NEWA		
AB	100MG	N75950 002	OCT 15, 2001	OCT	NEWA		
AB INVAMED	25MG	N75887 001	JAN 05, 2001	JAN	NEWA		
AB	50MG	N75887 002	JAN 05, 2001	JAN	NEWA		
AB	100MG	N75887 003	JAN 05, 2001	JAN	NEWA		
AB SYNTHON PHARMS	25MG	N75899 001	JAN 17, 2001	JAN	NEWA		
AB	50MG	N75899 002	JAN 17, 2001	JAN	NEWA		
AB	100MG	N75899 003	JAN 17, 2001	JAN	NEWA		
AB TORPHARM	25MG	N75902 001	MAY 07, 2001	MAY	NEWA		
AB	50MG	N75902 002	MAY 07, 2001	MAY	NEWA		
AB	100MG	N75902 003	MAY 07, 2001	MAY	NEWA		
AB WATSON LABS	25MG	N75894 001	APR 18, 2001	APR	NEWA		
AB	50MG	N75894 002	APR 18, 2001	APR	NEWA		
AB	100MG	N75894 003	APR 18, 2001	APR	NEWA		
AB ZENITH GOLDLINE	25MG	N75898 001	MAR 12, 2001	MAR	NEWA		
AB	50MG	N75898 002	MAR 12, 2001	MAR	NEWA		
AB	100MG	N75898 003	MAR 12, 2001	MAR	NEWA		
FOLIC ACID							
TABLET; ORAL							
FOLIC ACID							
@ IMPAX LABS	1MG	N80686 001	JUL 20, 1973	OCT	DISC		
FOLLITROPIN ALFA							
INJECTABLE; INJECTION							
GONAL-F							
+ SERONO	1,200 IU/VIAL	N20378 004	FEB 28, 2001	AUG	NEWA		
FORMOTEROL FUMARATE							
CAPSULE; INHALATION							
FORADIL							
+ NOVARTIS	0.012MG/INH	N20831 001	FEB 16, 2001	FEB	NEWA		

>A>	FROVATRIPTAN SUCCINATE						
>A>	TABLET; ORAL						
>A>	FROVA						
>A>	+ ELAN PHARMS	EQ 2.5MG BASE	N21006 001	NOV 08, 2001	NOV	NEWA	
	GABAPENTIN						
	CAPSULE; ORAL						
	NEURONTIN						
	PFIZER	100MG	N20235 001	DEC 30, 1993	MAR	CAHN	
		300MG	N20235 002	DEC 30, 1993	MAR	CAHN	
	+	400MG	N20235 003	DEC 30, 1993	MAR	CAHN	
	SOLUTION; ORAL						
	+ PARKE DAVIS	250MG/5ML	N21129 001	MAR 02, 2000	OCT	CMFD	
	GALANTAMINE HYDROBROMIDE						
	SOLUTION; ORAL						
	REMINYL						
	+ JANSSEN	4MG/ML	N21224 001	JUN 22, 2001	JUN	NEWA	
	TABLET; ORAL						
	JANSSEN	EQ 4MG BASE	N21169 001	FEB 28, 2001	FEB	NEWA	
		EQ 8MG BASE	N21169 002	FEB 28, 2001	FEB	NEWA	
	+	EQ 12MG BASE	N21169 003	FEB 28, 2001	FEB	NEWA	
	GEMFIBROZIL						
	TABLET; ORAL						
	GEMFIBROZIL						
AB	GENEVA PHARMS TECH	600MG	N74615 001	SEP 29, 1995	JAN	CAHN	
	GENTAMICIN SULFATE						
	CREAM; TOPICAL						
	GENTAMICIN SULFATE						
	@ BAUSCH AND LOMB	EQ 0.1% BASE	N64056 001	APR 29, 1994	MAY	DISC	
	INJECTABLE; INJECTION						
	@ GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N63149 001	NOV 21, 1991	MAY	DISC	
	@	EQ 40MG BASE/ML	N63106 002	NOV 21, 1991	APR	DISC	
	@ STERIS	EQ 10MG BASE/ML	N62318 002	AUG 20, 1981	APR	DISC	
	@	EQ 40MG BASE/ML	N62318 001	JUN 02, 1981	APR	DISC	
	U-GENCIN						
	@ PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	N62248 001	MAY 02, 1980	FEB	WDRP	
	@	EQ 40MG BASE/ML	N62248 002	MAY 02, 1980	FEB	WDRP	
	INJECTABLE; INTRATHECAL						
	GARAMYCIN						
	@ SCHERING	EQ 2MG BASE/ML	N50505 001	OCT 01, 1979	APR	DISC	
	OINTMENT; OPHTHALMIC						
	GENTACIDIN						
AT	NOVARTIS	EQ 0.3% BASE	N62501 001	JUL 26, 1984	FEB	CAHN	
	@	EQ 0.3% BASE	N62501 001	JUL 26, 1984	MAY	DISC	
	OINTMENT; TOPICAL						
	GARAMYCIN						
	@ SCHERING	EQ 0.1% BASE	N60463 001	MAR 15, 1966	SEP	DISC	
	GENTAMICIN						
AT	+ CLAY PARK	EQ 0.1% BASE	N62351 001	FEB 18, 1982	SEP	CTEC	

GENTAMICIN SULFATE

OINTMENT; TOPICAL

GENTAMICIN SULFATE

	@ BAUSCH AND LOMB	EQ 0.1% BASE	N64054 001	APR 29, 1994	MAY	DISC	

SOLUTION/DROPS; OPHTHALMIC

GENTACIDIN

AT	NOVARTIS	EQ 0.3% BASE	N62480 001	MAR 30, 1984	FEB	CAHN	

GENTAK

AT	AKORN	EQ 0.3% BASE	N64163 001	OCT 12, 2001	OCT	NEWA	

GENTAMICIN SULFATE

	@ ALCON UNIVERSAL	EQ 0.3% BASE	N62523 001	NOV 25, 1985	APR	DISC	

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB	GENEVA PHARMS TECH	5MG	N74542 001	JUN 20, 1995	JAN	CAHN	
AB		10MG	N74542 002	JUN 20, 1995	JAN	CAHN	
AB	TORPHARM	5MG	N75795 001	JUN 13, 2001	JUN	NEWA	
AB		10MG	N75795 002	JUN 13, 2001	JUN	NEWA	

GLUTETHIMIDE

TABLET; ORAL

GLUTETHIMIDE

	@ CELLTECH PHARMS	500MG	N85171 001	DEC 22, 1976	SEP	DISC	

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

	@ GENSIA SICOR PHARMS	0.2MG/ML	N81169 001	SEP 10, 1991	MAY	DISC	

TABLET; ORAL

ROBINUL

+	FIRST HORIZON	1MG	N12827 001	AUG 11, 1961	AUG	CAHN	

ROBINUL FORTE

+	FIRST HORIZON	2MG	N12827 002	AUG 11, 1961	AUG	CAHN	

GRANISETRON HYDROCHLORIDE

SOLUTION; ORAL

KYTRIL

+	ROCHE	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUN	NEWA	

GRISEOFULVIN, MICROCRYSTALLINE

SUSPENSION; ORAL

GRIFULVIN V

+	J AND J	125MG/5ML	N62483 001	JAN 26, 1984	MAR	CRLD	
	@ JOHNSON AND JOHNSON	125MG/5ML	N50448 001	MAY 19, 1972	MAR	DISC	

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

GRISACTIN ULTRA

	@ WYETH AYERST	125MG	N62178 001	MAR 13, 1980	APR	DISC	
	@	250MG	N62178 002	MAR 13, 1980	APR	DISC	

ULTRAGRIS-165

	@ SIDMAK LABS NJ	165MG	N62645 001	JUN 30, 1992	MAY	DISC	

GRISEOFULVIN, ULTRAMICROCRYSTALLINE
TABLET; ORAL
ULTRAGRIS-330
@ SIDMAK LABS NJ 330MG N62646 001 JUN 30, 1992 MAY DISC

HALOPERIDOL
TABLET; ORAL
HALOPERIDOL
@ DANBURY PHARMA 1MG N70982 001 MAR 06, 1987 JUL DISC
@ ROXANE 0.5MG N71128 001 FEB 17, 1987 AUG DISC
@ 1MG N71129 001 FEB 17, 1987 AUG DISC
@ 2MG N71130 001 FEB 17, 1987 AUG DISC
@ 5MG N71131 001 FEB 17, 1987 AUG DISC
>D> AB 10MG N71132 001 MAY 12, 1987 NOV DISC
>A> @ 10MG N71132 001 MAY 12, 1987 NOV DISC
@ 20MG N71133 001 MAY 12, 1987 AUG DISC

HALOPERIDOL LACTATE
CONCENTRATE; ORAL
HALOPERIDOL INTENSOL
@ ROXANE EQ 2MG BASE/ML N72045 001 APR 12, 1988 AUG DISC
INJECTABLE; INJECTION
HALOPERIDOL
AP AM PHARM PARTNERS EQ 5MG BASE/ML N75689 001 MAR 09, 2001 JUN CTNA
AP BEDFORD EQ 5MG BASE/ML N75858 001 JUN 18, 2001 JUN NEWA
AP GENSIA SICOR PHARMS EQ 5MG BASE/ML N76035 001 AUG 29, 2001 AUG NEWA
HALOPERIDOL LACTATE
AP AM PHARM PARTNERS EQ 5MG BASE/ML N75689 001 MAR 09, 2001 MAR NEWA

HALOTHANE
LIQUID; INHALATION
HALOTHANE
@ BH 99.99% N84977 001 JUL 14, 1976 JAN DISC

HEPARIN SODIUM
INJECTABLE; INJECTION
HEPARIN SODIUM
@ ABBOTT 10,000 UNITS/ML N40095 001 JUL 26, 1996 MAY DISC
HEPARIN SODIUM PRESERVATIVE FREE
@ PHARMA SERVE NY 1,000 UNITS/ML N86129 001 FEB 22, 1980 FEB WDRP

HOMATROPINE METHYLBROMIDE
TABLET; ORAL
HOMAPIN-10
@ MISSION PHARMA 10MG N86308 001 APR 11, 1979 JUL DISC
HOMAPIN-5
@ MISSION PHARMA 5MG N86309 001 APR 11, 1979 JUL DISC

HYALURONIDASE
INJECTABLE; INJECTION
WYDASE
@ WYETH AYERST 150 UNITS/ML N06343 002 MAR 22, 1950 JUL DISC
@ 150 UNITS/VIAL N06343 006 MAR 06, 1951 JUL DISC

		@	1,500 UNITS/VIAL	N06343 005	MAR 06, 1951	JUL	DISC	
		HYDRALAZINE HYDROCHLORIDE						
MAY	DISC	INJECTABLE; INJECTION						
		HYDRALAZINE HCL						
	AP	AM PHARM PARTNERS	20MG/ML	N40388 001	MAR 13, 2001	MAR	NEWA	
		HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE						
JUL	DISC	TABLET; ORAL						
AUG	DISC	RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE						
AUG	DISC	@ DANBURY PHARMA	25MG;15MG;0.1MG	N85549 001	SEP 29, 1977	MAY	DISC	
AUG	DISC							
AUG	DISC	HYDROCHLOROTHIAZIDE						
NOV	DISC	TABLET; ORAL						
NOV	DISC	HYDROCHLOROTHIAZIDE						
AUG	DISC	@ DANBURY PHARMA	50MG	N83232 001	JAN 24, 1975	MAY	DISC	
		@ HALSEY	25MG	N83972 001	OCT 03, 1974	MAY	DISC	
		@	50MG	N83972 002	OCT 03, 1974	MAY	DISC	
		@ IMPAX LABS	25MG	N84029 001	JUL 05, 1977	MAY	DISC	
		@	50MG	N83607 002	JUN 06, 1977	MAY	DISC	
AUG	DISC	@ PHARMERAL	25MG	N84325 001	JUN 24, 1976	MAY	DISC	
		@	50MG	N84324 001	JUN 24, 1976	MAY	DISC	
		@ PVT FORM	50MG	N86597 001	OCT 11, 1978	JUL	DISC	
JUN	CTNA	@ WEST WARD	50MG	N84878 001	JAN 31, 1977	MAY	DISC	
JUN	NEWA							
AUG	NEWA	HYDROCHLOROTHIAZIDE; RESERPINE						
		TABLET; ORAL						
MAR	NEWA	HYDRO-RESERP						
		@ ABC HOLDING	50MG;0.125MG	N84714 002	JUN 29, 1982	MAY	DISC	
		HYDROCHLOROTHIAZIDE W/ RESERPINE						
		@ DANBURY PHARMA	25MG;0.125MG	N84466 001	JAN 07, 1977	MAY	DISC	
		@	50MG;0.125MG	N84467 001	JAN 07, 1977	MAY	DISC	
JAN	DISC	RESERPINE AND HYDROCHLOROTHIAZIDE-50						
		@ WEST WARD	50MG;0.125MG	N88189 001	MAY 10, 1984	FEB	WDRP	
		HYDROCORTISONE						
		CREAM; TOPICAL						
MAY	DISC	DERMACORT						
		@ MONARCH PHARMS	1%	N83011 002	APR 26, 1973	SEP	WDAG	
FEB	WDRP	HC (HYDROCORTISONE)						
		@ C AND M PHARMA	0.5%	N80482 003	MAR 20, 1973	FEB	WDRP	
		@	1%	N80482 004	MAR 20, 1973	FEB	WDRP	
		HYDROCORTISONE						
		@ TOPIDERM	1%	N89273 001	FEB 17, 1989	FEB	WDRP	
JUL	DISC	NUTRACORT						
		@ HEALTHPOINT	1%	N80442 003	APR 04, 1972	JUL	DISC	
JUL	DISC	PROCTOCORT						
		@ MONARCH PHARMS	1%	N83011 001	APR 26, 1973	FEB	DISC	
		LOTION; TOPICAL						
		ACTICORT						
		@ BAKER NORTON	1%	N86535 001	FEB 04, 1981	JUL	DISC	
JUL	DISC	BETA-HC						
JUL	DISC	@ BETA DERMAC	1%	N89495 001	JAN 25, 1988	FEB	WDRP	

	HYDROCORTISONE						
	LOTION; TOPICAL						
	GLYCORT						
	@ HERAN	1%	N87489 001	OCT 03, 1983	FEB	WDRP	
	HYDROCORTISONE						
	@ MERICON	0.5%	N85282 001	JUN 05, 1978	MAY	DISC	
	@	1%	N85282 002	FEB 26, 1987	MAY	DISC	
	OINTMENT; TOPICAL						
	HC (HYDROCORTISONE)						
	@ C AND M PHARMA	1%	N80481 002	MAR 20, 1973	FEB	WDRP	
	POWDER; FOR RX COMPOUNDING						
	H-CORT						
	@ TORCH	100%	N87834 001	MAR 29, 1982	FEB	WDRP	
	SOLUTION; TOPICAL						
	TEXACORT						
AT	+ SIRIUS LABS	1%	N80425 001	DEC 22, 1971	JUN	CAHN	
	+	2.5%	N81271 001	APR 17, 1992	MAY	CAHN	
	TABLET; ORAL						
	HYDROCORTISONE						
	@ IMPAX LABS	20MG	N80781 001	AUG 02, 1973	OCT	DISC	
	@ LANNETT	20MG	N85070 001	MAY 07, 1976	MAY	DISC	
	HYDROCORTISONE ACETATE						
	CREAM; TOPICAL						
	MICORT-HC						
	FERNDALE LABS	2.5%	N40396 001	FEB 27, 2001	FEB	NEWA	
	HYDROCORTISONE ACETATE; NEOMYCIN SULFATE						
	OINTMENT; TOPICAL						
	NEO-CORTEF						
	@ PHARMACIA AND UPJOHN	1%;EQ 3.5MG BASE/GM	N60751 002	MAY 18, 1965	APR	DISC	
	SUSPENSION/DROPS; OPHTHALMIC						
	COR-OTICIN						
	@ AKORN	1.5%;EQ 3.5MG BASE/ML	N60188 001	OCT 26, 1968	FEB	WDRP	
	HYDROCORTISONE VALERATE						
	OINTMENT; TOPICAL						
	HYDROCORTISONE VALERATE						
AB	ALTANA	0.2%	N75085 001	JUL 31, 2001	JUL	NEWA	
	HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE						
	SOLUTION/DROPS; OTIC						
	NEO-OTOSOL-HC						
	@ ALCON	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62423 001	AUG 25, 1983	APR	DISC	
	SUSPENSION/DROPS; OPHTHALMIC						
	CORTISPORIN						
	+ MONARCH PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N50169 001	DEC 18, 1964	MAY	CTEC	
	NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE						
	@ ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62874 001	MAY 11, 1988	MAY	DISC	
	SUSPENSION/DROPS; OTIC						

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SUSPENSION/DROPS; OTIC
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

FEB WDRP		@ ALCON UNIVERSAL	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N62488 001	NOV 06, 1985	APR	DISC
MAY DISC							

HYDROXYZINE HYDROCHLORIDE
INJECTABLE; INJECTION
HYDROXYZINE HCL

MAY DISC		@ ABBOTT	50MG/ML	N86821 001	SEP 05, 1979	JUL	DISC
FEB WDRP		@ AM PHARM PARTNERS	25MG/ML	N88184 001	MAR 31, 1983	JUL	DISC
		@	50MG/ML	N88185 001	MAR 31, 1983	JUL	DISC
		@ STERIS	25MG/ML	N85778 001	OCT 05, 1979	MAY	DISC

TABLET; ORAL

FEB WDRP		@ PAR PHARM	10MG	N87602 001	JAN 22, 1982	JUL	DISC
JUN CAHN		@	25MG	N87603 001	JAN 22, 1982	JUL	DISC
MAY CAHN		@	50MG	N87604 001	JAN 22, 1982	JUL	DISC

HYDROXYZINE PAMOATE
CAPSULE; ORAL
HYDROXYZINE PAMOATE

OCT DISC		@ GENEVA PHARMS	EQ 50MG HCL	N81128 001	JUN 28, 1991	MAY	DISC
MAY DISC		@	EQ 100MG HCL	N81129 001	JUN 28, 1991	MAY	DISC
		@ VANGARD	EQ 50MG HCL	N88393 001	SEP 19, 1983	FEB	WDRP

IBUPROFEN
TABLET; ORAL
IBUPROFEN

FEB NEWA	>A>	AB	BASF	400MG	N75682 001	NOV 14, 2001	NOV	NEWA
	>A>	AB		600MG	N75682 002	NOV 14, 2001	NOV	NEWA
	>A>	AB		800MG	N75682 003	NOV 14, 2001	NOV	NEWA
APR DISC		AB	DR REDDYS LABS INC	400MG	N76112 001	OCT 31, 2001	OCT	NEWA
		AB		600MG	N76112 002	OCT 31, 2001	OCT	NEWA
		AB		800MG	N76112 003	OCT 31, 2001	OCT	NEWA
FEB WDRP			@ LEDERLE	400MG	N70629 001	SEP 19, 1986	OCT	DISC
			@	600MG	N70630 001	SEP 19, 1986	OCT	DISC

IMATINIB MESYLATE
CAPSULE; ORAL
GLEEVEC

JUL NEWA			NOVARTIS	50MG	N21335 001	MAY 10, 2001	MAY	NEWA
		+		100MG	N21335 002	MAY 10, 2001	MAY	NEWA

IMIPRAMINE HYDROCHLORIDE
TABLET; ORAL
IMIPRAMINE HCL

APR DISC			@ ROXANE	25MG	N83799 002	AUG 05, 1977	SEP	DISC
			@	50MG	N83799 003	AUG 05, 1977	SEP	DISC
			TOFRANIL					
MAY CTEC		AB	TYCO HLTHCARE	10MG	N87844 001	MAY 22, 1984	JUN	CAHN
		AB		25MG	N87845 001	MAY 22, 1984	JUN	CAHN
MAY DISC		AB	+	50MG	N87846 001	MAY 22, 1984	JUN	CAHN

IMIPRAMINE PAMOATE
CAPSULE; ORAL
TOFRANIL-PM

	TYCO HLTHCARE	EQ 75MG HCL	N17090 001	MAR 15, 1973	JUN	CAHN
		EQ 100MG HCL	N17090 004	MAR 08, 1974	JUN	CAHN
		EQ 125MG HCL	N17090 003	MAR 08, 1974	JUN	CAHN
+		EQ 150MG HCL	N17090 002	MAR 15, 1973	JUN	CAHN

INDAPAMIDE
TABLET; ORAL
INDAPAMIDE

AB	GENEVA PHARMS TECH	1.25MG	N74594 001	MAY 23, 1996	JAN	CAHN
AB		2.5MG	N74594 002	MAY 23, 1996	JAN	CAHN

INDINAVIR SULFATE
CAPSULE; ORAL
CRIXIVAN

	MERCK RES LABS	EQ 100MG BASE	N20685 006	APR 19, 2000	AUG	NEWA

INSULIN ASPART RECOMBINANT

>D>	INJECTABLE; INJECTION						
>D>	NOVOLOG						
>D>	+ NOVO NORDISK	100 UNITS/ML	N20986 001	JUN 07, 2000	NOV	CDFR
>A>	INJECTABLE; SUBCUTANEOUS						
>A>	NOVOLOG						
>A>	+ NOVO NORDISK	100 UNITS/ML	N20986 001	JUN 07, 2000	NOV	CDFR

INSULIN ASPART; INSULIN ASPART PROTAMINE
INJECTABLE; SUBCUTANEOUS

>A>	NOVOLOG MIX 70/30						
>A>	+ NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N21172 001	NOV 01, 2001	NOV	NEWA

IPRATROPIUM BROMIDE
SOLUTION; INHALATION
IPRATROPIUM BROMIDE

AN	ASLUNG PHARM	0.02%	N75693 001	JAN 26, 2001	JAN	NEWA
AN	BAUSCH AND LOMB	0.02%	N75835 001	OCT 15, 2001	OCT	NEWA
AN	NEPHRON	0.02%	N75562 001	SEP 27, 2001	SEP	NEWA
AN	NOVEX	0.02%	N75441 001	MAR 28, 2001	MAR	NEWA
AN	WARRICK PHARMS	0.02%	N75507 001	JAN 19, 2001	JAN	NEWA

ISOFLURANE
LIQUID; INHALATION
ISOFLURANE

AN	MINRAD	99.9%	N74416 001	SEP 30, 1994	FEB	CAHN

ISONIAZID
SYRUP; ORAL
ISONIAZID

+	CAROLINA MEDCL	50MG/5ML	N88235 001	NOV 10, 1983	MAY	CTEC
@	MIKART	50MG/5ML	N81118 001	JUL 21, 1997	MAY	DISC
	TABLET; ORAL						
@	HALSEY	100MG	N80136 001	NOV 13, 1970	MAY	DISC

ISOSORBIDE MONONITRATE
TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

JUN CAHN	AB		ZENITH GOLDLINE	30MG	N75448 002	AUG 07, 2001	AUG	NEWA
JUN CAHN	AB			120MG	N75448 003	AUG 07, 2001	AUG	NEWA

JUN CAHN
JUN CAHN

ISOTRETINOIN
CAPSULE; ORAL
ACCUTANE

		+	HLR	20MG	N18662 004	MAR 28, 1983	APR	CTEC

JAN CAHN

KANAMYCIN SULFATE
JAN CAHN INJECTABLE; INJECTION
KANAMYCIN SULFATE

			@ LOCH	EQ 75MG BASE/2ML	N63021 001	JUL 31, 1992	MAY	DISC
			@	EQ 500MG BASE/2ML	N63022 001	JUL 31, 1992	MAY	DISC
			@	EQ 1GM BASE/3ML	N63025 001	JUL 31, 1992	APR	DISC
AUG NEWA			@ STERIS	EQ 1GM BASE/3ML	N62520 003	MAY 09, 1985	MAY	DISC

KANTREX

		+	APOTHECON	EQ 75MG BASE/2ML	N61901 003	MAR 06, 1975	MAY	CTEC
		+		EQ 500MG BASE/2ML	N61901 001	MAR 06, 1975	MAY	CTEC
		+		EQ 1GM BASE/3ML	N61901 002	MAR 06, 1975	MAY	CTEC

NOV CDFR

KETOCONAZOLE
CREAM; TOPICAL
NOV CDFR NIZORAL

	AB	+	JANSSEN	2%	N19084 001	DEC 31, 1985	JUL	CAHN

KETOROLAC TROMETHAMINE
INJECTABLE; INJECTION
NOV NEWA KETOROLAC TROMETHAMINE

	AP		APOTEX	15MG/ML	N75631 002	JUN 29, 2001	JUN	NEWA
	AP			30MG/ML	N75626 001	JUL 24, 2001	JUL	NEWA
	AP			30MG/ML	N75631 001	JUN 29, 2001	JUN	NEWA
			@ APOTHECON	15MG/ML	N75348 001	NOV 28, 2000	MAY	DISC
JAN NEWA			@	30MG/ML	N75348 002	NOV 28, 2000	MAY	DISC
OCT NEWA			@ BEDFORD	15MG/ML	N75230 002	OCT 25, 1999	OCT	DISC
SEP NEWA			@	30MG/ML	N75230 001	OCT 25, 1999	OCT	DISC

MAR NEWA
JAN NEWA

LABETALOL HYDROCHLORIDE
INJECTABLE; INJECTION
LABETALOL HCL

			@ APOTHECON	5MG/ML	N75355 001	NOV 29, 1999	MAY	DISC

TRANDATE

FEB CAHN	AP	+	PROMETHEUS LABS	5MG/ML	N19425 001	DEC 31, 1985	MAY	CAHN

LACTULOSE
SOLUTION; ORAL
LACTULOSE

MAY CTEC	AA		VINTAGE PHARMS	10GM/15ML	N75993 001	JUL 26, 2001	JUL	NEWA

MAY DISC SOLUTION; ORAL, RECTAL

			@ ROXANE	10GM/15ML	N73590 001	MAY 29, 1992	SEP	DISC

MAY DISC

		LAMOTRIGINE						
		TABLET, CHEWABLE; ORAL						
		LAMICTAL CD						
		GLAXO WELLCOME	2MG	N20764 004	SEP 08, 2000	MAR	NEWA	
		LANSOPRAZOLE						
		FOR SUSPENSION, EXTENDED RELEASE; ORAL						
		PREVACID						
		TAP PHARM	15MG/PACKET	N21281 001	MAY 03, 2001	MAY	NEWA	
	+		30MG/PACKET	N21281 002	MAY 03, 2001	MAY	NEWA	
		LEPIRUDIN						
		INJECTABLE; INJECTION						
		REFLUDAN						
>D>	+	AVENTIS PHARMS	50MG/VIAL	N20807 001	MAR 06, 1998	NOV	CAHN	
>A>	+	BERLEX LABS	50MG/VIAL	N20807 001	MAR 06, 1998	NOV	CAHN	
		LEUCOVORIN CALCIUM						
		INJECTABLE; INJECTION						
		LEUCOVORIN CALCIUM PRESERVATIVE FREE						
	AP	LUITPOLD	EQ 50MG BASE/VIAL	N40338 001	JAN 31, 2001	JAN	NEWA	
		LEUPROLIDE ACETATE						
		INJECTABLE; INJECTION						
		LEUPROLIDE ACETATE						
>A>	AP	GENZYME	1MG/0.2ML	N75721 001	NOV 29, 2001	NOV	NEWA	
		LEVOCARNITINE						
		INJECTABLE; INJECTION						
		CARNITOR						
	AP +	SIGMA TAU	200MG/ML	N20182 001	DEC 16, 1992	MAR	CFTG	
		LEVOCARNITINE						
	AP	BEDFORD	200MG/ML	N75567 001	MAR 29, 2001	MAR	NEWA	
	AP	GENSIA SICOR PHARMS	200MG/ML	N75881 001	MAR 29, 2001	MAR	NEWA	
	AP	LUITPOLD	200MG/ML	N75861 001	JUN 22, 2001	JUN	NEWA	
		LEVODOPA						
		CAPSULE; ORAL						
		DOPAR						
		@ SHIRE LABS	250MG	N16913 001	JUN 04, 1970	MAY	DISC	
		TABLET; ORAL						
		@ SHIRE LABS	250MG	N16913 004	JUL 06, 1972	JUN	DISC	
		@	500MG	N16913 005	JUL 06, 1972	JUN	DISC	
		LARODOPA						
		ROCHE	250MG	N16912 003	JUN 04, 1970	JUN	CRLD	
	+		500MG	N16912 004	JUN 04, 1970	JUN	CRLD	
		LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		POLOCAINE W/ LEVONORDEFRIN						
	AP	DENTSPLY PHARM	0.05MG/ML;2%	N89517 001	APR 14, 1988	JUL	CAHN	

LEVOTHYROXINE SODIUM

TABLET; ORAL

LEVOXYL

BX	+ JONES PHARMA	0.025MG	N21301	001	MAY 25, 2001	MAY	NEWA
BX		0.025MG	N21301	001	MAY 25, 2001	JUL	CRLD
BX		0.05MG	N21301	002	MAY 25, 2001	MAY	NEWA
BX		0.075MG	N21301	003	MAY 25, 2001	MAY	NEWA
BX		0.088MG	N21301	004	MAY 25, 2001	MAY	NEWA
BX		0.1MG	N21301	005	MAY 25, 2001	MAY	NEWA
BX		0.112MG	N21301	006	MAY 25, 2001	MAY	NEWA
BX		0.125MG	N21301	007	MAY 25, 2001	MAY	NEWA
BX		0.137MG	N21301	008	MAY 25, 2001	MAY	NEWA
BX		0.15MG	N21301	009	MAY 25, 2001	MAY	NEWA
BX		0.175MG	N21301	010	MAY 25, 2001	MAY	NEWA
BX		0.2MG	N21301	011	MAY 25, 2001	MAY	NEWA
BX		0.3MG	N21301	012	MAY 25, 2001	MAY	NEWA
BX	+	0.3MG	N21301	012	MAY 25, 2001	JUL	CRLD

UNITHROID

BX	STEVENS J	0.025MG	N21210	001	AUG 21, 2000	MAY	CTEC
BX		0.05MG	N21210	002	AUG 21, 2000	MAY	CTEC
BX		0.075MG	N21210	003	AUG 21, 2000	MAY	CTEC
BX		0.088MG	N21210	004	AUG 21, 2000	MAY	CTEC
BX		0.1MG	N21210	005	AUG 21, 2000	MAY	CTEC
BX		0.112MG	N21210	006	AUG 21, 2000	MAY	CTEC
BX		0.125MG	N21210	007	AUG 21, 2000	MAY	CTEC
BX		0.15MG	N21210	008	AUG 21, 2000	MAY	CTEC
BX		0.175MG	N21210	009	AUG 21, 2000	MAY	CTEC
BX		0.2MG	N21210	010	AUG 21, 2000	MAY	CTEC
BX	+	0.3MG	N21210	011	AUG 21, 2000	MAY	CTEC

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL

	@ STERIS	1%	N80377	001	FEB 20, 1974	JUL	DISC
	@	2%	N80377	002	FEB 20, 1974	JUL	DISC

LIDOCATON

	@ PHARMATON	2%	N84727	001	AUG 17, 1983	FEB	WDRP

XYLOCAINE

	@ ASTRAZENECA	2%	N06488	002	NOV 19, 1948	SEP	DISC
AP	+ DENTSPLY PHARM	2%	N21380	001	NOV 19, 1948	SEP	NEWA

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN

	+ PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N50317	001	DEC 29, 1964	MAY	CTEC

LINCOMYCIN HCL

	@ STERIS	EQ 300MG BASE/ML	N63180	001	APR 16, 1991	MAY	DISC

LISINOPRIL

TABLET; ORAL

ZESTRIL

AB	ASTRAZENECA	10MG	N19777	002	MAY 19, 1988	APR	CTEC

LITHIUM CARBONATE
CAPSULE; ORAL
ESKALITH

AB		SMITHKLINE BEECHAM	300MG	N16860 001	APR 06, 1970	JUN	CRLD

LITHIUM CARBONATE

AB		ABLE	300MG	N76121 001	SEP 27, 2001	SEP	NEWA
	+	ROXANE	600MG	N17812 003	JAN 28, 1987	JUN	CRLD

LOMEFLOXACIN HYDROCHLORIDE
TABLET; ORAL
MAXAQUIN

	+	UNIMED PHARMS	EQ 400MG BASE	N20013 001	FEB 21, 1992	SEP	CAHN

LOPERAMIDE HYDROCHLORIDE
CAPSULE; ORAL
LOPERAMIDE HCL

		@ ROXANE	2MG	N73080 001	NOV 27, 1991	JUL	DISC

LORATADINE
TABLET; ORAL
CLARITIN

AB	+	SCHERING	10MG	N19658 001	APR 12, 1993	SEP	CFTG

LORAZEPAM
TABLET; ORAL
LORAZEPAM

AB		RANBAXY	0.5MG	N76045 001	AUG 29, 2001	AUG	NEWA
AB			1MG	N76045 002	AUG 29, 2001	AUG	NEWA
AB			2MG	N76045 003	AUG 29, 2001	AUG	NEWA
		@ WATSON LABS	0.5MG	N71086 001	MAR 23, 1987	JUL	DISC

LOSARTAN POTASSIUM
TABLET; ORAL
COZAAR

		MERCK RES LABS	50MG	N20386 002	APR 14, 1995	AUG	CRLD
	+		100MG	N20386 003	OCT 13, 1998	AUG	NEWA

LOTEPREDNOL ETABONATE
SUSPENSION/DROPS; OPHTHALMIC
ALREX

	+	BAUSCH AND LOMB	0.2%	N20803 001	MAR 09, 1998	OCT	CAHN

LOTEMAX

	+	BAUSCH AND LOMB	0.5%	N20583 001	MAR 09, 1998	OCT	CAHN

MANNITOL
INJECTABLE; INJECTION
MANNITOL 25%

		@ ASTRAZENECA	12.5GM/50ML	N89240 001	MAY 06, 1987	SEP	DISC

MECLIZINE HYDROCHLORIDE
TABLET; ORAL
MECLIZINE HCL
@ CHELSEA LABS 12.5MG N85269 001 NOV 11, 1976 MAY DISC

MEGESTROL ACETATE
SUSPENSION; ORAL
MEGACE
AB + BRISTOL MYERS SQUIBB 40MG/ML N20264 001 SEP 10, 1993 JUL CFTG
MEGESTROL ACETATE
AB PAR PHARM 40MG/ML N75671 001 JUL 25, 2001 JUL NEWA

MELOXICAM
TABLET; ORAL
MOBIC
BOEHRINGER INGELHEIM 7.5MG N20938 001 APR 13, 2000 JUL CRLD
+ 15MG N20938 002 AUG 23, 2000 JUL NEWA

MENOTROPINS (FSH;LH)
INJECTABLE; INJECTION
HUMEGON
@ ORGANON 75 IU/VIAL;75 IU/VIAL N20328 001 SEP 01, 1994 OCT DISC
@ 150 IU/VIAL;150 IU/VIAL N20328 002 SEP 01, 1994 OCT DISC
PERGONAL
BX + SERONO 75 IU/AMP;75 IU/AMP N17646 001 AUG 22, 1975 OCT CTEC
BX + 150 IU/AMP;150 IU/AMP N17646 002 MAY 20, 1985 OCT CTEC

MEPERIDINE HYDROCHLORIDE
INJECTABLE; INJECTION
MEPERIDINE HCL
@ ASTRAZENECA 50MG/ML N89784 001 MAR 31, 1989 JUN DISC
@ 100MG/ML N89788 001 MAR 31, 1989 JUN DISC

MEPIVACAINE HYDROCHLORIDE
INJECTABLE; INJECTION
MEPIVACAINE HCL
@ INTL MEDICATION 1% N87509 001 OCT 05, 1982 JUL DISC
POLOCAINE
AP DENTSPLY PHARM 3% N88653 001 AUG 21, 1984 JUL CAHN

MEPROBAMATE
TABLET; ORAL
AMOSENE
@ FERNDALE LABS 400MG N84030 001 MAY 10, 1974 FEB WDRP
MEPROBAMATE
@ HALSEY 400MG N80699 002 OCT 16, 1972 MAY DISC
@ IMPAX LABS 200MG N14322 002 JUL 23, 1973 AUG DISC
@ 400MG N14322 001 JUL 15, 1963 AUG DISC

		MEQUINOL; TRETINOIN						
		SOLUTION; TOPICAL						
		SOLAGE						
	+	WESTWOOD SQUIBB	2%;0.01%	N20922 001	DEC 10, 1999	JUN	CAHN	
		MESALAMINE						
		SUPPOSITORY; RECTAL						
		CANASA						
	+	AXCAN SCANDIPHARM	500MG	N21252 001	JAN 05, 2001	JAN	NEWA	
		MESNA						
		INJECTABLE; INTRAVENOUS						
		MESNA						
AP		AM PHARM PARTNERS	100MG/ML	N75811 001	APR 26, 2001	APR	NEWA	
AP		GENSIA SICOR PHARMS	100MG/ML	N75764 001	APR 27, 2001	APR	NEWA	
		MESNEX						
AP	+	ASTA	100MG/ML	N19884 001	DEC 30, 1988	APR	CFTG	
		METAPROTERENOL SULFATE						
		SOLUTION; INHALATION						
		METAPROTERENOL SULFATE						
AN		NEPHRON	0.4%	N71855 001	JUL 14, 1988	AUG	CAHN	
AN			0.6%	N71726 001	JUL 14, 1988	AUG	CAHN	
AN		NOVEX	0.4%	N75402 001	FEB 28, 2001	FEB	NEWA	
AN			0.6%	N75403 001	FEB 28, 2001	FEB	NEWA	
		SYRUP; ORAL						
>D>		ALUPENT						
>D>	AA +	BOEHRINGER INGELHEIM	10MG/5ML	N17571 001	MAY 23, 1975	NOV	DISC	
>A>		@	10MG/5ML	N17571 001	MAY 23, 1975	NOV	DISC	
		METAPROTERENOL SULFATE						
>D>	AA	COPLEY PHARM	10MG/5ML	N73034 001	AUG 30, 1991	NOV	DISC	
>A>		@	10MG/5ML	N73034 001	AUG 30, 1991	NOV	DISC	
>D>	AA	MORTON GROVE	10MG/5ML	N74702 001	MAR 24, 1997	NOV	CRLD	
>A>	AA +		10MG/5ML	N74702 001	MAR 24, 1997	NOV	CRLD	
>D>	AA	TEVA	10MG/5ML	N72761 001	FEB 27, 1992	NOV	DISC	
>A>		@	10MG/5ML	N72761 001	FEB 27, 1992	NOV	DISC	
		METHADONE HYDROCHLORIDE						
		TABLET; ORAL						
		METHADONE HCL						
>D>	AA	EON	40MG	N75082 001	MAR 25, 1998	NOV	CDFR	
>A>	AA		40MG	N75082 001	MAR 25, 1998	NOV	CDFR	
>D>	AA +	ROXANE	40MG	N17058 001	MAR 14, 1973	NOV	CDFR	
>A>	AA +		40MG	N17058 001	MAR 14, 1973	NOV	CDFR	
>D>	AA		40MG	N74081 001	APR 28, 1995	NOV	CDFR	
>A>	AA		40MG	N74081 001	APR 28, 1995	NOV	CDFR	
		METHADOSE						
>D>	AA	MALLINCKRODT	40MG	N74184 001	APR 29, 1993	NOV	CDFR	
>A>	AA		40MG	N74184 001	APR 29, 1993	NOV	CDFR	

METHAMPHETAMINE HYDROCHLORIDE
TABLET; ORAL
DESOXYN
\+ ABBOTT 5MG N05378 002 DEC 31, 1943 JUL CTEC
METHAMPHETAMINE HCL
@ REXAR 5MG N84931 001 JAN 19, 1976 JUL DISC
@ 10MG N84931 002 AUG 22, 1977 JUL DISC

METHAZOLAMIDE
TABLET; ORAL
METHAZOLAMIDE
@ APPLIED ANAL 25MG N40011 001 JUL 17, 1997 MAY DISC
@ 50MG N40011 002 JUL 17, 1997 MAY DISC

METHIMAZOLE
TABLET; ORAL
METHIMAZOLE
AB EON 5MG N40411 001 MAR 27, 2001 MAR NEWA
AB 10MG N40411 002 MAR 27, 2001 MAR NEWA
\+ GENPHARM 20MG N40350 003 JUN 07, 2001 JUN NEWA

METHOTREXATE SODIUM
TABLET; ORAL
TREXALL
BARR EQ 5MG BASE N40385 001 MAR 21, 2001 MAR NEWA
EQ 7.5MG BASE N40385 002 MAR 21, 2001 MAR NEWA
EQ 10MG BASE N40385 003 MAR 21, 2001 MAR NEWA
\+ EQ 15MG BASE N40385 004 MAR 21, 2001 MAR NEWA

METHOXAMINE HYDROCHLORIDE
INJECTABLE; INJECTION
VASOXYL
@ GLAXO WELLCOME 20MG/ML N06772 001 MAR 28, 1949 SEP WDAG

METHSCOPOLAMINE BROMIDE
TABLET; ORAL
METHSCOPOLAMINE BROMIDE
@ PVT FORM 2.5MG N80970 001 OCT 18, 1976 MAY DISC
PAMINE
\+ BRADLEY PHARMS 2.5MG N08848 001 APR 09, 1953 MAY CTEC

METHYCLOTHIAZIDE
TABLET; ORAL
METHYCLOTHIAZIDE
@ PAR PHARM 2.5MG N89135 001 FEB 12, 1986 JUL DISC
@ 5MG N89136 001 FEB 12, 1986 JUL DISC

METHYLDOPA
TABLET; ORAL
METHYLDOPA
@ LEDERLE 125MG N70070 003 OCT 15, 1985 MAY DISC

	METHYLPHENIDATE HYDROCHLORIDE						
	CAPSULE, EXTENDED RELEASE; ORAL						
	METADATE CD						
	+ CELLTECH PHARMS	20MG	N21259 001	APR 03, 2001	APR	NEWA	
	TABLET; ORAL						
	METHYLPHENIDATE HCL						
AB	ABLE	5MG	N40404 001	MAR 29, 2001	MAR	NEWA	
AB		10MG	N40404 002	MAR 29, 2001	MAR	NEWA	
AB		20MG	N40404 003	MAR 29, 2001	MAR	NEWA	
	TABLET, EXTENDED RELEASE; ORAL						
	METADATE ER						
AB	CELLTECH PHARMS	10MG	N40306 001	OCT 20, 1999	APR	CTEC	
	METHYLPHENIDATE HCL						
AB	ABLE	20MG	N76032 001	MAY 09, 2001	MAY	NEWA	
AB	DANBURY PHARMA	20MG	N40410 001	FEB 09, 2001	FEB	NEWA	
	METHYLPREDNISOLONE ACETATE						
	INJECTABLE; INJECTION						
	DEPO-MEDROL						
	PHARMACIA AND UPJOHN	40MG/ML	N11757 001	APR 27, 1959	MAY	CTEC	
	METHYLPREDNISOLONE ACETATE						
	@ STERIS	40MG/ML	N85600 001	MAR 14, 1979	MAY	DISC	
	METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE						
	CREAM; TOPICAL						
	NEO-MEDROL ACETATE						
	@ PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	N60611 002	DEC 07, 1964	MAY	DISC	
	@	1%;EQ 3.5MG BASE/GM	N60611 001	DEC 07, 1964	MAY	DISC	
	METHYLPREDNISOLONE SODIUM SUCCINATE						
	INJECTABLE; INJECTION						
	METHYLPREDNISOLONE SODIUM SUCCINATE						
	@ GENSIA SICOR PHARMS	EQ 500MG BASE/VIAL	N81267 001	NOV 30, 1992	MAY	DISC	
	@	EQ 1GM BASE/VIAL	N81268 001	NOV 30, 1992	MAY	DISC	
	METHYLTESTOSTERONE						
	TABLET; BUCCAL						
	ORETON						
	@ SCHERING	10MG	N80281 001	AUG 03, 1979	FEB	DISC	
	TABLET; BUCCAL/SUBLINGUAL						
	METHYLTESTOSTERONE						
	@ IMPAX LABS	10MG	N84287 001	JUL 16, 1974	JUL	DISC	
	@ LILLY	10MG	N80256 001	DEC 22, 1971	JUL	DISC	
	TABLET; ORAL						
	@ LILLY	25MG	N80256 002	DEC 22, 1971	JUL	DISC	
	METIPRANOLOL HYDROCHLORIDE						
	SOLUTION/DROPS; OPHTHALMIC						
	METIPRANOLOL						
AT	FALCON PHARMS	0.3%	N75720 001	AUG 06, 2001	AUG	NEWA	
	OPTIPRANOLOL						
AT	+ BAUSCH AND LOMB	0.3%	N19907 001	DEC 29, 1989	AUG	CFTG	

		METOCLOPRAMIDE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		METOCLOPRAMIDE HCL						
APR	NEWA	@ ABBOTT	EQ 5MG BASE/ML	N70506 001	JUN 22, 1989	MAY	DISC	
		SOLUTION; INJECTION						
		METOCLOPRAMIDE						
MAR	NEWA	AA UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	JAN	NEWA	
MAR	NEWA	SOLUTION; ORAL						
MAR	NEWA	AA UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	MAY	CDFR	
		METOCLOPRAMIDE HCL						
	>D>	AA LIQUIPHARM	EQ 5MG BASE/5ML	N71402 001	JUN 25, 1993	NOV	CAHN	
APR	CTEC	>A> AA PHARM VENTURES	EQ 5MG BASE/5ML	N71402 001	JUN 25, 1993	NOV	CAHN	
		TABLET; ORAL						
MAY	NEWA	AB GENEVA PHARMS TECH	EQ 5MG BASE	N74478 001	OCT 05, 1995	JAN	CAHN	
FEB	NEWA	AB	EQ 10MG BASE	N74478 002	OCT 05, 1995	JAN	CAHN	
		@ MUTUAL PHARM	EQ 5MG BASE	N71536 002	JAN 16, 1997	JUL	DISC	
		@	EQ 10MG BASE	N71536 001	APR 28, 1993	JUL	DISC	
		METOCURINE IODIDE						
MAY	CTEC	INJECTABLE; INJECTION						
		METUBINE IODIDE						
MAY	DISC	@ LILLY	2MG/ML	N06632 003	FEB 15, 1952	SEP	WDAG	
		METOPROLOL SUCCINATE						
		TABLET, EXTENDED RELEASE; ORAL						
		TOPROL-XL						
MAY	DISC	+ ASTRAZENECA	EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	FEB	NEWA	
MAY	DISC		EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	JUL	CRLD	
			EQ 100MG TARTRATE	N19962 002	JAN 10, 1992	JUL	CRLD	
		METRONIDAZOLE						
		INJECTABLE; INJECTION						
MAY	DISC	METRO I.V.						
MAY	DISC	@ B BRAUN	500MG/100ML	N18674 001	AUG 31, 1982	MAY	DISC	
		METRONIDAZOLE						
		@ ABBOTT	500MG/100ML	N18889 001	NOV 18, 1983	MAY	DISC	
		@ ELKINS SINN	500MG/100ML	N18907 001	MAR 30, 1984	MAY	DISC	
		TABLET; ORAL						
FEB	DISC	PROTOSTAT						
		@ JOHNSON RW	250MG	N18871 001	MAR 02, 1983	MAR	DISC	
		@	500MG	N18871 002	MAR 02, 1983	MAR	DISC	
JUL	DISC	MEZLOCILLIN SODIUM MONOHYDRATE						
JUL	DISC	INJECTABLE; INJECTION						
		MEZLIN						
JUL	DISC	@ BAYER	EQ 1GM BASE/VIAL	N62372 005	JAN 13, 1983	MAY	DISC	
		@	EQ 2GM BASE/VIAL	N62372 001	MAY 13, 1982	MAY	DISC	
		@	EQ 3GM BASE/VIAL	N62372 002	MAY 13, 1982	MAY	DISC	
		@	EQ 4GM BASE/VIAL	N62372 003	MAY 13, 1982	MAY	DISC	
AUG	NEWA	@	EQ 20GM BASE/VIAL	N62372 004	MAR 02, 1988	MAY	DISC	
AUG	CFTG							

MIDAZOLAM HYDROCHLORIDE
INJECTABLE; INJECTION
MIDAZOLAM HCL

AP	AM PHARM PARTNERS	EQ 1MG BASE/ML	N75154 002	JUN 20, 2000	OCT	CAHN
AP		EQ 5MG BASE/ML	N75154 001	JUN 20, 2000	OCT	CAHN
	@ APOTHECON	EQ 1MG BASE/ML	N75620 001	NOV 01, 2000	MAY	DISC
	@	EQ 5MG BASE/ML	N75620 002	NOV 01, 2000	MAY	DISC
	@	EQ 5MG BASE/ML	N75641 001	OCT 19, 2000	MAY	DISC
	@ ASTRAZENECA	EQ 5MG BASE/ML	N75263 001	JUN 26, 2000	MAY	DISC
	@ BEDFORD	EQ 5MG BASE/ML	N75249 001	JUN 23, 2000	SEP	DISC
	@ BEN VENUE	EQ 5MG BASE/ML	N75455 001	JUN 20, 2000	SEP	DISC

MINOCYCLINE HYDROCHLORIDE
CAPSULE; ORAL
MINOCIN

AB	LEDERLE	EQ 75MG BASE	N50649 003	FEB 12, 2001	MAR	NEWA
AB +		EQ 100MG BASE	N50649 002	MAY 31, 1990	MAR	CRLD

MINOCYCLINE HCL

AB	DANBURY PHARMA	EQ 100MG BASE	N63065 001	DEC 30, 1991	MAR	CRLD
AB	IMPAX LABS	EQ 75MG BASE	N65005 003	APR 18, 2001	APR	NEWA

VECTRIN

	@ MEDICIS	EQ 75MG BASE	N63067 002	SEP 15, 1999	MAY	DISC
	@	EQ 100MG BASE	N63067 001	JUL 31, 1990	MAY	DISC

POWDER, EXTENDED RELEASE; DENTAL
ARESTIN

+	ORAPHARMA	EQ 1MG BASE	N50781 001	FEB 16, 2001	FEB	NEWA

MIRTAZAPINE
TABLET, ORALLY DISINTEGRATING; ORAL
REMERON SOLTAB

+	ORGANON INC	15MG	N21208 001	JAN 12, 2001	JAN	NEWA
		30MG	N21208 002	JAN 12, 2001	JAN	NEWA
		45MG	N21208 003	JAN 12, 2001	JAN	NEWA

MORPHINE SULFATE
CAPSULE, EXTENDED RELEASE; ORAL
KADIAN

+	FAULDING PHARMS	20MG	N20616 001	JUL 03, 1996	JUN	CAHN
+		30MG	N20616 004	MAR 09, 2001	JUN	NEWA
+		50MG	N20616 002	JUL 03, 1996	JUN	CAHN
+		60MG	N20616 005	MAR 09, 2001	JUN	NEWA
+		100MG	N20616 003	JUL 03, 1996	JUN	CAHN

TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

AB	WATSON LABS	100MG	N75656 001	JAN 30, 2001	JAN	NEWA

ORAMORPH SR

BC	ELAN PHARMS	15MG	N19977 004	NOV 23, 1994	SEP	CAHN
BC		30MG	N19977 001	AUG 15, 1991	SEP	CAHN
BC		60MG	N19977 002	AUG 15, 1991	SEP	CAHN
BC		100MG	N19977 003	AUG 15, 1991	SEP	CAHN

	MOXIFLOXACIN HYDROCHLORIDE						
>A>	INJECTABLE; IV (INFUSION)						
>A>	AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER						
>A>	+ BAYER	160MG/100ML	N21277 001	NOV 30, 2001	NOV	NEWA	
	NABUMETONE						
	TABLET; ORAL						
	NABUMETONE						
AB	TEVA	750MG	N75189 002	SEP 24, 2001	SEP	NEWA	
	NADOLOL						
	TABLET; ORAL						
	CORGARD						
AB	APOTHECON	40MG	N18063 001	DEC 10, 1979	AUG	CRLD	
	NADOLOL						
AB	GENEVA PHARMS TECH	20MG	N74501 001	NOV 09, 1995	JAN	CAHN	
AB		40MG	N74501 002	NOV 09, 1995	JAN	CAHN	
AB		80MG	N74501 003	NOV 09, 1995	JAN	CAHN	
	NAFCILLIN SODIUM						
	INJECTABLE; INJECTION						
	NAFCILLIN SODIUM						
	@ APOTHECON	EQ 500MG BASE/VIAL	N61984 001	APR 29, 1976	MAY	DISC	
	+	EQ 500MG BASE/VIAL	N62527 001	AUG 02, 1984	MAY	CRLD	
	@	EQ 1GM BASE/VIAL	N61984 002	APR 29, 1976	MAY	DISC	
	@	EQ 2GM BASE/VIAL	N61984 003	APR 29, 1976	MAY	DISC	
	@	EQ 4GM BASE/VIAL	N61984 005	APR 29, 1976	MAY	DISC	
	@ MARSAM	EQ 500MG BASE/VIAL	N62844 001	OCT 26, 1988	MAY	DISC	
	@	EQ 1GM BASE/VIAL	N62844 002	OCT 26, 1988	MAY	DISN	
	@	EQ 1.5GM BASE/VIAL	N62844 003	OCT 26, 1988	MAY	DISC	
	@	EQ 2GM BASE/VIAL	N62844 004	OCT 26, 1988	MAY	DISC	
	@	EQ 4GM BASE/VIAL	N62844 005	OCT 26, 1988	MAY	DISC	
	@	EQ 10GM BASE/VIAL	N63008 001	SEP 29, 1988	MAY	DISC	
	NALLPEN						
	@ SMITHKLINE BEECHAM	EQ 500MG BASE/VIAL	N61999 001	JUL 10, 1978	MAY	DISC	
	@	EQ 1GM BASE/VIAL	N61999 002	JUL 10, 1978	MAY	DISC	
	@	EQ 2GM BASE/VIAL	N61999 003	JUL 10, 1978	MAY	DISC	
	@	EQ 10GM BASE/VIAL	N61999 004	JUL 17, 1978	MAY	DISC	
	UNIPEN						
	@ WYETH AYERST	EQ 500MG BASE/VIAL	N50320 001	JUN 23, 1970	MAY	DISC	
	@	EQ 500MG BASE/VIAL	N62717 001	DEC 16, 1986	MAY	DISC	
	@	EQ 1GM BASE/VIAL	N62717 002	DEC 16, 1986	MAY	DISC	
	@	EQ 2GM BASE/VIAL	N50320 003	JUN 23, 1970	MAY	DISC	
	@	EQ 2GM BASE/VIAL	N62717 004	DEC 16, 1986	MAY	DISC	
	@	EQ 4GM BASE/VIAL	N50320 004	JUN 23, 1970	MAY	DISC	
	@	EQ 10GM BASE/VIAL	N50320 005	DEC 21, 1978	MAY	DISC	
	UNIPEN IN PLASTIC CONTAINER						
	@ WYETH AYERST	EQ 1GM BASE/VIAL	N50320 002	JUN 23, 1970	MAY	DISC	

NALBUPHINE HYDROCHLORIDE
INJECTABLE; INJECTION
NALBUPHINE HCL

	@ ASTRAZENECA	10MG/ML	N72070 001	APR 10, 1989	JUN	DISC
	@	20MG/ML	N72073 001	APR 10, 1989	JUN	DISC

NALOXONE HYDROCHLORIDE
INJECTABLE; INJECTION
NALOXONE

	@ WYETH AYERST	0.02MG/ML	N70188 001	SEP 24, 1986	JAN	DISC
	@	0.02MG/ML	N70189 001	SEP 24, 1986	JAN	DISC
	@	0.4MG/ML	N70190 001	SEP 24, 1986	JAN	DISC
	@	0.4MG/ML	N70191 001	SEP 24, 1986	JAN	DISC

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE
TABLET; ORAL
NALOXONE HCL AND PENTAZOCAINE

AB	AMIDE PHARM	EQ 0.5MG BASE;EQ 50MG BASE	N75735 001	JUL 11, 2001	JUL	NEWA

NANDROLONE PHENPROPIONATE
INJECTABLE; INJECTION
DURABOLIN

>D>	+ ORGANON	25MG/ML	N11891 001	OCT 30, 1959	NOV	DISC
>A>	@	25MG/ML	N11891 001	OCT 30, 1959	NOV	DISC
>D>	+	50MG/ML	N11891 002	APR 05, 1961	NOV	DISC
>A>	@	50MG/ML	N11891 002	APR 05, 1961	NOV	DISC

NAPHAZOLINE HYDROCHLORIDE
SOLUTION/DROPS; OPHTHALMIC
ALBALON

AT	ALLERGAN	0.1%	N80248 001	MAR 24, 1972	JUL	CRLD
AT	+	0.1%	N80248 001	MAR 24, 1972	AUG	CRLD

NAPHCON FORTE

	@ ALCON	0.1%	N80229 001	MAR 06, 1974	JUL	DISC

OPCON

	@ BAUSCH AND LOMB	0.1%	N87506 001	DEC 01, 1981	JUL	DISC

VASOCON

AT	NOVARTIS	0.1%	N80235 002	MAR 24, 1983	FEB	CAHN

NAPROXEN
TABLET, EXTENDED RELEASE; ORAL
NAPROXEN

AB	+ ALPHAPHARM	375MG	N75390 001	APR 19, 2001	APR	NEWA
AB	+	500MG	N75390 002	APR 19, 2001	APR	NEWA

NAPROXEN SODIUM
TABLET; ORAL
NAPROXEN SODIUM

AB	GENEVA PHARMS TECH	EQ 250MG BASE	N74495 001	DEC 05, 1994	JAN	CAHN
AB		EQ 500MG BASE	N74495 002	DEC 05, 1994	JAN	CAHN

NEDOCROMIL SODIUM
AEROSOL, METERED; INHALATION
TILADE
+ AVENTIS 1.75MG/INH N19660 001 DEC 30, 1992 SEP CAHN

NEFAZODONE HYDROCHLORIDE
TABLET; ORAL
SERZONE
BRISTOL MYERS SQUIBB 50MG N20152 001 DEC 22, 1994 APR CTEC

NEOMYCIN SULFATE; POLYMYXIN B SULFATE
SOLUTION; IRRIGATION
NEOMYCIN AND POLYMYXIN B SULFATES
@ STERIS EQ 40MG BASE/ML;200,000 UNITS/ML N62664 001 APR 08, 1986 MAY DISC
NEOSPORIN G.U. IRRIGANT
>D> MONARCH PHARMS EQ 40MG BASE/ML;200,000 UNITS/ML N60707 001 JUN 28, 1966 NOV CRLD
>A> + EQ 40MG BASE/ML;200,000 UNITS/ML N60707 001 JUN 28, 1966 NOV CRLD
EQ 40MG BASE/ML;200,000 UNITS/ML N60707 001 JUN 28, 1966 MAY CTEC
SOLUTION/DROPS; OPHTHALMIC
STATROL
@ ALCON EQ 3.5MG BASE/ML;16,250 UNITS/ML N62339 001 NOV 30, 1984 JUL DISC

NESIRITIDE
FOR SOLUTION; INTRAVENOUS
NATRECOR
+ SCIOS 1.5MG/VIAL N20920 001 AUG 10, 2001 AUG NEWA

NETILMICIN SULFATE
INJECTABLE; INJECTION
NETROMYCIN
@ SCHERING EQ 100MG BASE/ML N50544 003 FEB 28, 1983 MAY DISC

NIFEDIPINE
CAPSULE; ORAL
NIFEDIPINE
@ CHASE LABS NJ 10MG N72409 001 JUL 04, 1990 FEB WDRP
@ 20MG N73421 001 JUN 19, 1991 FEB WDRP
TABLET, EXTENDED RELEASE; ORAL
ADALAT CC
AB1 BAYER 30MG N20198 001 APR 21, 1993 APR CTEC
NIFEDIPINE
AB2 BIOVAIL 30MG N75289 002 FEB 06, 2001 FEB NEWA
AB1 ELAN PHARM 60MG N75659 001 OCT 26, 2001 OCT NEWA
PROCARDIA XL
AB2 + PFIZER 30MG N19684 001 SEP 06, 1989 FEB CTEC

NITROFURAZONE

OINTMENT; TOPICAL

NITROFURAZONE

@ CLAY PARK 0.2% N84968 001 JAN 25, 1978 MAY DISC

POWDER; TOPICAL

FURACIN

@ ROBERTS LABS 0.2% N83791 001 OCT 17, 1975 FEB WDRP

SOLUTION; TOPICAL

NITROFURAZONE

@ CLAY PARK 0.2% N85130 001 NOV 02, 1978 MAY DISC

\+ WENDT 0.2% N87081 001 JUL 22, 1981 MAY CTEC

NITROGLYCERIN

AEROSOL; SUBLINGUAL

NITROLINGUAL

@ POHL BOSKAMP 0.4MG/SPRAY N18705 001 OCT 31, 1985 APR DISC

NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

RAVOCAINE AND NOVOCAIN W/ LEVOPHED

@ EASTMAN KODAK EQ 0.033MG BASE/ML;2%;0.4% N08592 003 MAR 11, 1955 SEP WDAG

NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE

AB BARR 5MG N75951 001 MAY 25, 2001 MAY NEWA

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

PAMELOR

AB TYCO HLTHCARE EQ 10MG BASE N18013 001 AUG 01, 1977 JUN CAHN

AB EQ 25MG BASE N18013 002 AUG 01, 1977 JUN CAHN

AB EQ 50MG BASE N18013 004 JUN 14, 1979 JUN CAHN

AB \+ EQ 75MG BASE N18013 003 JUN 14, 1979 JUN CAHN

SOLUTION; ORAL

AA TYCO HLTHCARE EQ 10MG BASE/5ML N18012 001 AUG 01, 1977 JUN CAHN

NYSTATIN

CREAM; TOPICAL

NILSTAT

@ LEDERLE 100,000 UNITS/GM N61445 001 APR 02, 1971 MAY DISC

NYSTATIN

@ TEVA 100,000 UNITS/GM N61966 001 MAY 25, 1976 MAY DISC

OINTMENT; TOPICAL

NILSTAT

@ LEDERLE 100,000 UNITS/GM N61444 001 MAR 29, 1971 MAY DISC

NYSTATIN

AT \+ ALTANA 100,000 UNITS/GM N62124 002 SEP 23, 1982 MAY CTEC

SUSPENSION; ORAL

@ ROXANE 100,000 UNITS/ML N62832 001 DEC 27, 1991 MAY DISC

@ TEVA 100,000 UNITS/ML N62670 001 JUN 18, 1987 MAY DISC

@ 100,000 UNITS/ML N62776 001 DEC 17, 1987 MAY DISC

		@ THAMES	100,000 UNITS/ML	N62876 001	FEB 29, 1988	JUL	DISC	
		TABLET; ORAL						
		@ EON	500,000 UNITS	N62065 001	JUL 22, 1977	MAY	DISC	
		@ ROSEMONT	500,000 UNITS	N62524 001	NOV 26, 1985	MAY	DISC	
		TABLET; VAGINAL						
		KOROSTATIN						
		@ HOLLAND RANTOS	100,000 UNITS	N61718 001	SEP 30, 1974	FEB	WDRP	
		NYSTATIN; TRIAMCINOLONE ACETONIDE						
		OINTMENT; TOPICAL						
		MYCO-TRIACET II						
		@ TEVA	100,000 UNITS/GM;0.1%	N62045 002	NOV 26, 1985	MAY	DISC	
		NYSTATIN AND TRIAMCINOLONE ACETONIDE						
		@ CLAY PARK	100,000 UNITS/GM;0.1%	N62280 002	OCT 10, 1985	MAY	DISC	
		OLANZAPINE						
		TABLET; ORAL						
		ZYPREXA						
		LILLY	15MG	N20592 005	SEP 09, 1997	JUN	CRLD	
	+		20MG	N20592 006	SEP 09, 1997	JUN	CMFD	
		OMEPRAZOLE						
		CAPSULE, DELAYED REL PELLETS; ORAL						
>A>		OMEPRAZOLE						
>A>	AB	ANDRX PHARMS	10MG	N75347 001	NOV 16, 2001	NOV	NEWA	
>A>	AB		20MG	N75347 002	NOV 16, 2001	NOV	NEWA	
>A>	AB		40MG	N75347 003	NOV 16, 2001	NOV	NEWA	
		PRILOSEC						
>D>		ASTRAZENECA	10MG	N19810 003	OCT 05, 1995	NOV	CFTG	
>A>	AB		10MG	N19810 003	OCT 05, 1995	NOV	CFTG	
>D>	+		20MG	N19810 001	SEP 14, 1989	NOV	CFTG	
>A>	AB +		20MG	N19810 001	SEP 14, 1989	NOV	CFTG	
>D>	+		40MG	N19810 002	JAN 15, 1998	NOV	CFTG	
>A>	AB +		40MG	N19810 002	JAN 15, 1998	NOV	CFTG	
		OXACILLIN SODIUM						
		INJECTABLE; INJECTION						
		BACTOCILL						
		@ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N62736 001	DEC 19, 1986	FEB	DISC	
		@	EQ 2GM BASE/VIAL	N62736 002	DEC 19, 1986	FEB	DISC	
		OXACILLIN SODIUM						
AP	+	APOTHECON	EQ 1GM BASE/VIAL	N61490 003	APR 08, 1971	FEB	CRLD	
AP	+		EQ 2GM BASE/VIAL	N62737 002	DEC 23, 1986	FEB	CRLD	
		@ IBI	EQ 125MG BASE/VIAL	N62798 003	DEC 11, 1995	MAY	DISC	
		@	EQ 250MG BASE/VIAL	N62798 004	DEC 11, 1995	MAY	DISC	
		@	EQ 500MG BASE/VIAL	N62798 005	DEC 11, 1995	MAY	DISC	
		@	EQ 1GM BASE/VIAL	N62798 001	DEC 11, 1995	MAY	DISC	
		@	EQ 2GM BASE/VIAL	N62798 002	DEC 11, 1995	MAY	DISC	
		OXAPROZIN						
		TABLET; ORAL						
		DAYPRO						
AB	+	SEARLE	600MG	N18841 004	OCT 29, 1992	JAN	CFTG	

OXAPROZIN
TABLET; ORAL
OXAPROZIN

AB	DR REDDYS LABS LTD	600MG	N75855 001	JAN 31, 2001	JAN	NEWA
AB	EON	600MG	N75845 001	JAN 31, 2001	JAN	NEWA
AB	GENEVA PHARMS	600MG	N75850 001	APR 27, 2001	APR	NEWA
AB	GENPHARM	600MG	N75847 001	FEB 28, 2001	FEB	NEWA
AB	INVAMED	600MG	N75842 001	APR 12, 2001	APR	NEWA
AB	MYLAN	600MG	N75851 001	AUG 17, 2001	AUG	NEWA
AB	PUREPAC PHARM	600MG	N75843 001	OCT 03, 2001	OCT	NEWA
AB	WATSON LABS	600MG	N75848 001	FEB 09, 2001	FEB	NEWA

OXAZEPAM
CAPSULE; ORAL
SERAX

AB	FAULDING PHARMS	10MG	N15539 002	SEP 29, 1966	JUN	CAHN
AB		15MG	N15539 004	SEP 29, 1966	JUN	CAHN
AB	+	30MG	N15539 006	SEP 29, 1966	JUN	CAHN

TABLET; ORAL

	+ FAULDING PHARMS	15MG	N15539 008	NOV 16, 1967	JUN	CAHN

OXCARBAZEPINE
SUSPENSION; ORAL
TRILEPTAL

	+ NOVARTIS	300MG/5ML	N21285 001	MAY 25, 2001	MAY	NEWA

OXYCODONE HYDROCHLORIDE
TABLET; ORAL
ROXICODONE

	ELAN PHARMS	15MG	N21011 001	AUG 31, 2000	SEP	CAHN
+		30MG	N21011 002	AUG 31, 2000	SEP	CAHN

TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN

	@ PURDUE PHARMA LP	160MG	N20553 005	MAR 15, 2000	JUN	DISC

OXYTETRACYCLINE HYDROCHLORIDE
CAPSULE; ORAL
OXYTETRACYCLINE HCL

	@ IMPAX LABS	EQ 250MG BASE	N60760 001	AUG 09, 1967	FEB	DISC
	@ PROTER	EQ 250MG BASE	N60869 001	JAN 29, 1964	FEB	WDRP
	@ WEST WARD	EQ 250MG BASE	N60770 001	SEP 29, 1967	MAY	DISC

TERRAMYCIN

	+ PFIZER	EQ 250MG BASE	N50286 002	SEP 08, 1964	MAY	CTEC

PACLITAXEL
INJECTABLE; INJECTION
PACLITAXEL

AP	BEDFORD	6MG/ML	N75190 001	JUL 27, 2001	JUL	NEWA
AP	MYLAN	6MG/ML	N75278 001	JUL 23, 2001	JUL	NEWA
AP	ZENITH GOLDLINE	6MG/ML	N75297 001	MAR 27, 2001	MAR	NEWA

PAMIDRONATE DISODIUM
INJECTABLE; INJECTION
AREDIA
AP + NOVARTIS 30MG/VIAL N20036 001 OCT 31, 1991 APR CFTG
AP + 90MG/VIAL N20036 004 MAY 06, 1993 APR CFTG
PAMIDRONATE DISODIUM
AP BEDFORD 30MG/VIAL N75290 001 APR 30, 2001 APR NEWA
AP 90MG/VIAL N75290 003 APR 30, 2001 APR NEWA

PANCURONIUM BROMIDE
INJECTABLE; INJECTION
PANCURONIUM BROMIDE
@ ASTRAZENECA 1MG/ML N72210 001 MAR 31, 1988 JUL DISC
@ 2MG/ML N72211 001 MAR 31, 1988 JUL DISC
@ 2MG/ML N72213 001 MAR 31, 1988 JUL DISC

PANTOPRAZOLE SODIUM
INJECTABLE; IV (INFUSION)
PROTONIX IV
+ WYETH AYERST EQ 40MG BASE/VIAL N20988 001 MAR 22, 2001 MAR NEWA
TABLET, DELAYED RELEASE; ORAL
PROTONIX
+ WYETH AYERST EQ 20MG BASE N20987 002 JUN 12, 2001 JUN NEWA

PEMOLINE
TABLET; ORAL
PEMOLINE
AB MALLINCKRODT 18.75MG N75726 003 MAR 30, 2001 MAR NEWA
AB 37.5MG N75726 002 MAR 30, 2001 MAR NEWA
AB 75MG N75726 001 MAR 30, 2001 MAR NEWA
AB WATSON LABS 18.75MG N75287 001 JUN 13, 2001 JUN NEWA

PENCICLOVIR SODIUM
CREAM; TOPICAL
DENAVIR
+ NOVARTIS 1% N20629 001 SEP 24, 1996 JUL CAHN

PENICILLIN G POTASSIUM
FOR SOLUTION; ORAL
PENICILLIN
@ TEVA 200,000 UNITS/5ML N60307 002 MAY 27, 1964 JUL DISC
@ 400,000 UNITS/5ML N60307 004 MAY 27, 1964 JUL DISC
PENICILLIN-2
@ TEVA 250,000 UNITS/5ML N60307 003 MAY 27, 1964 JUL DISC
TABLET; ORAL
PENICILLIN G POTASSIUM
>D> AB MYLAN 200,000 UNITS N60781 001 FEB 11, 1966 NOV DISC
>A> @ 200,000 UNITS N60781 001 FEB 11, 1966 NOV DISC
>D> AB 250,000 UNITS N60781 002 FEB 11, 1966 NOV DISC
>A> @ 250,000 UNITS N60781 002 FEB 11, 1966 NOV DISC
>D> AB 400,000 UNITS N60781 003 FEB 11, 1966 NOV DISC
>A> @ 400,000 UNITS N60781 003 FEB 11, 1966 NOV DISC

>D>	AB		500,000 UNITS	N60781 005	MAR 10, 1980	NOV	DISC
>A>		@	500,000 UNITS	N60781 005	MAR 10, 1980	NOV	DISC
>D>		+	800,000 UNITS	N60781 004	FEB 11, 1966	NOV	DISC
>A>		@	800,000 UNITS	N60781 004	FEB 11, 1966	NOV	DISC
		@ TEVA	200,000 UNITS	N60306 001	JUN 01, 1964	MAY	DISC
		@	250,000 UNITS	N60306 002	JUN 01, 1964	MAY	DISC
		@	400,000 UNITS	N60306 003	JUN 01, 1964	MAY	DISC
		@	500,000 UNITS	N60306 004	JUN 26, 1979	MAY	DISC
>D>	AB	WYETH AYERST	200,000 UNITS	N60413 001	JUL 23, 1948	NOV	CTEC
>A>			200,000 UNITS	N60413 001	JUL 23, 1948	NOV	CTEC
>D>	AB		250,000 UNITS	N60413 002	JUL 23, 1948	NOV	CTEC
>A>			250,000 UNITS	N60413 002	JUL 23, 1948	NOV	CTEC
>D>	AB		400,000 UNITS	N60413 003	JUL 23, 1948	NOV	CRLD
>A>		+	400,000 UNITS	N60413 003	JUL 23, 1948	NOV	CRLD

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

PENICILLIN G PROCAINE

	@ PFIZER	300,000 UNITS/VIAL	N60099 001	NOV 10, 1948	MAY	DISC
	@	1,500,000 UNITS/VIAL	N60099 002	NOV 10, 1948	MAY	DISC

PFIZERPEN-AS

	@ PFIZER	300,000 UNITS/ML	N60286 001	NOV 01, 1950	MAY	DISC
	@	600,000 UNITS/ML	N60286 002	NOV 01, 1950	MAY	DISC

WYCILLIN

+	KING PHARMS	300,000 UNITS/ML	N60101 002	APR 26, 1948	MAY	CTEC
+		600,000 UNITS/ML	N60101 001	APR 26, 1948	MAY	CTEC

PENICILLIN G SODIUM

INJECTABLE; IM-IV

PENICILLIN G SODIUM

+	BIOCHEMIE	5,000,000 UNITS/VIAL	N65068 001	FEB 26, 2001	FEB	NEWA
	@ MARSAM	5,000,000 UNITS/VIAL	N63014 001	SEP 13, 1988	FEB	DISC

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN V POTASSIUM

	@ MYLAN	EQ 125MG BASE/5ML	N61624 002	AUG 07, 1972	MAY	DISC
	@	EQ 250MG BASE/5ML	N61624 001	JUN 05, 1972	MAY	DISC

V-CILLIN K

	@ LILLY	EQ 125MG BASE/5ML	N60004 001	AUG 21, 1958	MAY	DISC
	@	EQ 250MG BASE/5ML	N60004 002	APR 07, 1967	MAY	DISC

TABLET; ORAL

PEN-VEE K

AB	+ WYETH AYERST	EQ 500MG BASE	N60006 003	JAN 13, 1958	MAY	CRLD

PENICILLIN V POTASSIUM

AB	+ BIOCHEMIE	EQ 500MG BASE	N64071 002	NOV 30, 1995	MAY	CTEC
	@ MYLAN	EQ 250MG BASE	N61530 001	NOV 18, 1971	MAY	DISC
	@	EQ 500MG BASE	N61530 002	MAR 20, 1972	MAY	DISC

V-CILLIN K

	@ LILLY	EQ 125MG BASE	N60003 001	SEP 17, 1957	MAY	DISC
	@	EQ 250MG BASE	N60003 002	SEP 17, 1957	MAY	DISC
	@	EQ 500MG BASE	N60003 003	SEP 17, 1957	MAY	DISC

PENTOBARBITAL							
ELIXIR; ORAL							
NEMBUTAL							
@ ABBOTT		18.2MG/5ML	N83244	001	JAN 08, 1975	JUL	DISC
PENTOBARBITAL SODIUM							
CAPSULE; ORAL							
NEMBUTAL SODIUM							
@ ABBOTT		50MG	N84093	001	JAN 14, 1975	JUL	DISC
SUPPOSITORY; RECTAL							
NEMBUTAL							
@ ABBOTT		30MG	N83247	001	JAN 25, 1982	JUL	DISC
@		60MG	N83247	002	JAN 25, 1982	JUL	DISC
@		120MG	N83247	003	JAN 25, 1982	JUL	DISC
@		200MG	N83247	004	JAN 25, 1982	JUL	DISC
PERFLUTREN							
INJECTABLE; INTRAVENOUS							
DEFINITY							
+ DUPONT PHARMS		6.52MG/ML	N21064	001	JUL 31, 2001	JUL	NEWA
PERPHENAZINE							
CONCENTRATE; ORAL							
PERPHENAZINE							
+ PHARM ASSOC		16MG/5ML	N40360	001	MAY 25, 2001	MAY	NEWA
TRILAFON							
@ SCHERING		16MG/5ML	N11557	001	DEC 12, 1958	MAR	DISC
PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM							
TABLET; ORAL							
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL							
+ ABLE		200MG;800MG;160MG	N21105	001	JUN 26, 2001	JUN	NEWA
PHENDIMETRAZINE TARTRATE							
CAPSULE; ORAL							
PHENDIMETRAZINE TARTRATE							
@ EON		35MG	N85633	001	JUL 13, 1978	JUL	DISC
@		35MG	N85694	001	JUN 05, 1978	MAY	DISC
AA +		35MG	N85695	001	JUN 05, 1978	JUL	CRLD
@		35MG	N85702	001	JUN 07, 1978	JUL	DISC
CAPSULE, EXTENDED RELEASE; ORAL							
BC + EON		105MG	N18074	001	APR 16, 1979	JUL	CRLD
@ GENEVA PHARMS		105MG	N87378	001	NOV 03, 1981	JUL	DISC
TABLET; ORAL							
PHENAZINE-35							
@ ABC HOLDING		35MG	N85512	001	MAY 06, 1977	MAY	DISC
PHENDIMETRAZINE TARTRATE							
@ EON		35MG	N85402	001	MAY 19, 1978	MAY	DISC
@		35MG	N85497	001	AUG 19, 1977	MAY	DISC
@ MIKART		35MG	N89452	001	OCT 30, 1991	JUL	DISC
@ ROSEMONT		35MG	N84399	001	MAY 28, 1981	MAY	DISC
STATOBEX							

PHENDIMETRAZINE TARTRATE
TABLET; ORAL
STATOBEX
@ TEVA 35MG N86013 001 DEC 16, 1977 JUL DISC
X-TROZINE
@ SHIRE RICHWOOD 35MG N86550 001 SEP 16, 1981 JUL DISC
@ 35MG N86551 001 SEP 16, 1981 JUL DISC
@ 35MG N86552 001 SEP 16, 1981 JUL DISC

PHENTERMINE HYDROCHLORIDE
CAPSULE; ORAL
OBY-TRIM
@ SHIRE RICHWOOD 30MG N87764 001 MAR 18, 1982 JUL DISC
PHENTERMINE HCL
@ ABC HOLDING 30MG N85411 001 SEP 10, 1980 MAY DISC
AA ABLE 30MG N40403 001 AUG 30, 2001 AUG NEWA
AA 30MG N40427 001 AUG 30, 2001 AUG NEWA
@ ROSEMONT 30MG N84487 001 APR 09, 1982 MAY DISC
TABLET; ORAL
AA ABLE 37.5MG N40402 001 AUG 30, 2001 AUG NEWA
+ EON 30MG N88605 001 SEP 28, 1987 MAY CMFD

PHENYTOIN
SUSPENSION; ORAL
PHENYTOIN
AB UDL 125MG/5ML N40342 001 JAN 31, 2001 JAN NEWA

PIPERAZINE CITRATE
SYRUP; ORAL
PIPERAZINE CITRATE
@ LANNETT EQ 500MG BASE/5ML N80963 001 JUL 25, 1974 MAY DISC
TABLET; ORAL
@ IMPAX LABS EQ 250MG BASE N80874 001 JUL 19, 1973 MAY DISC

PIPOBROMAN
TABLET; ORAL
VERCYTE
@ ABBOTT 25MG N16245 002 JUL 01, 1966 JUL DISC

PORACTANT ALFA
SUSPENSION; INTRATRACHEAL
CUROSURF
+ DEY 80MG/ML N20744 001 NOV 18, 1999 SEP CAIN

POTASSIUM CHLORIDE
TABLET, EXTENDED RELEASE; ORAL
K-DUR 10
AB KEY PHARMS 10MEQ N19439 002 JUN 13, 1986 APR CTEC

PRAZOSIN HYDROCHLORIDE
CAPSULE; ORAL
PRAZOSIN HCL
@ PUREPAC PHARM EQ 1MG BASE N72991 001 MAY 16, 1989 JUL DISC

		@	EQ 2MG BASE	N72921 001	MAY 16, 1989	JUL	DISC
		@	EQ 5MG BASE	N72992 001	MAY 16, 1989	JUL	DISC
		PREDNICARBATE					
		OINTMENT; TOPICAL					
		DERMATOP					
	+	AVENTIS PHARMS	0.1%	N19568 001	SEP 23, 1991	MAR	CMFD
		PREDNISOLONE					
		SYRUP; ORAL					
		PREDNISOLONE					
AA		KV PHARM	5MG/5ML	N40423 001	OCT 22, 2001	OCT	NEWA
		PRELONE					
AA	+	MURO	5MG/5ML	N89654 001	JAN 17, 1989	OCT	CFTG
		TABLET; ORAL					
		PREDNISOLONE					
		@ CHELSEA LABS	5MG	N85085 002	FEB 23, 1977	MAY	DISC
		PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM					
		OINTMENT; OPHTHALMIC					
		VASOCIDIN					
AT		NOVARTIS	0.5%;10%	N88791 001	OCT 05, 1984	FEB	CAHN
		SUSPENSION/DROPS; OPHTHALMIC					
		METIMYD					
	+	SCHERING	0.5%;10%	N10210 001	FEB 24, 1956	FEB	CTEC
		PREDAMIDE					
		@ AKORN	0.5%;10%	N88059 001	JUL 29, 1983	FEB	WDRP
		SULPHRIN					
		@ BAUSCH AND LOMB	0.5%;10%	N88089 001	DEC 28, 1982	FEB	WDRP
		PREDNISOLONE SODIUM PHOSPHATE					
		SOLUTION/DROPS; OPHTHALMIC					
		INFLAMASE FORTE					
AT	+	NOVARTIS	EQ 0.9% PHOSPHATE	N80751 002	DEC 19, 1973	FEB	CAHN
		INFLAMASE MILD					
AT	+	NOVARTIS	EQ 0.11% PHOSPHATE	N80751 001	DEC 19, 1973	FEB	CAHN
		PREDNISOLONE SODIUM PHOSPHATE					
		@ AKORN	EQ 0.11% PHOSPHATE	N83358 001	AUG 21, 1974	FEB	WDRP
		@	EQ 0.9% PHOSPHATE	N83358 002	AUG 21, 1974	FEB	WDRP
		@ ALCON UNIVERSAL	EQ 0.11% PHOSPHATE	N81043 001	OCT 24, 1991	MAY	DISC
		@	EQ 0.9% PHOSPHATE	N81044 001	OCT 24, 1991	MAY	DISC
		PREDNISONE					
		TABLET; ORAL					
>D>		METICORTEN					
>D>	AB	SCHERING	1MG	N09766 002	SEP 15, 1955	NOV	DISC
>A>		@	1MG	N09766 002	SEP 15, 1955	NOV	DISC
		PREDNISONE					
		@ CHELSEA LABS	5MG	N85084 002	DEC 15, 1981	MAY	DISC
>D>	BX	EVERYLIFE	1MG	N84440 001	FEB 25, 1975	NOV	DISC
>A>		@	1MG	N84440 001	FEB 25, 1975	NOV	DISC
>D>	BX		2.5MG	N84440 002	FEB 25, 1975	NOV	DISC
>A>		@	2.5MG	N84440 002	FEB 25, 1975	NOV	DISC

>D>	BX		5MG	N84440 003	FEB 25, 1975	NOV	DISC
>A>		@	5MG	N84440 003	FEB 25, 1975	NOV	DISC
		@ GENEVA PHARMS	5MG	N80336 002	JUL 29, 1976	MAY	DISC
		@ HALSEY	10MG	N86595 001	APR 10, 1979	JUL	DISC
		@ LANNETT	20MG	N84275 001	JUN 27, 1974	MAY	DISC
>D>	AB	ROXANE	1MG	N87800 001	APR 22, 1982	NOV	CRLD
>A>	AB	+	1MG	N87800 001	APR 22, 1982	NOV	CRLD
	AB	TRIGEN	5MG	N40362 002	AUG 29, 2001	AUG	NEWA
	AB		10MG	N40362 001	AUG 29, 2001	AUG	NEWA
		PRILOCAINE HYDROCHLORIDE					
		INJECTABLE; INJECTION					
		CITANEST PLAIN					
		@ ASTRAZENECA	4%	N14763 007	NOV 18, 1965	SEP	DISC
		+ DENTSPLY PHARM	4%	N21382 001	NOV 18, 1965	SEP	NEWA
		PRIMIDONE					
		SUSPENSION; ORAL					
		MYSOLINE					
		+ XCEL PHARMS	250MG/5ML	N10401 001	JUL 05, 1956	JUL	CAHN
		TABLET; ORAL					
	AB	ELAN PHARMA	50MG	N09170 003	MAR 08, 1954	MAY	CFTG
	AB	XCEL PHARMS	50MG	N09170 003	MAR 08, 1954	JUL	CAHN
	AB	+	250MG	N09170 002	MAR 08, 1954	JUL	CAHN
		PRIMIDONE					
	AB	LANNETT	50MG	N84903 002	MAY 24, 2001	MAY	NEWA
		PROCHLORPERAZINE					
		SUPPOSITORY; RECTAL					
		COMPAZINE					
	AB	SMITHKLINE BEECHAM	2.5MG	N11127 003	FEB 09, 1959	JUL	CFTG
	AB		5MG	N11127 001	SEP 27, 1957	JUL	CFTG
		PROCHLORPERAZINE					
	AB	ABLE	2.5MG	N40407 001	JUL 11, 2001	JUL	NEWA
	AB		5MG	N40407 002	JUL 11, 2001	JUL	NEWA
	AB		25MG	N40407 003	JUL 11, 2001	JUL	NEWA
		PROCHLORPERAZINE EDISYLATE					
		INJECTABLE; INJECTION					
		PROCHLORPERAZINE EDISYLATE					
		@ WYETH AYERST	EQ 5MG BASE/ML	N86348 001	JUL 05, 1979	JUL	DISC
		PROCHLORPERAZINE MALEATE					
		TABLET; ORAL					
		PROCHLORPERAZINE MALEATE					
	AB	GENEVA PHARMS TECH	EQ 5MG BASE	N40101 001	JUL 19, 1996	JAN	CAHN
	AB		EQ 10MG BASE	N40101 002	JUL 19, 1996	JAN	CAHN
	AB		EQ 25MG BASE	N40101 003	JUL 19, 1996	JAN	CAHN
		PROGESTERONE					
		INJECTABLE; INJECTION					
		PROGESTERONE					
	AO	AM PHARM PARTNERS	50MG/ML	N75906 001	APR 25, 2001	APR	NEWA

AO	+	SCHEIN	50MG/ML	N17362 002	MAY 08, 1978	OCT	CAHN
AO	+	STERIS	50MG/ML	N17362 002	MAY 08, 1978	APR	CFTG

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PROMETHACON

@ POLYMEDICA 50MG N84902 001 OCT 05, 1981 MAY DISC

TABLET; ORAL

PHENERGAN

WYETH AYERST 12.5MG N07935 002 MAR 29, 1951 MAY CTEC

PROMETHAZINE HCL

@ LANNETT 12.5MG N80949 001 JUL 28, 1976 MAY DISC

@ 25MG N80949 002 JUN 28, 1976 MAY DISC

@ 50MG N80949 003 JUN 28, 1976 MAY DISC

@ PVT FORM 25MG N83658 001 OCT 01, 1976 MAY DISC

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HCL

>A>	AB		MUTUAL PHARM	150MG	N75998 001	NOV 29, 2001	NOV	NEWA
>A>	AB			225MG	N75998 002	NOV 29, 2001	NOV	NEWA
>A>	AB			300MG	N75998 003	NOV 29, 2001	NOV	NEWA

RYTHMOL

>D>		+	ABBOTT	300MG	N19151 002	NOV 27, 1989	NOV	CFTG
>A>	AB	+		300MG	N19151 002	NOV 27, 1989	NOV	CFTG

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HCL

@ GENEVA PHARMS 65MG N83125 002 APR 14, 1976 MAY DISC

@ IMPAX LABS 65MG N83317 001 OCT 23, 1973 MAY DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

WYETH AYERST LABS 60MG N18553 004 MAR 18, 1987 AUG CRLD

80MG N18553 002 APR 19, 1983 AUG CRLD

120MG N18553 003 APR 19, 1983 AUG CRLD

TABLET; ORAL

PROPRANOLOL HCL

@ LEDERLE 10MG N70125 001 JUL 30, 1985 MAY DISC

@ 20MG N70126 001 JUL 30, 1985 OCT DISC

@ 40MG N70127 001 JUL 30, 1985 SEP DISC

@ WATSON LABS 20MG N70549 001 APR 11, 1986 MAY DISC

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

PROTRIPTYLINE HCL

AB			ODYSSEY PHARMS	5MG	N73644 001	AUG 24, 1995	JAN	CAHN
AB				10MG	N73645 001	AUG 24, 1995	JAN	CAHN

VIVACTIL

AB			ODYSSEY PHARMS	5MG	N73644 001	AUG 24, 1995	MAR	CTNA
AB	+			10MG	N73645 001	AUG 24, 1995	MAR	CTNA

	@ SIDMAK LABS	5MG	N16012 001	SEP 27, 1967	MAR	DISC	
	@	10MG	N16012 002	SEP 27, 1967	MAR	DISC	
	PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE						
	SYRUP; ORAL						
	TRILITRON						
	@ NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	N88474 001	FEB 12, 1985	FEB	WDRP	
	QUETIAPINE FUMARATE						
	TABLET; ORAL						
	SEROQUEL						
>D>	+ ASTRAZENECA	EQ 200MG BASE	N20639 003	SEP 26, 1997	NOV	CRLD	
>A>	ZENECA	EQ 200MG BASE	N20639 003	SEP 26, 1997	NOV	CRLD	
>A>	+	EQ 300MG BASE	N20639 005	JUL 26, 2000	NOV	NEWA	
	QUINIDINE GLUCONATE						
	TABLET, EXTENDED RELEASE; ORAL						
	QUINAGLUTE						
BX	+ BERLEX LABS	324MG	N16647 001	DEC 08, 1969	MAR	CTEC	
	QUINIDINE GLUCONATE						
BX	DANBURY PHARMA	324MG	N87810 001	SEP 29, 1982	MAR	CTEC	
	@ GENEVA PHARMS	324MG	N89894 001	DEC 15, 1988	MAR	DISC	
BX	MUTUAL PHARM	324MG	N89338 001	FEB 11, 1987	MAR	CTEC	
	QUINIDINE SULFATE						
	TABLET; ORAL						
	QUINIDINE SULFATE						
	@ IMPAX LABS	200MG	N83347 001	DEC 08, 1976	FEB	DISC	
	@ MUTUAL PHARM	300MG	N81031 001	APR 14, 1989	MAY	DISC	
	@ WEST WARD	200MG	N83862 001	SEP 02, 1976	MAY	DISC	
	RANITIDINE HYDROCHLORIDE						
	CAPSULE; ORAL						
	ZANTAC 150						
	@ GLAXO WELLCOME	EQ 150MG BASE	N20095 001	MAR 08, 1994	AUG	DISC	
	TABLET; ORAL						
	RANITIDINE HCL						
	@ BOEHRINGER INGELHEIM	EQ 150MG BASE	N74662 001	AUG 29, 1997	SEP	DISC	
	@	EQ 300MG BASE	N74662 002	AUG 29, 1997	SEP	DISC	
	RIBAVIRIN						
	CAPSULE; ORAL						
	REBETOL						
	+ SCHERING PLOUGH RES	200MG	N20903 002	JUL 25, 2001	AUG	NEWA	
	RIFAMPIN						
	CAPSULE; ORAL						
	RIFAMPIN						
AB	VERSAPHARM	150MG	N65028 001	MAR 14, 2001	MAR	NEWA	
AB		300MG	N65028 002	MAR 14, 2001	MAR	NEWA	

RIMANTADINE HYDROCHLORIDE
TABLET; ORAL
FLUMADINE

>D>		+	FOREST LABS	100MG	N19649 001	SEP 17, 1993	NOV	CFTG
>A>	AB	+		100MG	N19649 001	SEP 17, 1993	NOV	CFTG
>A>			RIMANTADINE HCL					
>A>	AB		COREPHARMA	100MG	N75916 001	NOV 02, 2001	NOV	NEWA

RISPERIDONE
TABLET; ORAL
RISPERDAL

			JANSSEN	0.5MG	N20272 007	JAN 27, 1999	APR	CRLD
		+		1MG	N20272 001	DEC 29, 1993	APR	CRLD
				4MG	N20272 004	DEC 29, 1993	APR	CRLD

SECOBARBITAL SODIUM
CAPSULE; ORAL
SECOBARBITAL SODIUM

			@ ICN	100MG	N85477 001	DEC 10, 1981	FEB	WDRP

SECRETIN
INJECTABLE; INJECTION
SECRETIN-FERRING

			@ FERRING	75CU/VIAL	N18290 001	MAY 29, 1981	JUN	DISC

SILVER SULFADIAZINE
DRESSING; TOPICAL
SILDAFLO

>A>			@ FRANKLIN PHARMS	1%	N19608 001	NOV 30, 1989	NOV	CAHN
>D>			@ QUESTCOR PHARMS	1%	N19608 001	NOV 30, 1989	NOV	CAHN
			@	1%	N19608 001	NOV 30, 1989	MAY	CTNA

SIMVASTATIN
TABLET; ORAL
ZOCOR

			MERCK	5MG	N19766 001	DEC 23, 1991	APR	CTEC

SODIUM IODIDE, I-131
CAPSULE; ORAL
SODIUM IODIDE I 131

			@ CIS	100uCi	N17316 002	NOV 10, 1976	OCT	DISC

SODIUM POLYSTYRENE SULFONATE
SUSPENSION; ORAL, RECTAL
SPS

AA		+	CAROLINA MEDCL	15GM/60ML	N87859 001	DEC 08, 1982	MAY	CRLD

SODIUM TETRADECYL SULFATE
INJECTABLE; INJECTION
SOTRADECOL

			@ ELKINS SINN	1%	N05970 004	AUG 13, 1946	JUL	DISC
			@	3%	N05970 005	AUG 13, 1946	JUL	DISC

SOMATROPIN RECOMBINANT

INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS

SAIZEN

	+ SERONO	8.8MG/VIAL	N19764 003	AUG 29, 2000	AUG	NEWA

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SORINE

AB	UPSHER SMITH	80MG	N75500 001	APR 27, 2001	APR	NEWA
AB		120MG	N75500 004	APR 27, 2001	APR	NEWA
AB		160MG	N75500 002	APR 27, 2001	APR	NEWA
AB		240MG	N75500 003	APR 27, 2001	APR	NEWA

SOTALOL HCL

AB	MUTUAL PHARM	80MG	N75515 001	OCT 15, 2001	OCT	NEWA
AB		120MG	N75515 004	OCT 15, 2001	OCT	NEWA
AB		160MG	N75515 002	OCT 15, 2001	OCT	NEWA
AB		240MG	N75515 003	OCT 15, 2001	OCT	NEWA

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

AB	MYLAN	25MG	N40424 001	AUG 20, 2001	AUG	NEWA
AB		50MG	N40424 002	AUG 20, 2001	AUG	NEWA
AB		100MG	N40424 003	AUG 20, 2001	AUG	NEWA

STREPTOMYCIN SULFATE

INJECTABLE; INJECTION

STREPTOMYCIN SULFATE

	@ PFIZER	EQ 1GM BASE/VIAL	N60076 001	FEB 18, 1946	MAY	DISC
	@	EQ 5GM BASE/VIAL	N60076 002	FEB 18, 1946	MAY	DISC
	+ PHARMA TEK	EQ 1GM BASE/VIAL	N64210 001	JUN 30, 1998	MAY	CTEC

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

BLEPH-10

	@ ALLERGAN	10%	N84015 001	JAN 07, 1975	MAY	DISC

CETAMIDE

AT	+ ALCON	10%	N80021 001	SEP 27, 1972	MAY	CTEC

SODIUM SULAMYD

	@ SCHERING	10%	N05963 002	NOV 26, 1947	MAY	DISC

SOLUTION/DROPS; OPHTHALMIC

BLEPH-10

AT	+ ALLERGAN	10%	N80028 001	MAY 25, 1971	MAY	CRLD

BLEPH-30

AT	+ ALLERGAN	30%	N80028 002	MAY 25, 1971	MAY	CRLD

SODIUM SULAMYD

	@ SCHERING	10%	N05963 001	AUG 01, 1946	MAY	DISC
	@	30%	N05963 003	NOV 26, 1947	MAY	DISC

SULF-10

	@ NOVARTIS	10%	N80025 001	JUN 03, 1971	FEB	CAHN
AT		10%	N80025 001	JUN 03, 1971	SEP	CMFD

SULF-15

SULFACETAMIDE SODIUM
SOLUTION/DROPS; OPHTHALMIC
SULF-15
AT NOVARTIS 15% N89047 001 OCT 31, 1995 FEB CAHN
SULTEN-10
@ BAUSCH AND LOMB 10% N87818 001 FEB 03, 1983 FEB WDRP

SULFAMETHOXAZOLE
TABLET; ORAL
GANTANOL
\+ ROCHE 500MG N12715 002 NOV 17, 1961 MAY CTEC
SULFAMETHOXAZOLE
@ GENEVA PHARMS 500MG N85844 001 MAR 23, 1978 MAY DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM
INJECTABLE; INJECTION
BACTRIM
AP + WOMEN FIRST HLTHCARE 80MG/ML;16MG/ML N18374 001 JUN 23, 1981 OCT CAHN
SUSPENSION; ORAL
@ WOMEN FIRST HLTHCARE 200MG/5ML;40MG/5ML N17560 001 APR 16, 1975 OCT CAHN
BACTRIM PEDIATRIC
AB + WOMEN FIRST HLTHCARE 200MG/5ML;40MG/5ML N17560 002 DEC 10, 1979 OCT CAHN
TRIMETH/SULFA
@ NASKA 200MG/5ML;40MG/5ML N72399 001 MAY 23, 1988 FEB WDRP
TABLET; ORAL
BACTRIM
AB WOMEN FIRST HLTHCARE 400MG;80MG N17377 001 JUL 30, 1973 OCT CAHN
BACTRIM DS
AB + WOMEN FIRST HLTHCARE 800MG;160MG N17377 002 MAR 01, 1978 OCT CAHN
SULFAMETHOXAZOLE AND TRIMETHOPRIM
@ ROXANE 400MG;80MG N72768 001 AUG 30, 1991 OCT DISC
@ TEVA 400MG;80MG N18242 001 MAY 19, 1981 MAY DISC
@ 800MG;160MG N18242 002 MAY 19, 1981 MAY DISC
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH
@ ROXANE 800MG;160MG N72769 001 AUG 30, 1991 SEP DISC
AB TEVA 800MG;160MG N70037 001 JUN 02, 1987 OCT CAHN

SULFANILAMIDE
CREAM; VAGINAL
AVC
AT + NOVAVAX 15% N06530 003 JAN 27, 1987 JAN CAHN
SUPPOSITORY; VAGINAL
\+ NOVAVAX 1.05GM N06530 004 JAN 27, 1987 JAN CAHN

SULFISOXAZOLE
TABLET; ORAL
SULFISOXAZOLE
@ GENEVA PHARMS 500MG N85628 001 JUN 13, 1977 JUL DISC

TECHNETIUM TC-99M APCITIDE
INJECTABLE; INJECTION
ACUTECT
BERLEX LABS N/A N20887 001 SEP 14, 1998 MAY CAHN

	DIATIDE RES LABS	N/A	N20887 001	SEP 14, 1998	APR	CAHN
		N/A	N20887 001	SEP 14, 1998	JUL	CAHN
	TECHNETIUM TC-99M PENTETATE KIT					
	INJECTABLE; INJECTION					
	MPI DTPA KIT - CHELATE					
	@ NYCOMED AMERSHAM	N/A	N17255 001	APR 15, 1976	SEP	WDAG
	TEMAZEPAM					
	CAPSULE; ORAL					
	RESTORIL					
	TYCO HLTHCARE	7.5MG	N18163 003	OCT 25, 1991	JUN	CAHN
AB		15MG	N18163 001	FEB 27, 1981	JUN	CAHN
AB +		30MG	N18163 002	FEB 27, 1981	JUN	CAHN
	TENOFOVIR DISOPROXIL FUMARATE					
	TABLET; ORAL					
	VIREAD					
	+ GILEAD	300MG	N21356 001	OCT 26, 2001	OCT	NEWA
	TERAZOSIN HYDROCHLORIDE					
	CAPSULE; ORAL					
	TERAZOSIN HCL					
AB	TORPHARM	EQ 1MG BASE	N75498 001	APR 12, 2001	APR	NEWA
AB		EQ 2MG BASE	N75498 002	APR 12, 2001	APR	NEWA
AB		EQ 5MG BASE	N75498 003	APR 12, 2001	APR	NEWA
AB		EQ 10MG BASE	N75498 004	APR 12, 2001	APR	NEWA
AB	ZENITH GOLDLINE	EQ 1MG BASE	N75614 002	JAN 30, 2001	JAN	NEWA
AB		EQ 2MG BASE	N75614 001	JAN 30, 2001	JAN	NEWA
AB		EQ 5MG BASE	N75614 003	JAN 30, 2001	JAN	NEWA
AB		EQ 10MG BASE	N75614 004	JAN 30, 2001	JAN	NEWA
	TERBUTALINE SULFATE					
	TABLET; ORAL					
	BRETHINE					
AB	NOVARTIS	2.5MG	N17849 001	MAY 17, 1976	JUN	CFTG
AB +		5MG	N17849 002	MAY 17, 1976	JUN	CFTG
	TERBUTALINE SULFATE					
AB	IMPAX LABS	2.5MG	N75877 001	JUN 26, 2001	JUN	NEWA
AB		5MG	N75877 002	JUN 26, 2001	JUN	NEWA
	TETRACYCLINE HYDROCHLORIDE					
	CAPSULE; ORAL					
	PANMYCIN					
	@ PHARMACIA AND UPJOHN	250MG	N60347 001	SEP 28, 1954	MAY	DISC
	ROBITET					
	@ WYETH AYERST	250MG	N61734 001	JUN 06, 1973	MAY	DISC
	@	500MG	N61734 002	JUN 06, 1973	MAY	DISC
	TETRACYCLINE HCL					
	@ DANBURY PHARMA	250MG	N62343 001	OCT 02, 1981	MAY	DISC
	@	500MG	N62343 002	OCT 02, 1981	MAY	DISC
	@ EON	250MG	N61471 001	OCT 28, 1971	MAY	DISC
	@ WEST WARD	250MG	N60768 001	AUG 24, 1964	MAY	DISC

	@	500MG	N60768 002	NOV 07, 1977	MAY	DISC	
	@ WYETH AYERST	250MG	N61685 001	DEC 11, 1972	JUL	DISC	
	@	500MG	N61685 002	DEC 11, 1972	JUL	DISC	
	THALLOUS CHLORIDE, TL-201						
	INJECTABLE; INJECTION						
	THALLOUS CHLORIDE TL 201						
>A> AP	MOUNT SINAI MEDCTR	1mCi/ML	N75569 001	NOV 21, 2001	NOV	NEWA	
	THIORIDAZINE HYDROCHLORIDE						
	TABLET; ORAL						
	THIORIDAZINE HCL						
	@ CHELSEA LABS	10MG	N88561 001	MAY 11, 1984	JUL	DISC	
	@ TEVA	10MG	N88493 001	MAY 17, 1985	JUL	DISC	
	@ ZENITH GOLDLINE	50MG	N88194 001	APR 14, 1983	JUL	DISC	
	THIOTEPA						
	INJECTABLE; INJECTION						
	THIOPLEX						
AP +	IMMUNEX	15MG/VIAL	N20058 001	DEC 22, 1994	APR	CFTG	
	THIOTEPA						
AP	AAIPHARMA	15MG/VIAL	N75698 001	SEP 20, 2001	SEP	NEWA	
AP	BEDFORD	15MG/VIAL	N75547 001	APR 02, 2001	APR	NEWA	
AP	GENSIA SICOR PHARMS	15MG/VIAL	N75730 001	APR 20, 2001	APR	NEWA	
+		30MG/VIAL	N75730 002	APR 20, 2001	APR	NEWA	
	@ IMMUNEX	15MG/VIAL	N11683 001	FEB 19, 1959	APR	DISC	
	THYROGLOBULIN						
	TABLET; ORAL						
	THYROGLOBULIN						
	@ IMPAX LABS	64.8MG	N80151 001	AUG 07, 1973	FEB	DISC	
	TICARCILLIN DISODIUM						
	INJECTABLE; INJECTION						
	TICAR						
	@ SMITHKLINE BEECHAM	EQ 3GM BASE/VIAL	N62690 001	DEC 19, 1986	MAY	DISC	
	TOBRAMYCIN						
	SOLUTION; INHALATION						
	TOBI						
+	CHIRON	300MG/5ML	N50753 001	DEC 22, 1997	SEP	CAHN	
	SOLUTION/DROPS; OPHTHALMIC						
	TOBRAMYCIN						
	@ ALCON UNIVERSAL	0.3%	N63176 001	MAY 25, 1994	MAY	DISC	
AT	ALTANA	0.3%	N65026 001	SEP 11, 2001	SEP	NEWA	
	TOBRAMYCIN SULFATE						
	INJECTABLE; INJECTION						
	NEBCIN						
AP +	LILLY	EQ 1.2GM BASE/VIAL	N50519 001	JUN 11, 1979	AUG	CFTG	
	TOBRAMYCIN						
AP	PHARMA TEK	EQ 1.2GM BASE/VIAL	N65013 001	AUG 17, 2001	AUG	NEWA	
	TOBRAMYCIN SULFATE						

TOBRAMYCIN SULFATE						
INJECTABLE; INJECTION						
TOBRAMYCIN SULFATE						
@ ASTRAZENECA	EQ 10MG BASE/ML	N63119 001	OCT 31, 1994	AUG	DISC
@	EQ 40MG BASE/ML	N63121 001	OCT 31, 1994	MAY	DISC
@ ELKINS SINN	EQ 10MG BASE/ML	N63128 001	NOV 27, 1991	MAY	DISC
@	EQ 40MG BASE/ML	N63127 001	NOV 27, 1991	MAY	DISC
@ LEDERLE	EQ 10MG BASE/ML	N63113 001	APR 26, 1991	MAY	DISC
TOLMETIN SODIUM						
CAPSULE; ORAL						
TOLMETIN SODIUM						
@ GENEVA PHARMS	EQ 400MG BASE	N73462 001	APR 30, 1992	JUL	DISC
TOPIRAMATE						
TABLET; ORAL						
TOPAMAX						
+ JOHNSON RW	25MG	N20505 004	DEC 24, 1996	MAR	CRLD
	200MG	N20505 002	DEC 24, 1996	MAR	CRLD
TRAVOPROST						
SOLUTION/DROPS; OPHTHALMIC						
TRAVATAN						
+ ALCON UNIVERSAL	0.004%	N21257 001	MAR 16, 2001	MAR	NEWA
TRIAMCINOLONE						
TABLET; ORAL						
TRIAMCINOLONE						
@ IMPAX LABS	4MG	N84340 001	APR 22, 1975	FEB	DISC
TRIAMCINOLONE ACETONIDE						
AEROSOL, METERED; INHALATION						
AZMACORT						
+ AVENTIS	0.1MG/INH	N18117 001	APR 23, 1982	SEP	CAHN
AEROSOL, METERED; NASAL						
NASACORT						
+ AVENTIS	0.055MG/INH	N19798 001	JUL 11, 1991	SEP	CAHN
CREAM; TOPICAL						
TRIAMCINOLONE ACETONIDE						
@ TARO	0.025%	N40038 001	OCT 26, 1994	MAY	DISC
@ TOPIDERM	0.025%	N89274 001	FEB 21, 1989	FEB	WDRP
@	0.1%	N89275 001	FEB 21, 1989	FEB	WDRP
@	0.5%	N89276 001	FEB 21, 1989	FEB	WDRP
OINTMENT; TOPICAL						
ARISTOCORT						
@ FUJISAWA HLTHCARE	0.5%	N80745 002	MAY 28, 1974	JUL	DISC
ARISTOCORT A						
@ FUJISAWA HLTHCARE	0.5%	N80745 003	SEP 23, 1975	JUL	DISC
TRIAMCINOLONE ACETONIDE						
@ G AND W LABS	0.025%	N89795 001	DEC 23, 1988	JUL	DISC
@	0.1%	N89796 001	DEC 23, 1988	JUL	DISC
AT THAMES	0.025%	N40374 001	JUN 05, 2001	JUN	NEWA
AT	0.5%	N40386 001	JUN 05, 2001	JUN	NEWA

	TRIAMCINOLONE ACETONIDE						
	SPRAY; TOPICAL						
	TRIAMCINOLONE ACETONIDE						
	SPRAY; TOPICAL						
	KENALOG						
	+ APOTHECON	0.147MG/GM	N12104 001	DEC 24, 1959	JUL	CDFR	
	SPRAY, METERED; NASAL						
	NASACORT AQ						
	+ AVENTIS	0.055MG/SPRAY	N20468 001	MAY 20, 1996	SEP	CAHN	
	TRICHLORMETHIAZIDE						
	TABLET; ORAL						
	TRICHLOREX						
	@ LANNETT	4MG	N83436 001	AUG 11, 1980	MAY	DISC	
	@	4MG	N85630 001	MAY 16, 1977	FEB	WDRP	
	TRICHLORMETHIAZIDE						
	@ IMPAX LABS	4MG	N83967 001	JAN 17, 1978	OCT	DISC	
	TRIFLUOPERAZINE HYDROCHLORIDE						
	CONCENTRATE; ORAL						
	TRIFLUOPERAZINE HCL						
	@ GENEVA PHARMS	EQ 10MG BASE/ML	N85787 001	APR 15, 1982	MAY	DISC	
	TABLET; ORAL						
AB	GENEVA PHARMS TECH	EQ 1MG BASE	N40153 001	OCT 25, 1996	JAN	CAHN	
AB		EQ 2MG BASE	N40153 002	OCT 25, 1996	JAN	CAHN	
AB		EQ 5MG BASE	N40153 003	OCT 25, 1996	JAN	CAHN	
AB		EQ 10MG BASE	N40153 004	OCT 25, 1996	JAN	CAHN	
	TRIHEXYPHENIDYL HYDROCHLORIDE						
	ELIXIR; ORAL						
	TRIHEXYPHENIDYL HCL						
>D> AA	LIQUIPHARM	2MG/5ML	N89514 001	APR 07, 1989	NOV	CAHN	
>A> AA	PHARM VENTURES	2MG/5ML	N89514 001	APR 07, 1989	NOV	CAHN	
	TRIMETHOBENZAMIDE HYDROCHLORIDE						
	INJECTABLE; INJECTION						
	TRIMETHOBENZAMIDE HCL						
	@ STERIS	100MG/ML	N86577 001	OCT 19, 1982	JUL	DISC	
	TRIMETHOPRIM HYDROCHLORIDE						
	SOLUTION; ORAL						
	PRIMSOL						
	@ ASCENT PEDS	EQ 25MG BASE/5ML	N74374 001	JUN 23, 1995	JUN	DISC	
	TRIMIPRAMINE MALEATE						
	CAPSULE; ORAL						
	SURMONTIL						
	SIDMAK LABS	EQ 25MG BASE	N16792 001	JUN 12, 1979	AUG	CAHN	
		EQ 50MG BASE	N16792 002	JUN 12, 1979	AUG	CAHN	
	+	EQ 100MG BASE	N16792 003	SEP 15, 1982	AUG	CAHN	

TRIPELENNAMINE HYDROCHLORIDE
TABLET; ORAL
TRIPELENNAMINE HCL
@ IMPAX LABS 50MG N80785 001 AUG 07, 1973 OCT DISC

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)
CREAM; VAGINAL
TRIPLE SULFA
@ FOUGERA 3.7%;2.86%;3.42% N86424 001 MAY 31, 1979 JUN DISC

TRIPTORELIN PAMOATE
INJECTABLE; INTRAMUSCULAR
TRELSTAR
\+ DEBIO RECHERCHE 11.25MG/VIAL N21288 001 JUN 29, 2001 JUN NEWA
\+ PHARMACIA AND UPJOHN 11.25MG/VIAL N21288 001 JUN 29, 2001 SEP CAHN
TRELSTAR DEPOT
\+ DEBIO RECHERCHE EQ 3.75MG BASE/VIAL N20715 001 JUN 15, 2000 JUN CDFR
\+ PHARMACIA AND UPJOHN EQ 3.75MG BASE/VIAL N20715 001 JUN 15, 2000 SEP CAHN

TUBOCURARINE CHLORIDE
INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE
>D> AP + APOTHECON 3MG/ML N05657 001 FEB 20, 1945 NOV CAHN
>A> AP + BRISTOL MYERS SQUIBB 3MG/ML N05657 001 FEB 20, 1945 NOV CAHN
@ LILLY 3MG/ML N06325 001 NOV 28, 1947 SEP WDAG

URACIL MUSTARD
CAPSULE; ORAL
URACIL MUSTARD
@ SHIRE PHARM 1MG N12892 001 SEP 13, 1962 JUN DISC

UREA, C-13
FOR SOLUTION; ORAL
BREATHTEK UBT FOR H-PYLORI
\+ MERETEK EQ 75MG /POUCHE N20586 002 MAY 10, 2001 AUG NEWA
MERETEK UBT KIT (W/ PRANACTIN)
@ MERETEK 125MG/VIAL N20586 001 SEP 17, 1996 AUG DISC

>A> VALDECOXIB
>A> TABLET; ORAL
>A> BEXTRA
>A> SEARLE 10MG N21341 002 NOV 16, 2001 NOV NEWA
>A> + 20MG N21341 003 NOV 16, 2001 NOV NEWA

VALGANCICLOVIR HYDROCHLORIDE
TABLET; ORAL
VALCYTE
\+ SYNTEX (USA) INC LLC EQ 450MG BASE N21304 001 MAR 29, 2001 MAR NEWA

VALPROIC ACID
CAPSULE; ORAL
VALPROIC ACID

@ PAR PHARM	250MG	N70431 001	FEB 28, 1986	MAY	DISC
@ SCHERER RP	250MG	N70195 001	JUL 02, 1987	JUL	DISC

VALSARTAN
TABLET; ORAL
DIOVAN

NOVARTIS	80MG	N21283 001	JUL 18, 2001	JUL	NEWA
	160MG	N21283 002	JUL 18, 2001	JUL	NEWA
+	320MG	N21283 003	JUL 18, 2001	JUL	NEWA

VANCOMYCIN HYDROCHLORIDE
INJECTABLE; INJECTION
VANCOMYCIN HCL

@ ELKINS SINN	EQ 500MG BASE/VIAL	N62879 001	AUG 02, 1988	MAY	DISC
@	EQ 1GM BASE/VIAL	N62879 002	AUG 02, 1988	MAY	DISC

VECURONIUM BROMIDE
INJECTABLE; INJECTION
VECURONIUM BROMIDE

+ ABBOTT	4MG/VIAL	N75558 001	SEP 11, 2001	SEP	NEWA

VINBLASTINE SULFATE
INJECTABLE; INJECTION
VELBAN

@ LILLY	10MG/VIAL	N12665 001	MAR 06, 1961	MAY	DISC

VINBLASTINE SULFATE

AP	+ BEDFORD	10MG/VIAL	N89395 001	APR 09, 1987	MAY	CRLD

VITAMIN A PALMITATE
CAPSULE; ORAL
VITAMIN A

@ WEST WARD	EQ 50,000 UNITS BASE	N80967 001	MAY 04, 1973	FEB	WDRP

INJECTABLE; INJECTION
AQUASOL A

+ NEOSAN PHARMS	EQ 50,000 UNITS BASE/ML	N06823 001	MAY 18, 1949	AUG	CAHN

WARFARIN SODIUM
TABLET; ORAL
COUMADIN

AB	DUPONT MERCK	2.5MG	N09218 018	NOV 29, 1961	JUL	CRLD
AB	+	5MG	N09218 007	FEB 17, 1964	JUL	CRLD
AB		5MG	N09218 007	FEB 17, 1964	AUG	CRLD

ZIPRASIDONE HYDROCHLORIDE
CAPSULE; ORAL
GEODON

PFIZER	20MG	N20825 001	FEB 05, 2001	FEB	NEWA
	40MG	N20825 002	FEB 05, 2001	FEB	NEWA
	60MG	N20825 003	FEB 05, 2001	FEB	NEWA

+		80MG	N20825 004	FEB 05, 2001	FEB	NEWA

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)

ZOMETA

+	NOVARTIS	EQ 4MG BASE/VIAL	N21223 001	AUG 20, 2001	SEP	CPOT
+		4.264MG/VIAL	N21223 001	AUG 20, 2001	AUG	NEWA

ZOLMITRIPTAN

TABLET, ORALLY DISINTEGRATING; ORAL

ZOMIG-ZMT

	ASTRAZENECA	2.5MG	N21231 001	FEB 13, 2001	FEB	NEWA

1-76

FEB NEWA

ACETAMINOPHEN
SUPPOSITORY; RECTAL
ACETAMINOPHEN

	@ ABLE	120MG	N73106 001	FEB 27, 1995	SEP	WDAG
	@	325MG	N73107 001	FEB 27, 1995	SEP	WDAG
SEP CPOT	@	650MG	N73108 001	FEB 27, 1995	SEP	WDAG
AUG NEWA	ALPHARMA US PHARM	120MG	N18337 003	SEP 12, 1983	MAR	CAHN
		325MG	N18337 002	AUG 21, 1981	MAR	CAHN
	+	650MG	N18337 001	APR 22, 1980	MAR	CAHN
	INFANTS' FEVERALL					
FEB NEWA	ALPHARMA US PHARM	80MG	N18337 004	AUG 26, 1992	MAR	CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE
TABLET; ORAL
ACETAMINOPHEN, ASPIRIN AND CAFFEINE

>A>	PERRIGO	250MG;250MG;65MG	N75794 001	NOV 26, 2001	NOV	NEWA

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET; ORAL
TAVIST ALLERGY/SINUS/HEADACHE

+	NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N21082 001	MAR 01, 2001	MAR	NEWA

ALCOHOL; CHLORHEXIDINE GLUCONATE
SOLUTION; TOPICAL
AVAGARD

+	3M	61%;1%	N21074 001	JUN 07, 2001	JUN	NEWA

ASPIRIN
TABLET; ORAL
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

+	BAYER	500MG	N21317 001	OCT 18, 2001	OCT	NEWA

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
BROMATAPP

	@ COPLEY PHARM	12MG;75MG	N71099 001	JUL 02, 1987	JUL	DISC

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
TAVIST-D

	@ NOVARTIS	1.34MG;75MG	N18298 002	AUG 21, 1992	JAN	DISC
	@	1.34MG;75MG	N20640 001	AUG 09, 1996	JAN	DISC

CLOTRIMAZOLE
CREAM; VAGINAL
TRIVAGIZOLE 3

	TARO	2%	N21143 001	APR 12, 2000	JUL	CRLD

CROMOLYN SODIUM
SPRAY, METERED; NASAL
CROMOLYN SODIUM

	ALPHARMA	5.2MG/INH	N74800 001	JUL 26, 2001	JUL	NEWA

	BAUSCH AND LOMB	5.2MG/SPRAY	N75702 001	JUL 03, 2001	JUL	NEWA
	FAMOTIDINE					
	TABLET; ORAL					
	FAMOTIDINE					
>A>	DANBURY PHARMA	10MG	N75404 001	NOV 28, 2001	NOV	NEWA
	DR REDDYS LABS LTD	10MG	N75758 001	AUG 17, 2001	AUG	NEWA
	TEVA	10MG	N75312 001	MAY 31, 2001	MAY	NEWA
	ZENITH GOLDLINE	10MG	N75512 001	JUL 26, 2001	JUL	NEWA
	IBUPROFEN					
	TABLET; ORAL					
	ACHES-N-PAIN					
	@ LEDERLE	200MG	N71065 001	MAY 28, 1987	OCT	DISC
	IBUPROFEN					
>A>	DR REDDYS LABS INC	100MG	N76117 001	NOV 20, 2001	NOV	NEWA
	IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE					
	TABLET; ORAL					
	IBUPROHM COLD AND SINUS					
	OHM LABS	200MG;30MG	N74567 001	APR 17, 2001	APR	NEWA
	INSULIN PURIFIED PORK					
	INJECTABLE; INJECTION					
	REGULAR PURIFIED PORK INSULIN					
+	NOVO NORDISK	100 UNITS/ML	N18381 001	MAR 17, 1980	MAY	CTEC
	INSULIN RECOMBINANT HUMAN					
	INJECTABLE; INJECTION					
	NOVOLIN R					
+	NOVO NORDISK	100 UNITS/ML	N19938 001	JUN 25, 1991	MAY	CTEC
	INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN					
	INJECTABLE; INJECTION					
	HUMULIN 50/50					
+	LILLY	50 UNITS/ML;50 UNITS/ML	N20100 001	APR 29, 1992	MAY	CTEC
	NOVOLIN 70/30					
+	NOVO NORDISK	30 UNITS/ML;70 UNITS/ML	N19991 001	JUN 25, 1991	MAY	CTEC
	INSULIN RECOMBINANT PURIFIED HUMAN					
	INJECTABLE; INJECTION					
	VELOSULIN BR HUMAN					
	@ NOVO NORDISK	100 UNITS/ML	N19450 001	MAY 30, 1986	SEP	WDAG
	MICONAZOLE NITRATE					
	CREAM; TOPICAL					
	MONISTAT 3 COMBINATION PACK					
+	PERSONAL PRODS	2%;4%	N21261 001	FEB 02, 2001	FEB	NEWA
	CREAM; TOPICAL, VAGINAL					
+	PERSONAL PRODS	2%;4%	N21261 001	FEB 02, 2001	MAY	CDFR

MINOXIDIL

SOLUTION; TOPICAL

MINOXIDIL EXTRA STRENGTH (FOR MEN)

PERRIGO 5% N75598 001 JUN 13, 2001 JUN NEWA

MINOXIDIL EXTRA STRENGTH FOR MEN

NOVEX 5% N75839 001 OCT 01, 2001 OCT NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE (ORANGE)

\+ SMITHKLINE BEECHAM EQ 4MG BASE N20066 004 SEP 25, 2000 OCT NEWA

NICORETTE (ORANGE)

\+ SMITHKLINE BEECHAM EQ 2MG BASE N18612 004 SEP 25, 2000 OCT NEWA

TIOCONAZOLE

OINTMENT; VAGINAL

TIOCONAZOLE

>A> PERRIGO 6.5% N75915 001 NOV 21, 2001 NOV NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 11 NOVEMBER '01

NO NOVEMBER 2001 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
November 2001

Generic Name: **T-cell depleted stem cell enriched cellular product from peripheal blood stem cells**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of chronic granulomatous disease*
Sponsor: Nexell Therapeutics Inc.
Address: 9 Parker, Irvine CA 92618-1605
Date Designated: 11/1/2001
Market Approval Date: Not currently Approved

Generic Name: **(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of circadian rhythm sleep disorders in blind people with no light perception*
Sponsor: Phase 2 Discovery, Inc.
Address: 3130 Highland Avenue, Third Floor, Cincinnati OH 45219-2374
Date Designated: 10/3/2001
Market Approval Date: Not currently Approved

Generic Name: **2-chloroethyl-3-sarcosinamide-1-nitrosourea**
Trade Name: Sarmustine
Designated Indication: *Treatment for malignant glioma*
Sponsor: Pangene Corporation
Address: 5500 Stewart Avenue, Fremont CA 94538
Date Designated: 11/15/2001
Market Approval Date: Not currently Approved

Generic Name: **2-chloroethyl-3-sarcosinamide-1-nitrosourea**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment for malignant gliomas*
Sponsor: Lawrence Panasci, MD
Address: Professor of Medicine, McGill University, 3755 Cote Ste Catherine, Montreal, Quebec H3T 1E2
Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name: **2-methoxyestradiol** | Trade Name: Panzem

Designated Indication: *Treatment of multiple myeloma*

Sponsor: EntreMed, Inc.
Address: 9640 Medical Center Drive, Rockville MD 20850

Date Designated: 7/10/2001
Market Approval Date: Not currently Approved

Generic Name: **3-(4'aminoisoindoline-1'-one)-1-piperidine-2,6-dione** | Trade Name: Revimid (proposed)

Designated Indication: *Treatment for multiple myeloma*

Sponsor: Celegene Corporation
Address: 7 Powder Horn Drive, Warren NJ 07059

Date Designated: 9/20/2001
Market Approval Date: Not currently Approved

Generic Name: **9-nitro-20-(S)-camptothecin** | Trade Name: Camvirex

Designated Indication: *Treatment of pediatric HIV infection/AIDS*

Sponsor: NovoMed Pharmaceuticals, Inc.
Address: P.O. Box 900, Germantown MD 20875-0900

Date Designated: 5/15/2001
Market Approval Date: Not currently Approved

Generic Name: **acetylcysteine** | Trade Name: Acetadote

Designated Indication: *For the intravenous treatment of moderate to severe acetaminophen overdose*

Sponsor: Cumberland Pharmaceuticals Inc.
Address: 209 10th Street South, Suite 332, Nashville TN 37203

Date Designated: 10/19/2001
Market Approval Date: Not currently Approved

Generic Name: **Adeno-associated viral vector containing the gene for human coagulation factor IX** | Trade Name: Coagulin-B

Designated Indication: *Intramuscular treatment of patients with moderate to severe hemophilia*

Sponsor: Avigen, Inc.
Address: 1301 Harbor Bay Parkway, Alameda CA 94502

Date Designated: 6/13/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name: **Adeno-associated viral vector containing the gene for human coagulation factor IX**
Trade Name: Coagulin-B
Designated Indication: *Intrahepatic treatment of patients with moderate to severe hemophilia*
Sponsor: Avigen, Inc.
Address: 1301 Harbor Bay Parkway
Alameda CA 94502
Date Designated: 6/13/2001
Market Approval Date: Not currently Approved

Generic Name: **adenovirus-mediated herpes simplex virus-thymidine kinase gene**
Trade Name: NONE ASSIGNED
Designated Indication: *Use with gancyclovir in the treatment of malignant glioma*
Sponsor: Ark Therapeutics Ltd
Address: 6 Warren Mews
London W1T6AR UK
Date Designated: 7/31/2001
Market Approval Date: Not currently Approved

Generic Name: **Alendronate disodium**
Trade Name: Fosamax
Designated Indication: *Treatment of the bone manifestations of Gaucher disease*
Sponsor: Richard J. Wenstrup, M.D.
Address: Division of Human Genetics
Children's Hospital Research Foundation
Cincinnati OH 45229-3039
Date Designated: 2/13/2001
Market Approval Date: Not currently Approved

Generic Name: **Angiotensin 1-7**
Trade Name: MARstem
Designated Indication: *Treatment of myelodysplastic syndrome*
Sponsor: Maret Pharmaceutical Corporation
Address: 4041 MacArthur Boulevard, Suite 375
Newport Beach CA 92660
Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Generic Name: **arsenic**
Trade Name: Trisenox
Designated Indication: *Treatment of acute myelocytic leukemia subtypes M0, M1, M2, M4, M5, M6 and M7*
Sponsor: Cell Therapeutics, Inc.
Address: 201 Elliott Avenue West
Suite 400
Seattle WA 98119
Date Designated: 11/2/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name: **arsenic trioxide** — Trade Name: Trisenox

Designated Indication: *Treatment of chronic myeloid leukemia*

Sponsor: Cell Therapeutics, Inc.
Address: 201 Elliott Avenue West, Suite 400, Seattle WA 98119

Date Designated: 10/18/2001
Market Approval Date: Not currently Approved

Generic Name: **augmerosen** — Trade Name: Genasense

Designated Indication: *Treatment of acute myelocytic leukemia*

Sponsor: Genta Incorporated
Address: Two Oak Way, Berkeley Heights NJ 07922

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **augmerosen** — Trade Name: Genasense

Designated Indication: *Treatment of multiple myeloma*

Sponsor: Genta Incorporated
Address: Two Oak Way, Berkeley Heights NJ 07922

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **augmerosen** — Trade Name: Genasense

Designated Indication: *Treatment of chronic lymphocytic leukemia*

Sponsor: Genta Incorporated
Address: Two Oak Way, Berkeley Heights NJ 07922

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **azacitidine** — Trade Name: NONE ASSIGNED

Designated Indication: *Treatament of myelodysplastic syndromes*

Sponsor: Pharmion Corporation
Address: 4865 Riverbend Road, Boulder CO 80301

Date Designated: 12/3/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name: **B Lymphocyte Stimulator**
Trade Name: BLyS
Designated Indication: *Treatment of common variable immunodeficiency (CVID)*
Sponsor: Human Genome Sciences, Inc.
Address: 9410 Key West Avenue, Rockville MD 20850
Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

Generic Name: **beclomethasone 17,21-dipropionate**
Trade Name: NONE ASSIGNED
Designated Indication: *Prevention of gastrointestinal graft-versus-host disease*
Sponsor: Enteron Pharmaceuticals, Inc.
Address: 1680 Michigan Ave., Suite 700, Miami FL 33139
Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide**
Trade Name: Total Block VL SPF 75
Designated Indication: *For the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy*
Sponsor: Fallien Cosmeceuticals Ltd.
Address: 677 W. Dekalb Pike, King of Prussia PA 19406
Date Designated: 8/13/2001
Market Approval Date: Not currently Approved

Generic Name: **bryostatin-1**
Trade Name: NONE ASSIGNED
Designated Indication: *For use in combination with paclitaxel in the treatment of esophageal cancer*
Sponsor: GPC Biotech, Inc.
Address: 610 Lincoln Street, Waltham MA 02451
Date Designated: 12/3/2001
Market Approval Date: Not currently Approved

Generic Name: **Busulfan**
Trade Name: Spartajet-Busulfan
Designated Indication: *Intrathecal therapy for neoplastic meningitis*
Sponsor: SuperGen, Inc.
Address: 4140 Dublin Boulevard, Dublin CA 94568
Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name **Coenzyme Q10** Trade Name: NONE ASSIGNED

Designated Indication: *For the treatrment of Huntington's disease*

Sponsor: Vitaline Corporation
Address: 385 Williamson Way
Ashland OR 97520

Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

Generic Name **conjugate of human transferrin and a mutant diphtheria toxin (CRM 107)** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of malignant tumors of the central nervous system*

Sponsor: INTELLIgene Expressions Inc.
Address: 1938-94 St.
Edmonton, AB T6N 1J3

Date Designated: 12/3/2001
Market Approval Date: Not currently Approved

Generic Name **deferiprone** Trade Name: Ferriprox

Designated Indication: *Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy*

Sponsor: Apotex Research Inc.
Address: 150 Signet Drive
Toronto, Canada M9L 1T9

Date Designated: 12/12/2001
Market Approval Date: Not currently Approved

Generic Name **DHA-paclitaxel** Trade Name: Taxoprexin

Designated Indication: *Treatment of pancreatic cancer*

Sponsor: Protarga, Inc.
Address: 2200 Renaissance Blvd.
Suite 450
King of Prussia PA 19406

Date Designated: 9/25/2001
Market Approval Date: Not currently Approved

Generic Name **digitoxin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of soft tissue sarcomas*

Sponsor: PrimeCyte, Inc.
Address: 130 Fifth Ave., N.
Seattle WA 98109-4933

Date Designated: 10/18/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name **digitoxin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ovarian cancer*

Sponsor: PrimeCyte, Inc.
Address: 130 Fifth Ave., N.
Seattle WA 98109-4933

Date Designated: 11/2/2001
Market Approval Date: Not currently Approved

Generic Name **docosahexanoic acid-paclitaxel** Trade Name: Taxoprexin

Designated Indication: *Treatment of hormone-refractory prostate cancer.*

Sponsor: Protarga, Inc.
Address: 1100 East Hector Street
Suite 450
Conshohocken PA 19428-2377

Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

Generic Name **Glatiramer acetate for injection** Trade Name: Copaxone

Designated Indication: *Treatment of primary-progressive multiple sclerosis*

Sponsor: TEVA Pharmaceuticals, USA
Address: 1090 Horsham Road
North Wales PA 19454

Date Designated: 6/5/2001
Market Approval Date: Not currently Approved

Generic Name **h5G1.1mAb** Trade Name: NONE ASSIGNED

Designated Indication: *Idiopathic membranous glomerular nephropathy*

Sponsor: Alexion Pharmaceuticals, Inc.
Address: 352 Knotter Drive
Cheshire CT 06410

Date Designated: 3/5/2001
Market Approval Date: Not currently Approved

Generic Name **Hsp E7** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of recurrent respiratory papillomatosis (RRP)*

Sponsor: StressGen Biotechnologies, Inc.
Address: 409 2nd Avenue
Suite 201
Collegeville PA 19426-2655

Date Designated: 3/19/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name: **Hu1D10, humanized monoclonal antibody** Trade Name: Remitogen

Designated Indication: *For use in the treatment of 1D10+ B cell non-Hodgkin's lymphoma*

Sponsor: Protein Design Labs, Inc.
Address: 34801 Campus Drive
Fremont CA 94555

Date Designated: 11/28/2001
Market Approval Date: Not currently Approved

Generic Name: **human gammaglobulin** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment for juvenile rheumatoid arthritis*

Sponsor: Protein Therapeutics, Inc
Address: 9040 S. Rita Rd., Suite 1100
Tucson AZ 84747

Date Designated: 5/25/2001
Market Approval Date: Not currently Approved

Generic Name: **humanized monoclonal antibody against Shiga-like toxin II** Trade Name: NONE ASSIGNED

Designated Indication: *To prevent the development of or to decrease the incidence and severity of hemolytic uremic syndrome and associated sequelae of Shiga-like toxin-producing E. coli.*

Sponsor: Teijin America, Inc.
Address: 600 Alexander Park
Suite 304
Princeton NJ 08540

Date Designated: 9/12/2001
Market Approval Date: Not currently Approved

Generic Name: **iduronate-2-sulfatase** Trade Name: NONE ASSIGNED

Designated Indication: *Long term enzyme replacement therapy for patients with MPS II (Hunter Syndrome)*

Sponsor: Transkaryotic Therapies Inc.
Address: 195 Albany Street
Cambridge MA 02139

Date Designated: 11/28/2001
Market Approval Date: Not currently Approved

Generic Name: **IL13-PE38QQR** Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of malignant glioma*

Sponsor: NeoPharm, Inc.
Address: 150 Field Drive
Suite 195
Lake Forest IL 60045

Date Designated: 11/2/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name: **Imatinib** | Trade Name: Gleevec

Designated Indication: *Treatment of chronic myelogenous leukemia*

Sponsor: Novartis Pharmaceuticals Corporation
Address: 59 Route 10
East Hanover NJ 07936-1080

Date Designated: 1/31/2001
Market Approval Date: 5/10/2001

Generic Name: **imatinib mesylate** | Trade Name: Gleevec

Designated Indication: *Treatment of gastrointestinal stromal tumors*

Sponsor: Novartis Pharmaceuticals Corp.
Address: One Health Plaza
East Hanover NJ 07936-1080

Date Designated: 11/1/2001
Market Approval Date: Not currently Approved

Generic Name: **Imexon** | Trade Name: n/a

Designated Indication: *Treatment of metastatic malignant melanoma*

Sponsor: AmpliMed Corporation
Address: 2321 Camino La Zorrela
Tucson AZ 85718

Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Generic Name: **INH-A00021** | Trade Name: NONE ASSIGNED

Designated Indication: *Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.*

Sponsor: Inhibitex, Inc.
Address: 8995 Westside Parkway
Suite 150
Alpharetta GA 30004

Date Designated: 6/13/2001
Market Approval Date: Not currently Approved

Generic Name: **Interferon-alfa-1b** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of multiple myeloma*

Sponsor: Ernest C.Borden
Address: Center for Cancer Drud Discovery and
9500 Euclid Avenue
Clevland OH 44195

Date Designated: 4/17/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name: **Intraoral fluoride releasing system**
Trade Name: IFRS

Designated Indication: *Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer*

Sponsor: Digestive Care, Inc.
Address: 1120 Win Drive
Bethlehem PA 18017

Date Designated: 7/31/2001
Market Approval Date: Not currently Approved

Generic Name: **L-glutamine**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of sickle cell disease*

Sponsor: Orphan Drugs International, LLC (d.b.a. Hope
Address: PO Box 0401
Montrose CA 91021-0401

Date Designated: 8/1/2001
Market Approval Date: Not currently Approved

Generic Name: **Latrodectus immune F(ab)2**
Trade Name: Aracmyn

Designated Indication: *Treatment of black widow spider envenomations*

Sponsor: Rare Disease Therapeutics, Inc.
Address: 1101 Kermit Drive, Suite 608
Nashville TN 37217

Date Designated: 6/18/2001
Market Approval Date: Not currently Approved

Generic Name: **Medroxyprogesterone acetate**
Trade Name: Hematrol

Designated Indication: *Treatment of immune thrombocytopenic purpura.*

Sponsor: InKine Pharmaceutical Company, Inc.
Address: 1787 Sentry Parkway West
Building 18, Suite 440
Blue Bell PA 19422

Date Designated: 2/22/2001
Market Approval Date: Not currently Approved

Generic Name: **metreleptin**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy*

Sponsor: Amgen, Inc.
Address: One Amgen Center Drive
Thousand Oaks CA 91320-1799

Date Designated: 8/22/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name: **metreleptin**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of metabolic disorders secondary to lipodystrophy*

Sponsor: Amgen, Inc.,
Address: One Amgen Center Drive
Thousand Oaks CA 91320-1799

Date Designated: 8/22/2001
Market Approval Date: Not currently Approved

Generic Name: **MTC-DOX for Injection**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of hepatocellular carcinoma*

Sponsor: FeRx Incorporated
Address: 4330 La Jolla Village Drive
Suite #250
San Diego CA 92122

Date Designated: 1/3/2001
Market Approval Date: Not currently Approved

Generic Name: **muramyltripeptide, phosphatidyl-ethanolamine encased in multi-lamellar liposomes**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of children and adolescent osteosarcoma*

Sponsor: Jenner Biotherapies, Inc.
Address: 541 Kenosa Street
Walworth WI 53184

Date Designated: 6/5/2001
Market Approval Date: Not currently Approved

Generic Name: **nitazoxanide**
Trade Name: Cryptaz

Designated Indication: *Treatment for intestinal amebiasis*

Sponsor: Romark Laboratories, L.C.
Address: 6200 Courtney Campbell Causeway
Suite 880
Tampa FL 33607

Date Designated: 10/23/2001
Market Approval Date: Not currently Approved

Generic Name: **Nitisinone**
Trade Name: Orfadin

Designated Indication: *Treatment of alkaptonuria*

Sponsor: Swedish Orphan AB
Address: Kungsgatan 37, 7th Floor
SE-111 56
Stockholm, Sweden

Date Designated: 10/19/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name: **Nitroprusside** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.*

Sponsor: Thomas, MD, Jeffrey Evan
Address: Thomas Jefferson University and Wills
834 Walnut Street, Suite 650
Philadelphia PA 19107-5102

Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

Generic Name: **nolatrexed** | Trade Name: THYMITAQ

Designated Indication: *Treatment of hepatocellular carcinoma*

Sponsor: Zarix, Inc.
Address: 1055 Westlakes Drive
Suite 200
Berwyn PA 19312

Date Designated: 10/18/2001
Market Approval Date: Not currently Approved

Generic Name: **Novel Acting Thrombolytic (NAT)** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of peripheral arterial occlusion (PAO)*

Sponsor: Amgen, Inc.
Address: One Amgen Center Drive
Thousand Oaks CA 91320-1799

Date Designated: 1/26/2001
Market Approval Date: Not currently Approved

Generic Name: **NZ-1002** | Trade Name: NONE ASSIGNED

Designated Indication: *Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.*

Sponsor: Novazyme Pharmaceuticals, Inc.
Address: 800 Research Parkway
Suite 200
Oklahoma City OK 73104

Date Designated: 4/11/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name: **oglufanide disodium** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of ovarian cancer*

Sponsor: Cytran, Inc.
Address: 10230 NE Points Dr., NE
Suite 530
Kirkland WA 98033-7869

Date Designated: 9/24/2001
Market Approval Date: Not currently Approved

Generic Name: **p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt** | Trade Name: NONE ASSIGNED

Designated Indication: *For the treatment of cystic fibrosis*

Sponsor: Inspire Pharmaceuticals, Inc.
Address: 4222 Emperor Blvd.
Suite 470
Durham NC 27703

Date Designated: 3/7/2001
Market Approval Date: Not currently Approved

Generic Name: **pemetrexed disodium** | Trade Name: Alimta

Designated Indication: *Treatment of malignant pleural mesothelioma*

Sponsor: Eli Lilly and Company
Address: Lilly Corporate Center
Indianapolis IN 46285

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **Perflubron** | Trade Name: LiquiVent

Designated Indication: *Treatment of acute respiratory distress disease (ARDS) in adults*

Sponsor: Alliance Pharmaceutical Corp.
Address: 3040 Science Park Road
San Diego CA 92191

Date Designated: 4/26/2001
Market Approval Date: Not currently Approved

Generic Name: **Polyethylene glycol (PEG)-uricase** | Trade Name: NONE ASSIGNED

Designated Indication: *To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.*

Sponsor: Bio-Technology General Corporation
Address: 70 Wood Avenue South
Iselin NJ 08830

Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name: **porfimer** | Trade Name: Photofrin

Designated Indication: *For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy*

Sponsor: Axcan Scandipharm Inc.
Address: 22 Inverness Parkway, Suite 310, Birmingham AL 35242

Date Designated: 10/19/2001
Market Approval Date: Not currently Approved

Generic Name: **Pyruvate** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of interstitial lung disease.*

Sponsor: Cellular Sciences, Inc
Address: 84 park Avenue, P.O. Box 968, Flemington NJ 08822

Date Designated: 2/21/2001
Market Approval Date: Not currently Approved

Generic Name: **recombinant human alpha 1-antitrypsin (rAAT)** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of cystic fibrosis*

Sponsor: Arriva Pharmaceuticals, Inc.
Address: 2020 Challenger Drive, Alameda CA 94501

Date Designated: 11/20/2001
Market Approval Date: Not currently Approved

Generic Name: **recombinant human alpha-1 antitrypsin (rAAT)** | Trade Name: NONE ASSIGNED

Designated Indication: *To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis*

Sponsor: Baxter Healthcare Corporation
Address: 550 N. Brand Blvd., Glendale CA 91203

Date Designated: 8/28/2001
Market Approval Date: Not currently Approved

Generic Name: **Recombinant Human Alpha-Fetoprotein (rhAFP)** | Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of myasthenia gravis*

Sponsor: Atlantic Biopharmaceuticals, Inc.
Address: 50 Church Street, 5th floor, Cambridge MA 02138

Date Designated: 2/22/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name: **recombinant human endostatin protein**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of neuroendocrine tumors.*
Sponsor: EntreMed, Inc.
Address: 9640 Medical Center Drive, Rockville MD 20850
Date Designated: 8/13/2001
Market Approval Date: Not currently Approved

Generic Name: **Reviparin sodium**
Trade Name: Clivarine
Designated Indication: *Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients*
Sponsor: Knoll AG
Address: Ludwigshafen, Germany
Date Designated: 6/18/2001
Market Approval Date: Not currently Approved

Generic Name: **Reviparin sodium**
Trade Name: Clivarine
Designated Indication: *Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients*
Sponsor: Knoll AG
Address: Ludwigshafen, Germany
Date Designated: 6/18/2001
Market Approval Date: Not currently Approved

Generic Name: **squalamine lactate**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of ovarian cancer refractory or resistant to standard chemotherapy*
Sponsor: Genaera Corporation
Address: 5110 Campus Drive, Plymouth Meeting PA 19462
Date Designated: 5/11/2001
Market Approval Date: Not currently Approved

Generic Name: **Synthetic Human Parathyroid Hormone 1-34**
Trade Name: NONE ASSIGNED
Designated Indication: *Treatment of hypoparathyroidism*
Sponsor: Orphan Pharmaceuticals, U.S., Inc.
Address: 1101 Kermit Drive, Suite 608, Nashville TN 37217
Date Designated: 1/26/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name: **Thyrotropin alfa**
Trade Name: Thyrogen

Designated Indication: *Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid*

Sponsor: Genzyme Corporation
Address: One Kendall Square
Cambridge MA 02139-1562

Date Designated: 8/3/2001
Market Approval Date: Not currently Approved

Generic Name: **tri-antennary glycotripeptide derivative of 5-fluorodeoxyuridine monophosphate**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment for hepatocellular carcinoma*

Sponsor: Cell Works Inc.
Address: 6200 Seaforth Street
Baltimore MD 21224-6506

Date Designated: 11/23/2001
Market Approval Date: Not currently Approved

Generic Name: **Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of renal cell carcinoma.*

Sponsor: Wilex Biotechnology GmbH
Address: Grillparzerstrasse 10B
81675 Munich
Germany DE

Date Designated: 3/22/2001
Market Approval Date: Not currently Approved

Generic Name: **Vasoactive intestinal peptide**
Trade Name: NONE ASSIGNED

Designated Indication: *Treatment of Acute Respiratory Distress Syndrome.*

Sponsor: Sami I. Said, M.D.
Address: State University of New York at Stony Brook
Health Sciences Center T17, 040
Stony Brook NY 11794-8172

Date Designated: 3/9/2001
Market Approval Date: Not currently Approved

Orphan Products Designations and Approvals List
November 2001

Generic Name **Virulizin**

Trade Name: Virulizin

Designated Indication: *Treatment of pancreatic cancer.*

Sponsor: Lorus Therapeutics Inc.
Address: 7100 Woodbine Avenue, Suite 215
Markham, ON L3R 5J2
Canada

Date Designated: 2/1/2001
Market Approval Date: Not currently Approved

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO NOVEMBER 2001 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021205 001	ABACAVIR SULFATE;TRIZIVIR	6180639	JAN 30, 2018	U-248		
			6294540	MAY 14, 2018	U-65		
			6294540*PED	NOV 14, 2018	U-65		
			6180639*PED	JUL 30, 2018	U-248		
	020977 001	ABACAVIR SULFATE;ZIAGEN	6294540	MAY 14, 2018	U-65		
			6294540*PED	NOV 14, 2018	U-65		
	020978 001	ABACAVIR SULFATE;ZIAGEN	6294978	MAY 14, 2018	U-65		
			6294978*PED	NOV 14, 2018	U-65		
			6294540*PED	NOV 14, 2018	U-65		
			6294540	MAY 14, 2018	U-65		
	021082 001	ACETAMINOPHEN;TAVIST ALLERGY/SINUS				NC	MAR 01, 2004
	021123 001	ACETAMINOPHEN;ULTRACET	5336691	AUG 09, 2011		NC	AUG 15, 2004
	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018			
	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018		NCE	DEC 18, 2002
	020949 001	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
	020949 002	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
	020950 001	ALBUTEROL SULFATE;DUONEB				NP	MAR 21, 2004
	020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6251368	DEC 04, 2012		I-235	SEP 23, 2001
						I-262	JUN 02, 2002
	021074 001	ALCOHOL;AVAGARD	5897031	JUN 21, 2016		NC	JUN 07, 2004
	020560 001	ALENDRONATE SODIUM;FOSAMAX	6194004	DEC 02, 2012			
	020560 004	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
	020560 005	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
	021001 001	ALMOTRIPTAN MALATE;AXERT	5565447	MAR 27, 2014		NCE	MAY 07, 2006
	021001 002	ALMOTRIPTAN MALATE;AXERT	5565447	MAR 27, 2014		NCE	MAY 07, 2006
	021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX	5360800	FEB 02, 2010			
			6284770	OCT 05, 2018	U-405		
	019787 001	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
			4572909	JUL 31, 2006			
			4879303*PED	SEP 25, 2007			
			4572909*PED	JAN 31, 2007			
	019787 002	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
			4572909	JUL 31, 2006			
			4879303*PED	SEP 25, 2007			
			4572909*PED	JAN 31, 2007			
	019787 003	AMLODIPINE BESYLATE;NORVASC	4879303	MAR 25, 2007			
			4572909	JUL 31, 2006			
			4879303*PED	SEP 25, 2007			
			4572909*PED	JAN 31, 2007			
>ADD>	021303 001	AMPHETAMINE ASPARTATE;ADDERALL XR 10				NDF	OCT 11, 2004
>ADD>	021303 002	AMPHETAMINE ASPARTATE;ADDERALL XR 20				NDF	OCT 11, 2004
>ADD>	021303 003	AMPHETAMINE ASPARTATE;ADDERALL XR 30				NDF	OCT 11, 2004
	020883 001	ARGATROBAN;ACOVA	5214052	MAR 13, 2012			
>ADD>	021317 001	ASPIRIN;BAYER EXTRA STRENGTH				NP	OCT 18, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013	U-406	NC	JUL 14, 2003
		5053432	OCT 01, 2008			
		6291488	NOV 25, 2013			
021078 002	ATOVAQUONE;MALARONE PEDIATRIC	5053432	OCT 01, 2008		NC	JUL 14, 2003
		6291488	NOV 25, 2013	U-406		
019408 002	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
021056 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015		ODE	DEC 29, 2006
		5962731	OCT 05, 2016			
		5466861	NOV 14, 2012			
020498 001	BICALUTAMIDE;CASODEX	1712251	SEP 18, 2001	U-391		
		5712251	SEP 18, 2001	U-391		
021275 001	BIMATOPROST;LUMIGAN	5688819	SEP 21, 2012		NCE	MAR 16, 2006
021290 001	BOSENTAN;TRACLEER				ODE	NOV 20, 2008
					NCE	NOV 20, 2006
021290 002	BOSENTAN;TRACLEER				ODE	NOV 20, 2008
					NCE	NOV 20, 2006
020490 001	BRIMONIDINE TARTRATE;ALPHAGAN				NCE	SEP 06, 2001
					PED	MAR 06, 2002
020613 001	BRIMONIDINE TARTRATE;ALPHAGAN	6194415	JUN 28, 2015	U-394	NCE	SEP 06, 2001
		6248741	JUN 28, 2015	U-394	PED	MAR 06, 2002
		6194415*PED	DEC 28, 2015	U-394		
		6248741*PED	DEC 28, 2015	U-394		
021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	6194415*PED	DEC 28, 2015	U-395	NP	MAR 16, 2004
		5736165	APR 07, 2015	U-399	PED	SEP 16, 2004
		5736165*PED	OCT 07, 2015	U-399	NCE	SEP 06, 2001
		6248741	JUN 28, 2015	U-395	PED	MAR 06, 2002
		6194415	JUN 28, 2015	U-395		
		6248741*PED	DEC 28, 2015	U-395		
		5424078	JUN 13, 2012			
		5424078*PED	DEC 13, 2012			
020816 001	BRINZOLAMIDE;AZOPT	5378703	APR 01, 2012	U-224		
021324 001	BUDESONIDE;ENTOCORT EC	5643602	JUL 01, 2014		NP	OCT 02, 2004
020746 001	BUDESONIDE;RHINOCORT	6291445	APR 29, 2017			
020358 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
020358 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
020358 003	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
018731 001	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
>ADD>					PED	JAN 19, 2005
018731 002	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
>ADD>					PED	JAN 19, 2005
018731 003	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
>ADD>					PED	JAN 19, 2005
018731 004	BUSPIRONE HYDROCHLORIDE;BUSPAR				M-12	JUL 19, 2004
>ADD>					PED	JAN 19, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
074253 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
074253 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
075272 003	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 24, 2001
075467 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
076008 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	JAN 28, 2002
020524 001	BUTENAFINE HYDROCHLORIDE;MENTAX				I-333	JUN 06, 2004
>ADD> 018874 001	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001		PED	MAY 16, 2005
>ADD>		6051567	AUG 02, 2019		M-14	NOV 16, 2004
		4308264*PED	JUL 28, 2001			
		6051567*PED	FEB 02, 2020			
		6265392	AUG 02, 2019			
		6274169	AUG 02, 2019			
		6274169*PED	FEB 02, 2020			
		6265392*PED	FEB 02, 2020			
>ADD> 018874 002	CALCITRIOL;CALCIJEX	4308264	JAN 28, 2001		PED	MAY 16, 2005
>ADD>		6051567	AUG 02, 2019		M-14	NOV 16, 2004
		4308264*PED	JUL 28, 2001			
		6051567*PED	FEB 02, 2020			
		6265392	AUG 02, 2019			
		6274169	AUG 02, 2019			
		6274169*PED	FEB 02, 2020			
		6265392*PED	FEB 02, 2020			
019976 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
021160 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
021160 002	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
021160 003	CALCIUM ACETATE;PHOSLO GELCAPS	4870105	APR 07, 2007	U-381		
020896 001	CAPECITABINE;XELODA				I-323	APR 30, 2004
					I-341	SEP 07, 2004
020896 002	CAPECITABINE;XELODA				I-323	APR 30, 2004
					I-341	SEP 07, 2004
020297 001	CARVEDILOL;COREG				I-343	NOV 01, 2004
020297 002	CARVEDILOL;COREG				I-343	NOV 01, 2004
020297 003	CARVEDILOL;COREG				I-343	NOV 01, 2004
020297 004	CARVEDILOL;COREG				I-343	NOV 01, 2004
021227 001	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
		5378804	MAR 16, 2013			
		5514650	MAR 16, 2013			
		5792746	MAR 16, 2013			
		6136783	MAR 28, 2017			
021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
		5378804	MAR 16, 2013			
		5514650	MAR 16, 2013			
		5792746	MAR 16, 2013			
		6136783	MAR 28, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020998 001	CELECOXIB;CELEBREX				I-338	OCT 17, 2004
	020998 002	CELECOXIB;CELEBREX				I-338	OCT 17, 2004
	021197 001	CETRORELIX;CETROTIDE	6319192	APR 23, 2018	U-426		
	021197 002	CETRORELIX;CETROTIDE	6319192	APR 23, 2018	U-426		
	019111 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	4762709	AUG 09, 2005			
	021149 001	CHORIOGONADOTROPIN ALFA;OVIDREL	5767251	JUN 16, 2015		NP	SEP 20, 2003
	021022 001	CICLOPIROX;PENLAC	4957730	SEP 18, 2007	U-379		
	020839 001	CLOPIDOGREL BISULFATE;PLAVIX	4847265	NOV 17, 2011			
	020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	6177101	JUN 11, 2018			
>ADD>	021165 001	DESLORATADINE;CLARINEX	4659716	APR 21, 2004	U-427	NCE	DEC 21, 2006
>ADD>			4863931	SEP 15, 2008			
>ADD>			4804666	FEB 14, 2006	U-428		
>ADD>			5595997	DEC 30, 2014	U-429		
	021038 001	DEXMEDETOMIDINE;PRECEDEX	4910214	JUL 15, 2008	U-421		
	021278 001	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5922736	DEC 04, 2015	U-423	NP	NOV 13, 2004
			5908850	DEC 04, 2015	U-422		
			6255325	DEC 04, 2015	U-424		
	021278 002	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5922736	DEC 04, 2015	U-423	NP	NOV 13, 2004
			5908850	DEC 04, 2015	U-422		
			6255325	DEC 04, 2015	U-424		
	021278 003	DEXMETHYLPHENIDATE HYDROCHLORIDE;FOCALIN	5908850	DEC 04, 2015	U-422	NP	NOV 13, 2004
			5922736	DEC 04, 2015	U-423		
			6255325	DEC 04, 2015	U-424		
	020607 001	DICLOFENAC SODIUM;ARTHROTEC	5698225	MAY 03, 2010	U-392		
	020607 002	DICLOFENAC SODIUM;ARTHROTEC	5698225	MAY 03, 2010	U-392		
	021005 001	DICLOFENAC SODIUM;SOLARAZE	5639738	JUN 17, 2014	U-402	NP	OCT 16, 2003
			5792753	AUG 11, 2015			
			5852002	JUN 17, 2014	U-402		
			5914322	AUG 11, 2015			
			5929048	JUL 27, 2016	U-402		
			5985850	NOV 16, 2016			
	020154 002	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
			5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
			4861759*PED	MAR 01, 2007	U-248		
			5254539*PED	MAR 01, 2007	U-248		
			5616566*PED	MAR 01, 2007	U-180		
			5880106*PED	JAN 22, 2012			
	020154 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
			5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
			5254539	AUG 29, 2006	U-248		
			5880106	JUL 22, 2011			
			4861759*PED	MAR 01, 2007	U-248		
			5254539*PED	MAR 01, 2007	U-248		
			5616566*PED	MAR 01, 2007	U-180		
			5880106*PED	JAN 22, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020154 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
		5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
		5254539	AUG 29, 2006	U-248		
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020154 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	NS	OCT 28, 2002
		5254539	AUG 29, 2006	U-248	PED	APR 28, 2003
		5880106	JUL 22, 2011			
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5880106*PED	JAN 22, 2012			
020155 003	DIDANOSINE;VIDEX	5616566	AUG 29, 2006	U-180		
		4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
020155 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020156 001	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
		5616566	AUG 29, 2006	U-180		
		5254539	AUG 29, 2006	U-248		
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
		5616566*PED	MAR 01, 2007	U-180		
021183 001	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 002	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 003	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
021183 004	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
		5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
		4861759*PED	MAR 01, 2007	U-248		
		5254539*PED	MAR 01, 2007	U-248		
020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	6140321	DEC 30, 2016			
		6245911	DEC 01, 2018			
		5985864	DEC 30, 2016			
020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	6140321	DEC 30, 2016			
		6245911	DEC 01, 2018			
		5985864	DEC 30, 2016			
020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	6248735	APR 17, 2011			
021098 001	DROSPIRENONE;YASMIN				NC	MAY 11, 2004
021319 001	DUTASTERIDE;DUTASTERIDE				NCE	NOV 20, 2006
020706 001	EMEDASTINE DIFUMARATE;EMADINE	4430343	AUG 14, 2005	U-403		
		5441958	DEC 08, 2013	U-404		
020668 001	ENALAPRIL MALEATE;LEXXEL	4264611	JUN 19, 2001	U-3		
		4803081	APR 03, 2007			
		4264611*PED	DEC 19, 2001	U-3		
		4803081*PED	OCT 03, 2007			
020668 002	ENALAPRIL MALEATE;LEXXEL	4374829	DEC 30, 2001	U-3		
		4472380	SEP 18, 2001			
		4703038	OCT 07, 2005	U-3		
		4803081	APR 03, 2007			
		4264611	JUN 19, 2001	U-3		
		4264611*PED	DEC 19, 2001	U-3		
		4803081*PED	OCT 03, 2007			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018998 001	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
018998 002	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
018998 003	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
018998 005	ENALAPRIL MALEATE;VASOTEC				M-7	FEB 13, 2004
					PED	AUG 13, 2004
020164 002	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 003	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 004	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 005	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 006	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001			
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 007	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
020164 008	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
		4692435	DEC 24, 2004	U-123		
		5389618	FEB 14, 2012			
021268 001	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U-3	NC	NOV 01, 2004
					NCE	DEC 22, 2002
021268 002	EPROSARTAN MESYLATE;TEVETEN HCT	5185351	FEB 09, 2010	U-3	NC	NOV 01, 2004
					NCE	DEC 22, 2002
020718 001	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
020718 002	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
>ADD> 021337 001	ERTAPENEM SODIUM;INVANZ	5478820	FEB 02, 2013		NCE	NOV 21, 2006
>ADD>		5652233	FEB 02, 2013			
>ADD>		5952323	MAY 15, 2017			
019386 001	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
		6310094	JAN 12, 2021			
019386 002	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
019386 003	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	MAY 21, 2008			
		4593119	JUN 03, 2003			
021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
		4738974	APR 19, 2005	U-373		
		4636499	MAY 30, 2005	U-373		
		5900424	MAY 04, 2016	U-373		
		4786505	APR 20, 2007	U-373		
		4853230	APR 20, 2007	U-373		
		5714504	FEB 03, 2015	U-373		
		5877192	MAY 27, 2014	U-373		
		5093342	FEB 02, 2010	U-373		
		5599794	FEB 04, 2014	U-373		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
		5629305	FEB 04, 2014	U-373		
		5690960	NOV 25, 2014	U-373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4508905	FEB 20, 2001			
021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
		4738974	APR 19, 2005	U-373		
		4636499	MAY 30, 2005	U-373		
		5900424	MAY 04, 2016	U-373		
		4786505	APR 20, 2007	U-373		
		4853230	APR 20, 2007	U-373		
		5714504	FEB 03, 2015	U-373		
		5877192	MAY 27, 2014	U-373		
		5093342	FEB 02, 2010	U-373		
		5599794	FEB 04, 2014	U-373		
		5629305	FEB 04, 2014	U-373		
		5690960	NOV 25, 2014	U-373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4508905	FEB 20, 2001			
020870 001	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020870 002	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
		6024976	JAN 07, 2014			
020538 005	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 006	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 007	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 008	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020130 002	ETHINYL ESTRADIOL;ESTROSTEP FE	5010070	APR 23, 2008		I-331	JUL 01, 2004
020130 001	ETHINYL ESTRADIOL;ESTROSTEP 21	5010070	APR 23, 2008		I-331	JUL 01, 2004
021187 001	ETHINYL ESTRADIOL;NUVARING				NP	OCT 03, 2004
021180 001	ETHINYL ESTRADIOL;ORTHO EVRA				NP	NOV 20, 2004
020946 001	ETHINYL ESTRADIOL;PREVEN EMERGENCY CON	6156742	DEC 05, 2020	U-374		
020584 001	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
					PED	FEB 11, 2004
020584 002	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
					PED	FEB 11, 2004
020584 003	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
					PED	FEB 11, 2004
020457 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	RE35524	MAY 17, 2010			
020906 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	5041424	AUG 20, 2008	U-135		
		RE35524	MAY 17, 2010			
020906 002	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	5041424	AUG 20, 2008	U-135		
		RE35524	MAY 17, 2010			
075312 001	FAMOTIDINE;FAMOTIDINE				PC	NOV 28, 2001
020902 001	FAMOTIDINE;PEPCID AC				D-47	NOV 09, 2001
					PED	MAY 09, 2002
019834 001	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
		4803081	APR 03, 2007			
		4803081*PED	OCT 03, 2007			
019834 002	FELODIPINE;PLENDIL	4264611*PED	DEC 19, 2001	U-3		
		4264611	JUN 19, 2001	U-3		
		4803081	APR 03, 2007			
019834 004	FELODIPINE;PLENDIL	4264611*PED	DEC 19, 2001	U-3		
		4803081*PED	OCT 03, 2007			
		4264611	JUN 19, 2001	U-3		
		4803081	APR 03, 2007			
021203 001	FENOFIBRATE;TRICOR	4264611*PED	DEC 19, 2001	U-3		
		4803081*PED	OCT 03, 2007			
		4895726	JAN 19, 2009			
		6277405	JAN 09, 2018			
021203 003	FENOFIBRATE;TRICOR	6074670	JAN 09, 2018			
		4895726	JAN 19, 2009			
		6277405	JAN 09, 2018			
		6074670	JAN 09, 2018			
020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	6187791	MAY 11, 2012	U-138		
019452 001	FLUOCINOLONE ACETONIDE;DERMA-SMOOTHE/FS				I-340	OCT 10, 2004
020985 001	FLUOROURACIL;CARAC	4690825	OCT 04, 2005			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	074803 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
>ADD>	075049 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
>ADD>	075465 003	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
>ADD>	075506 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE				PC	JAN 29, 2002
>ADD>	075755 001	FLUOXETINE HYDROCHLORIDE;FLUOXETINE HCL				PC	JAN 29, 2002
>ADD>	075755 002	FLUOXETINE HYDROCHLORIDE;FLUOXETINE HCL				PC	JAN 29, 2002
	021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY	5910319	MAY 29, 2017	U-396	NDF	FEB 26, 2004
			5985322	MAY 29, 2017	U-397		
			5910319*PED	NOV 29, 2017	U-396		
			5985322*PED	NOV 29, 2017	U-397		
	018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM				PED	JAN 06, 2004
	021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	020549 001	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
	020549 002	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 3003	U-409		
	020549 003	FLUTICASONE PROPIONATE;FLOVENT	4335121	NOV 14, 2003	U-409		
	020833 001	FLUTICASONE PROPIONATE;FLOVENT DISKUS 50	4335121	NOV 14, 2003	U-409		
	020833 002	FLUTICASONE PROPIONATE;FLOVENT DISKUS 100	4335121	NOV 14, 2003	U-409		
	020833 003	FLUTICASONE PROPIONATE;FLOVENT DISKUS 250	4335121	NOV 14, 2003	U-409		
	020261 001	FLUVASTATIN SODIUM;LESCOL	5356896	DEC 12, 2011			
	020261 002	FLUVASTATIN SODIUM;LESCOL	5356896	DEC 12, 2011			
	021192 001	FLUVASTATIN SODIUM;LESCOL XL	5354772	OCT 11, 2011	U-413		
			5356896	DEC 12, 2011			
	020831 001	FORMOTEROL FUMARATE;FORADIL				NCE	FEB 16, 2006
	021279 001	FORMOTEROL FUMARATE;FORADIL				I-342	SEP 25, 2004
						NCE	FEB 16, 2006
	021006 001	FROVATRIPTAN SUCCINATE;FROVA	5464864	NOV 07, 2012	U-72	NCE	NOV 08, 2006
			5616603	APR 01, 2014	U-72		
			5637611	JUN 10, 2014	U-72		
			5827871	OCT 27, 2015	U-72		
			5962501	DEC 16, 2013	U-72		
>ADD>	020235 001	GABAPENTIN;NEURONTIN				PED	APR 12, 2004
>ADD>	020235 002	GABAPENTIN;NEURONTIN				PED	APR 12, 2004
>ADD>	020235 003	GABAPENTIN;NEURONTIN				PED	APR 12, 2004
>ADD>	020882 001	GABAPENTIN;NEURONTIN				PED	APR 12, 2004
>ADD>	020882 002	GABAPENTIN;NEURONTIN				PED	APR 12, 2004
>ADD>	021129 001	GABAPENTIN;NEURONTIN	4894476*PED	NOV 02, 2008		PED	APR 12, 2004
>ADD>			5084479*PED	JUL 02, 2010	U-258		
			4894476	MAY 02, 2008			
			5084479	JAN 02, 2010	U-258		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
			6099863	JUN 06, 2017			
	021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
			6099863	JUN 06, 2017			
	021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
			6099863	JUN 06, 2017			
	021224 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021061 001	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
	021061 002	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
	021062 001	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
	021062 002	GATIFLOXACIN;TEQUIN				D-69	OCT 12, 2004
	021178 001	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412		
	021178 002	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412		
	021178 003	GLYBURIDE;GLUCOVANCE	6303146	JUL 14, 2019	U-412		
	020239 001	GRANISETRON HYDROCHLORIDE;KYTRIL	6294548	MAY 04, 2019			
	020239 002	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-89		
			6294548	MAY 04, 2019			
	021238 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-105	I-264	JUL 27, 2002
	020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
	020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
	019778 001	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002			
	019778 002	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002	U-3		
	019778 003	HYDROCHLOROTHIAZIDE;PRINZIDE	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002	U-3		
	019888 001	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002	U-3		
	019888 002	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002	U-3		
	019888 003	HYDROCHLOROTHIAZIDE;ZESTORETIC	4374829	DEC 29, 2001	U-3		
			4374829*PED	JUN 29, 2002	U-3		
	020402 002	IBUPROFEN POTASSIUM;ADVIL MIGRAINE LIQUI				NP	MAR 16, 2003
	021128 001	IBUPROFEN;CHILDREN'S MOTRIN CO	6211246	JUN 10, 2019			
	021335 001	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
						ODE	MAY 10, 2008
	021335 002	IMATINIB MESYLATE;GLEEVEC	5521184	MAY 28, 2013		NCE	MAY 10, 2006
						ODE	MAY 10, 2008
>ADD>	020685 006	INDINAVIR SULFATE;CRIXIVAN	5413999	MAY 09, 2012	U-132		
>ADD>	020986 001	INSULIN ASPART;NOVOLOG				NR	DEC 21, 2004
	021172 001	INSULIN ASPART;NOVOLOG MIX 70/30				NC	NOV 01, 2004
	021081 001	INSULIN GLARGINE;LANTUS	5656722	SEP 12, 2014			
			5656722*PED	MAR 12, 2015			
	020394 001	IPRATROPIUM BROMIDE;ATROVENT				I-327	OCT 27, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
018662 002	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
		4464394*PED	FEB 07, 2002			
018662 003	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
		4464394*PED	FEB 07, 2002			
018662 004	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
		4464394*PED	FEB 07, 2002			
020657 001	ITRACONAZOLE;SPORANOX				I-332	MAY 09, 2004
020966 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005		I-332	MAY 09, 2004
019700 001	KETOROLAC TROMETHAMINE;ACULAR	4454151	MAR 22, 2002	U-75		
		5110493	MAY 05, 2009			
		4454151*PED	SEP 22, 2002	U-75		
		5110493*PED	NOV 05, 2009	U-75		
				U-75		
020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE	4454151	MAR 22, 2002			
		4454151*PED	SEP 22, 2002			
020857 001	LAMIVUDINE;COMBIVIR	6180639	JAN 30, 2018	U-248		
		6180639*PED	JUL 30, 2018	U-248		
020564 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
		6180639*PED	JUL 30, 2018	U-248		
020596 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
		6180639*PED	JUL 30, 2018	U-248		
021003 001	LAMIVUDINE;EPIVIR-HBV				I-339	AUG 16, 2004
					PED	FEB 16, 2005
021004 001	LAMIVUDINE;EPIVIR-HBV				PED	FEB 16, 2005
					I-339	AUG 16, 2004
021281 001	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
					M-1	JUL 06, 2002
					D-42	JUL 20, 2001
021281 002	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
					M-1	JUL 06, 2002
					D-42	JUL 20, 2001
020905 001	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
020905 002	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
020905 003	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
020726 001	LETROZOLE;FEMARA	4978672	JUN 03, 2011	U-203		
019732 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		6036976	DEC 13, 2013			
020011 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5631020	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
020517 001	LEUPROLIDE ACETATE;LUPRON DEPOT	5643607	JAN 02, 2013			
		5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020263 002	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		6036976	DEC 13, 2013			
020263 003	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
		5575987	SEP 02, 2013			
		5476663	NOV 01, 2004			
		6036976	DEC 13, 2013			
020263 004	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		6036976	DEC 13, 2013			
020263 005	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		6036976	DEC 13, 2013			
020263 006	LEUPROLIDE ACETATE;LUPRON DEPOT-PED	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5575987	SEP 02, 2013			
		6036976	DEC 13, 2013			
020708 001	LEUPROLIDE ACETATE;LUPRON DEPOT-3	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5643607	JAN 02, 2013			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			
020517 002	LEUPROLIDE ACETATE;LUPRON DEPOT-4	5631021	NOV 01, 2004			
		5476663	NOV 01, 2004			
		5643607	JAN 02, 2013			
		5814342	FEB 01, 2011			
		6036976	DEC 13, 2016			
		6235712	JUN 13, 2017			
021088 001	LEUPROLIDE ACETATE;VIADUR	4374829	DEC 29, 2001			
		4374829*PED	JUN 29, 2002			
019558 001	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
		4374829*PED	JUN 29, 2002			
019558 002	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
		4374829*PED	JUN 29, 2002			
019558 003	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
		4374829*PED	JUN 29, 2002			
019558 004	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
		4374829*PED	JUN 29, 2002			
019558 006	LISINOPRIL;PRINIVIL	4374829	DEC 29, 2001			
		4374829*PED	JUN 29, 2002			
019777 001	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
		4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
019777 002	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
		4374829*PED	JUN 29, 2002		PED	AUG 07, 2003

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019777 003	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
	019777 004	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
	019777 005	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
	019777 006	LISINOPRIL;ZESTRIL	4374829	DEC 29, 2001		I-288	FEB 07, 2003
			4374829*PED	JUN 29, 2002		PED	AUG 07, 2003
	021226 001	LOPINAVIR;KALETRA	6232333	NOV 07, 2017			
			6284767	FEB 14, 2016	U-401		
	021251 001	LOPINAVIR;KALETRA	6284767	FEB 14, 2016	U-401		
	020386 001	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
	020386 002	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
	020386 003	LOSARTAN POTASSIUM;COZAAR	5138069	AUG 11, 2009			
			5153197	OCT 06, 2009	U-3		
			5608075	MAR 04, 2014			
	019643 002	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
	019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
	019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
>ADD>	021249 001	LOVASTATIN;NICACIN/LOVASTATIN				NC	DEC 17, 2004
>ADD>	021249 002	LOVASTATIN;NICACIN/LOVASTATIN				NC	DEC 17, 2004
>ADD>	021249 003	LOVASTATIN;NICACIN/LOVASTATIN				NC	DEC 17, 2004
	075671 001	MEGESTROL ACETATE;MEGESTROL ACETATE				PC	JAN 12, 2002
	020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372	NP	AUG 01, 2003
	021259 001	METHYLPHENIDATE HYDROCHLORIDE;METADATE CD				NDF	APR 03, 2004
	019962 001	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 002	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 27, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U-107	NS	FEB 05, 2004
			5001161	MAR 19, 2008	U-107	I-194	FEB 05, 2004
			5081154	JAN 14, 2009	U-107		
			4927640	MAY 22, 2007			
			5246714	SEP 21, 2010			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATI	6153635	NOV 28, 2020			
		5514698	MAR 21, 2014			
019436 001	MILRINONE LACTATE;PRIMACOR	4313951	NOV 26, 2001			
		4313951*PED	MAY 26, 2002			
020343 001	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
		4313951*PED	MAY 26, 2002			
020343 002	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
		4313951*PED	MAY 26, 2002			
020343 003	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
		4313951*PED	MAY 26, 2002			
021208 001	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
021208 002	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
021208 003	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	4617319	JUN 13, 2005	U-390	I-324	OCT 13, 2003
020762 001	MOMETASONE FUROATE MONOHYDRATE;NASONEX	4472393	SEP 18, 2001		I-285	DEC 02, 2002
		5837699	JAN 27, 2014	U-249	PED	JUN 02, 2003
		6127353	OCT 03, 2017			
		4472393*PED	MAR 18, 2002			
		5837699*PED	JUL 27, 2014	U-249		
		6127353*PED	APR 03, 2018			
019543 001	MOMETASONE FUROATE;ELOCON	4472393	SEP 18, 2001			
		4472393*PED	MAR 18, 2002			
019625 001	MOMETASONE FUROATE;ELOCON	4808610	OCT 02, 2006			
		4472393	SEP 18, 2001			
		4472393*PED	MAR 18, 2002			
019796 001	MOMETASONE FUROATE;ELOCON	4808610*PED	APR 02, 2007			
		4775529	MAY 21, 2007			
		4472393	SEP 18, 2001			
		4472393*PED	MAR 18, 2002			
		4775529*PED	NOV 21, 2007			
020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	NCE	FEB 20, 2003
		5565473*PED	AUG 03, 2012	U-228	PED	AUG 20, 2003
020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	NCE	FEB 20, 2003
		5565473*PED	AUG 03, 2012	U-228	PED	AUG 20, 2003
020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228	I-300	MAR 03, 2003
		5565473*PED	AUG 03, 2012	U-228	NS	MAR 03, 2003
					NCE	FEB 20, 2003
					PED	SEP 03, 2003
					PED	AUG 20, 2003
					PED	SEP 03, 2003
021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX				I-329	APR 27, 2004
021277 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX IN SODIUM CHL				NCE	DEC 10, 2004
					NDF	NOV 30, 2004
					I-329	APR 27, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	075179 001	NABUMETONE;NABUMETONE				PC	FEB 23, 2002
	075189 001	NABUMETONE;NABUMETONE				PC	FEB 16, 2002
	075189 002	NABUMETONE;NABUMETONE				PC	FEB 23, 2002
	019583 001	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
			4420639*PED	JUN 13, 2003			
	019583 002	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
			4420639*PED	JUN 13, 2003			
	021204 001	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
			5463116	OCT 21, 2012			
			5488150	JAN 30, 2013			
	021204 002	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
			5463116	OCT 21, 2012			
			5488150	JAN 30, 2013			
	020920 001	NESIRITIDE;NATRECOR	5114923	MAY 19, 2009		NCE	AUG 10, 2006
			5674710	OCT 07, 2014			
	020165 004	NICOTINE;NICODERM CQ	6165497	JUN 14, 2008	U-388		
			5633008	JUN 14, 2008	U-389		
	020165 005	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
			6165497	JUN 14, 2008	U-388		
	020165 006	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
			6165497	JUN 14, 2008	U-388		
	075269 002	NIFEDIPINE;NIFEDIPINE				PC	JUN 05, 2001
>ADD>	019667 001	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
>ADD>	019667 002	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
>ADD>	019667 003	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
>ADD>	019667 004	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	MAY 19, 2015			
	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	020799 001	OFLOXACIN;FLOXIN	5401741	MAR 27, 2012	U-407		
	020592 001	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 002	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 003	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 004	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 005	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
			5605897	FEB 25, 2014	U-176		
			6251895	SEP 23, 2017			
	020592 006	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
			5229382	APR 23, 2011	U-149		
			5605897	FEB 25, 2014	U-176		
	021086 001	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 002	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021086 003	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
		6251895	SEP 23, 2017			
021086 004	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
		6251895	SEP 23, 2017			
020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL	5641805	JUN 06, 2015	U-184		
019810 001	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4255431*PED	OCT 05, 2001	U-108		
		4636499*PED	JAN 30, 2006			
		4786505*PED	OCT 20, 2007	U-108		
		4853230*PED	OCT 20, 2007	U-108		
		5093342*PED	AUG 02, 2010	U-166		
		5599794*PED	AUG 04, 2014	U-166		
		5629305*PED	AUG 04, 2014	U-188		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2018			
		6191148*PED	APR 09, 2019			
		4508905	APR 02, 2002			
		4508905*PED	OCT 02, 2002			
019810 002	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4255431*PED	OCT 05, 2001	U-108		
		4636499*PED	JAN 30, 2006			
		4786505*PED	OCT 20, 2007	U-108		
		4853230*PED	OCT 20, 2007	U-108		
		5093342*PED	AUG 02, 2010	U-166		
		5599794*PED	AUG 04, 2014			
		5629305*PED	AUG 04, 2014	U-166		
		6147103*PED	APR 09, 2019	U-188		
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2018			
		6191148*PED	APR 09, 2019			
		4508905	APR 02, 2002			
		4508905*PED	OCT 02, 2002			
019810 003	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		I-229	JUN 29, 2001
		6147103	OCT 09, 2018		PED	DEC 29, 2001
		6166213	NOV 10, 2018			
		6191148	OCT 09, 2018			
		4255431*PED	OCT 05, 2001	U-108		
		4636499*PED	JAN 30, 2006			
		4786505*PED	OCT 20, 2007	U-108		
		4853230*PED	OCT 20, 2007	U-108		
		5093342*PED	AUG 02, 2010	U-166		
		5599794*PED	AUG 04, 2014	U-166		
		5629305*PED	AUG 04, 2014	U-188		
		6147103*PED	APR 09, 2019			
		6150380*PED	MAY 10, 2019			
		6166213*PED	APR 09, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
			4508905*PED	OCT 02, 2002			
	020781 001	ONDANSETRON;ZOFRAN ODT	4753789	JUN 24, 2006	U-330		
	021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	5763483	DEC 27, 2016	U-376	I-317	NOV 17, 2003
			5866601	FEB 02, 2016		NDF	DEC 14, 2003
	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	5952375	FEB 02, 2016		NCE	OCT 27, 2004
			6124355	MAY 22, 2015	U-378		
	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	6262115	MAY 22, 2015	U-393		
			6124355	MAY 22, 2015	U-378		
	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	6262115	MAY 22, 2015	U-393		
			6124355	MAY 22, 2015	U-378		
	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	6262115	MAY 22, 2015	U-393		
			4861598	AUG 29, 2006			
			4970075	NOV 13, 2007			
			5266331	FEB 05, 2008			
			5549912	FEB 05, 2008			
	020553 005	OXYCODONE HYDROCHLORIDE;OXYCONTIN	4861598	AUG 29, 2006			
			4970075	NOV 13, 2007			
			5266331	FEB 05, 2008			
			5549912	FEB 05, 2008			
			5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
	020262 001	PACLITAXEL;TAXOL	6150398	MAY 08, 2011	U-380		
	020036 001	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
	020036 003	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
	020036 004	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
	075290 001	PAMIDRONATE DISODIUM;PAMIDRONATE DISODIUM				PC	MAY 05, 2002
	075290 003	PAMIDRONATE DISODIUM;PAMIDRONATE DISODIUM				PC	MAY 05, 2002
	020987 001	PANTOPRAZOLE SODIUM;PROTONIX				I-330	JUN 12, 2004
	020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV	4758579	JUL 19, 2005		NDF	MAR 22, 2004
						NCE	FEB 02, 2005
	020819 001	PARICALCITOL;ZEMPLAR				I-337	OCT 19, 2004
>ADD>	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL	5246925	APR 17, 2012	U-314		
>ADD>			6121291	MAR 17, 2017	U-286	I-326	APR 13, 2004
>ADD>	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-431	I-345	DEC 14, 2004
>ADD>			6121291	MAR 17, 2017	U-286	I-326	APR 13, 2004
>ADD>	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-431	I-345	DEC 14, 2004
>ADD>			6121291	MAR 17, 2017	U-286	I-326	APR 13, 2004
	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-431	I-345	DEC 14, 2004
>ADD>						I-326	APR 13, 2004
>ADD>	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL				I-345	DEC 14, 2004
>ADD>			6121291	MAR 17, 2017	U-286	I-326	APR 13, 2004
			6121291	MAR 17, 2017	U-431	I-345	DEC 14, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020710 001	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
>ADD>			6121291	MAR 17, 2017			
					U-431		
>ADD>	020885 001	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
>ADD>			6121291	MAR 17, 2017	U-431		
>ADD>	020885 002	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
>ADD>			6121291	MAR 17, 2017	U-431		
>ADD>	020885 003	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
>ADD>			6121291	MAR 17, 2017			
					U-431		
>ADD>	020885 004	PAROXETINE HYDROCHLORIDE;PAXIL	6121291	MAR 17, 2017	U-286		
>ADD>			6121291	MAR 17, 2017	U-431		
	020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006			
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			5789449	JAN 06, 2009	U-286		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-286		
			6172233	JAN 15, 2018			
	021064 001	PERFLUTREN;DEFINITY	5527521	APR 05, 2011		NCE	JUL 31, 2006
			5547656	APR 05, 2011			
			5769080	JUL 20, 2010			
>ADD>	021302 001	PIMECROLIMUS;ELIDEL	5912238	JUN 15, 2016		NCE	DEC 13, 2006
>ADD>			5912238*PED	DEC 15, 2016		PED	JUN 13, 2007
>ADD>	021073 001	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6329404	JUN 19, 2016	U-430		
			6211205	JUN 19, 2016	U-410		
			6271243	JUN 19, 2016	U-411		
			6303640	JUN 19, 2016	U-425		
			6166042	JUN 19, 2016	U-414		
			6166043	JUN 19, 2016	U-415		
			6172090	JUN 19, 2016	U-416		
			5965584	JUN 19, 2016	U-417		
			6150383	JUN 19, 2016	U-418		
			6150384	JUN 19, 2016	U-419		
>ADD>	021073 002	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6329404	JUN 19, 2016	U-430		
			6211205	JUN 19, 2016	U-410		
			6271243	JUN 19, 2016	U-411		
			6303640	JUN 19, 2016	U-425		
			6166042	JUN 19, 2016	U-414		
			6166043	JUN 19, 2016	U-415		
			6172090	JUN 19, 2016	U-416		
			5965584	JUN 19, 2016	U-417		
			6150383	JUN 19, 2016	U-418		
			6150384	JUN 19, 2016	U-419		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	021073 003	PIOGLITAZONE HYDROCHLORIDE;ACTOS	6329404	JUN 19, 2016	U-430		
			6211205	JUN 19, 2016	U-410		
			6271243	JUN 19, 2016	U-411		
			6303640	JUN 19, 2016	U-425		
			6166042	JUN 19, 2016	U-414		
			6166043	JUN 19, 2016	U-415		
			6172090	JUN 19, 2016	U-416		
			5965584	JUN 19, 2016	U-417		
			6150383	JUN 19, 2016	U-418		
			6150384	JUN 19, 2016			
	074726 001	POTASSIUM CHLORIDE;KLOR-CON M20				PC	FEB 28, 2002
	020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
>ADD>	019898 002	PRAVASTATIN SODIUM;PRAVACHOL				D-70	DEC 18, 2004
>ADD>	019898 003	PRAVASTATIN SODIUM;PRAVACHOL				D-70	DEC 18, 2004
>ADD>	019898 004	PRAVASTATIN SODIUM;PRAVACHOL				D-70	DEC 18, 2004
>ADD>	019898 008	PRAVASTATIN SODIUM;PRAVACHOL				NS	DEC 18, 2004
>ADD>						D-70	DEC 18, 2004
	019627 002	PROPOFOL;DIPRIVAN				I-322	FEB 20, 2004
						PED	AUG 20, 2004
	020639 001	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
	020639 002	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
	020639 003	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
	020639 004	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011			
>ADD>	020639 005	QUETIAPINE FUMARATE;SEROQUEL	4879288	SEP 26, 2011		NCE	SEP 26, 2002
	020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	SEP 03, 2008	U-385		
			5035899	APR 04, 2009	U-385		
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2002			
	019901 001	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 002	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 003	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
>ADD>	019090 001	RANITIDINE HYDROCHLORIDE;ZANTAC				PED	APR 29, 2003
>ADD>	019593 001	RANITIDINE HYDROCHLORIDE;ZANTAC				PED	APR 29, 2003
>ADD>	019593 002	RANITIDINE HYDROCHLORIDE;ZANTAC				PED	APR 29, 2003
>ADD>	019675 001	RANITIDINE HYDROCHLORIDE;ZANTAC				PED	APR 29, 2003
>ADD>	018703 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150				PED	APR 29, 2003
>ADD>	020095 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150				PED	APR 29, 2003
>ADD>	020251 001	RANITIDINE HYDROCHLORIDE;ZANTAC 150				PED	APR 29, 2003
>ADD>	020251 002	RANITIDINE HYDROCHLORIDE;ZANTAC 150				PED	APR 29, 2003
>ADD>	018703 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300				PED	APR 29, 2003
>ADD>	020095 002	RANITIDINE HYDROCHLORIDE;ZANTAC 300				PED	APR 29, 2003
	020741 001	REPAGLINIDE;PRANDIN	6143769	MAR 24, 2009			
	020741 002	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			
	020741 003	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020903 001	RIBAVIRIN;REBETOL	6335032	DEC 22, 2017		PED	JUN 09, 2002
>ADD>			6335032*PED	JUN 22, 2018		PED	DEC 03, 2001
>ADD>			6337090*PED	JUN 22, 2018			
>ADD>			6337090	DEC 22, 2017			
			5767097	JAN 23, 2016	U-235		
			5914128	DEC 22, 2017			
			6051252	DEC 22, 2017			
			6063772	JAN 23, 2016	U-375		
			6172046	SEP 21, 2017	U-377		
			5767097*PED	JUL 23, 2016	U-235		
			5914128*PED	JUN 22, 2018			
			6051252*PED	JUN 22, 2018			
			6063772*PED	JUL 23, 2016	U-375		
			6172046*PED	MAR 21, 2018	U-377		
>ADD>	020903 002	RIBAVIRIN;REBETOL	6335032	DEC 22, 2017			
>ADD>			6335032*PED	JUN 22, 2018			
>ADD>			5767097	JAN 23, 2016	U-235		
>ADD>			5767097*PED	JUL 23, 2016	U-235		
>ADD>			5914128	DEC 22, 2017			
>ADD>			5914128*PED	JUN 22, 2018			
>ADD>			6051252	DEC 22, 2017			
>ADD>			6051252*PED	JUN 22, 2018			
>ADD>			6063772	JAN 23, 2016	U-375		
>ADD>			6063772*PED	JUL 23, 2016			
>ADD>			6172046	SEP 21, 2017	U-377		
>ADD>			6172046*PED	MAR 21, 2018	U-377		
>ADD>			6337090	DEC 22, 2017			
>ADD>			6337090*PED	JUN 22, 2018			
	018859 001	RIBAVIRIN;VIRAZOLE	6150337	NOV 21, 2017	U-400		
	020945 001	RITONAVIR;NORVIR	6232333	NOV 07, 2017			
	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
			6239173	JUN 24, 2013			
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
			6239173	JUN 24, 2013			
	021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
			5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
	021052 001	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
	021052 002	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
	021071 002	ROSIGLITAZONE MALEATE;AVANDIA	6288095	FEB 11, 2017	U-420		
	021071 003	ROSIGLITAZONE MALEATE;AVANDIA	6288095	FEB 11, 2017	U-420		
	021071 004	ROSIGLITAZONE MALEATE;AVANDIA	6288095	FEB 11, 2017	U-420		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020692 001	SALMETEROL XINAFOATE;SEREVENT	5290815	MAR 01, 2011	U-386		
	020828 001	SAQUINAVIR;FORTOVASE	5196438	NOV 19, 2010			
	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
	019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
>ADD>	020478 001	SEVOFLURANE;ULTANE	6288127*PED	JUL 27, 2017			
			6288127	JAN 27, 2017			
	020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
						M-9	FEB 16, 2004
	020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
						M-9	FEB 16, 2004
	020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
						M-9	FEB 16, 2004
	021097 001	SODIUM PHOSPHATE, DIBASIC, ANHYDROUS;VISICOL	5616346	MAY 18, 2013	U-359		
	020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN	5633352	MAY 27, 2014		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
	020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN	5633352	MAY 27, 2014		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
			5633352	MAY 27, 2014		ODE	JUL 25, 2008
	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
			5633352	MAY 27, 2014		ODE	JUL 25, 2008
	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
			5633352	MAY 27, 2014		ODE	JUL 25, 2008
	020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27, 2014		I-334	JUL 25, 2004
			5633352	MAY 27, 2014		ODE	JUL 25, 2008
	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
			5633352	MAY 27, 2014		ODE	JUL 25, 2008
	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
			5633352	MAY 27, 2014		ODE	JUL 25, 2008
	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
			5633352	MAY 27, 2014		ODE	JUL 25, 2008
	020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27, 2014		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
	020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27, 2014		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
	020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27, 2014		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
	020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	5633352	MAY 27, 2014		I-334	JUL 25, 2004
						ODE	JUL 25, 2008
>ADD>	019865 001	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
>ADD>						M-13	OCT 01, 2004
>ADD>	019865 002	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
>ADD>						M-13	OCT 01, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	019865 003	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
>ADD>						M-13	OCT 01, 2004
>ADD>	019865 004	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
>ADD>						M-13	OCT 01, 2004
>ADD>	019865 005	SOTALOL HYDROCHLORIDE;BETAPACE				PED	APR 01, 2005
>ADD>						M-13	OCT 01, 2004
	021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
						PED	AUG 22, 2003
	021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
						PED	AUG 22, 2003
	021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				NP	FEB 22, 2003
						PED	AUG 22, 2003
	020412 001	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
			4978655*PED	DEC 24, 2008	U-94		
	020412 002	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
			4978655*PED	DEC 24, 2008	U-94		
	020412 003	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
			4978655*PED	DEC 24, 2008			
	020412 004	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
			4978655*PED	DEC 24, 2008	U-94		
	020412 005	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
			4978655*PED	DEC 24, 2008	U-94		
	021184 002	TAZAROTENE;TAZORAC				I-344	OCT 11, 2004
	021356 001	TENOFOVIR DISOPROXIL FUMARATE;VIREAD	5977089	JUL 25, 2017	U-248	NCE	OCT 26, 2006
			6043230	JUL 25, 2017	U-248		
			5935946	JUL 25, 2017	U-248		
			4808716	APR 25, 2006	U-248		
			6057305	MAY 02, 2017	U-248		
			5922695	JUL 25, 2017	U-248		
	019964 001	TERCONAZOLE;TERAZOL 3	4358449	NOV 09, 2001			
	020898 001	THYROTROPIN ALFA;THYROGEN	5674711	AUG 31, 2010			
			5602006	FEB 11, 2014			
			5658760	AUG 19, 2014			
			5240832	AUG 31, 2010			
			6114144	NOV 24, 2015			
			5840566	NOV 24, 2015			
	020330 001	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
	020330 002	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
	020397 002	TIZANIDINE HYDROCHLORIDE;ZANAFLEX				NCE	NOV 27, 2001
	020771 001	TOLTERODINE TARTRATE;DETROL	5559269	NOV 05, 2013	U-318		
	020771 002	TOLTERODINE TARTRATE;DETROL	5559269	NOV 05, 2013	U-318		
	020505 001	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
						I-335	AUG 28, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
020505 002	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 003	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 004	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 005	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020505 006	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020844 001	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020844 002	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020844 003	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
					I-335	AUG 28, 2004
020528 001	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
020528 002	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
020528 003	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
020591 001	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
020591 002	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
020591 003	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
020591 004	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
021257 001	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	U-382	NCE	MAR 16, 2006
		5631287	DEC 22, 2014	U-382		
		5849792	DEC 22, 2014	U-383		
		5889052	AUG 03, 2013	U-383		
		6235781	JUN 15, 2019	U-382		
019963 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131		
021108 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131		
		4603146	JUL 29, 2003	U-131		
020475 001	TRETINOIN;RETIN-A MICRO	5955109	SEP 21, 2016	U-134		
020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	6143329	JUL 03, 2016			
021288 001	TRIPTORELIN PAMOATE;TRELSTAR	5225205	JUL 20, 2010		NP	JUN 29, 2004
		5192741	MAR 09, 2010		NCE	JUN 15, 2005
020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5776885	JUL 07, 2015			
020759 001	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
020759 002	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
020586 002	UREA, C-13;BREATHTEK UBT FOR H-	4830010	OCT 27, 2009	U-147		
		5140993	AUG 24, 2009			
				U-148		
019415 004	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
		4845077	JUL 04, 2006	U-408		
		4725579	FEB 21, 2005	U-408		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
019415 005	UROFOLLITROPIN;FERTINEX	5767067	JUN 16, 2015			
		4845077	JUL 04, 2006	U-408		
		4725579	FEB 21, 2005	U-408		
020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX				D-67	JUN 25, 2004
020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX				D-67	JUN 25, 2004
021304 001	VALGANCICLOVIR HYDROCHLORIDE;VALCYTE	6083953	JUL 28, 2014	U-384	NE	MAR 29, 2004
021283 001	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
021283 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
021283 003	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR				I-325	MAY 02, 2004
020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017		I-325	MAY 02, 2004
		5916923	JUN 28, 2013	U-398		
020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017		I-325	MAY 02, 2004
		5916923	JUN 28, 2013	U-398		
020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017			
		5916923	JUN 28, 2013	U-398		
020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	6274171	MAR 20, 2017		I-325	MAY 02, 2004
		5916923	JUN 28, 2013	U-398		
021119 001	VERTEPORFIN;VISUDYNE	4833790	JAN 20, 2007	U-357	I-336	AUG 22, 2004
		5283255	JAN 20, 2007	U-357		
020547 001	ZAFIRLUKAST;ACCOLATE				I-328	SEP 17, 2002
020547 003	ZAFIRLUKAST;ACCOLATE				I-328	SEP 17, 2002
020859 001	ZALEPLON;SONATA				M-8	FEB 22, 2004
020859 002	ZALEPLON;SONATA				M-8	FEB 22, 2004
020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
		5312925	SEP 01, 2012			
021223 001	ZOLEDRONIC ACID;ZOMETA	4939130	NOV 13, 2007	U-53	NCE	AUG 20, 2006
		4777163	JUL 24, 2007		ODE	AUG 20, 2008
021231 001	ZOLMITRIPTAN;ZOMIG-ZMT				NDF	FEB 13, 2004

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 21ST EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

I-336
I-337
I-338
I-339
I-340
I-341
I-342
I-343
I-344
I-345

ABBREVIATIONS

REFERENCES

NEW DOSING SCHEDULE

D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL	M-6
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS	M-7 M-8
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI	
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES	M-9
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS	M-10 M-11
D-69	SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS	M-12 M-13
D-70	80MG ONCE DAILY DOSING REGIMEN	M-14

NEW INDICATION

I-321	JUVENILE RHEUMATOID ARTHRITIS	U-267
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS	
I-323	COLORECTAL CANCER	
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS	U-372 U-373
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION	
I-326	GENERALIZED ANXIETY DISORDER	
I-327	SYMPTOMATIC RELIEF OF RHINOORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER	U-374
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE	
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS	U-375
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD	U-376 U-377
I-331	TREATMENT OF MODERATE ACNE VULGARIS	
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (ETFN)	
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)	U-378 U-379
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE	U-380
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME	U-381 U-382

PATENT AND EXCLUSIVITY TERMS

REFERENCES

NEW INDICATION

I-336 EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS

I-337 PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME

I-338 MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA

I-339 TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS

I-340 ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5

I-341 BREAST CANCER COMBINATION THERAPY

I-342 USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA

I-343 USE OF COREG FOR SEVERE HEART FAILURE

I-344 ACNE VULGARIS

I-345 TREATMENT OF POSTTRAUMATIC STRESS DISORDER

MISCELLANEOUS EXCLUSIVITY CODES

M-6 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUOPHAGE/GLYBURIDE COMBINATION ADDED TO CLIN PHARM AND DOSING AND ADMIN

M-7 CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION

M-8 ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING

M-9 ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY

M-10 INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING

M-11 USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER

M-12 NEW LANGUAGE FOR PEDIATRIC USE

M-13 INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION

M-14 ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION

PATENT USE CODES

U-267 PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE

U-372 METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...

U-373 GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OFGERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE

U-374 KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX

U-375 METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C

U-376 TREATMENT OF INFLUENZA

U-377 METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS

U-378 METHOD FOR TREATING INCONTINENCE

U-379 METHOD OF TREATING ONYCHROMYCOSIS

U-380 COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS

U-381 TREATMENT OF HYPERPHOSPHATEMIA

U-382 METHOD OF STABLIZING PROSTAGLANDIN

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODES

U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN
U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391	USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392	TREATMENT OF PATIENTS FOR INFLAMMATION
U-393	MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394	METHOD OF USE OF ALPHAGAN
U-395	METHOD OF USE OF ALPHAGAN P
U-396	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398	TREATMENT OF GENERALIZED ANXIETY DISORDER
U-399	IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
U-400	USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401	USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402	TREATMENT OF ACTINIC KERATOSES
U-403	ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
U-404	TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405	METHOD OF USE OF LOTRONEX
U-406	METHOD OF USE OF ATOVAQUONE AND PROGUANIL
U-407	METHOD OF TREATING OTOPATHY
U-408	FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION
U-409	METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE
U-410	METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-411	METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION
U-412	TREATMENT OF TYPE 2 DIABETES
U-413	USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS
U-414	A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-415	A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-416	A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS
U-417	COMBINATION USE OF AD-4833 WITH A BIGUANIDE
U-418	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER
U-419	A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE
U-420	METHOD OF TREATMENT OF TYPE II DIABETES

PATENT AND EXCLUSIVITY TERMS

REFERENCES
PATENT USE CODES

U-421 USE FOR SEDATION
U-422 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER
U-423 METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA
U-424 FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS
U-425 METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN ECRETION ENHANCER
U-426 PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION
U-427 METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS
U-428 METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE
U-429 METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS
U-430 METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER
U-431 POSTTRAUMATIC STRESS DISORDER

*U.S. Government Printing Office: 2002 — 491-214/40006